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 I  
ABSTRACT 
Background 
The role of B-lymphocytes regarding bone turnover is controversial (1). Some studies showed 
that treatment with tumor necrosis factor alpha (TNFα) blockers could prevent structural bone 
damage and improve bone mineral density (BMD) in RA (2). Hence, we set up this study to 
determine rituximab will have similar effect on bone turnover and the possible mechanisms. 
 
Aim 
To assess the effect of rituximab on bone turnover and to correlate these changes with 
circulating B cells in RA. 
 
 
Materials & Methods 
45 RA patients starting rituximab were assessed over 5 visits for one year. Patients were 
treated with two courses of rituximab. Patients were assessed clinically using DAS28, BMD 
using DXA scan, bone formation markers (BAP, P1NP), osteocyte markers (DKK1 and 
sclerostin), resorption markers (TRAP5b and CTX) and flow cytometry of peripheral blood 
CD19+ cells including subsets. 
 
Results 
Subjects were 59.3±12.1 years old mostly females (80%). 57.8% were postmenopausal. 
Patients had severe active disease at baseline DAS28=6.1±1.3. 68.9% of patients had vitamin 
D deficiency at baseline. 15(33.3%) of patients took prednisolone 11.2±9.8 mg. DAS28 score 
at 12 months decreased to 4.7±1.4 compared to 6.1±1.3 at baseline (P<0.001). Median 
(95%CI) P1NP levels increased from 41.9 (34.1-46.4) to 47.7 (42.0-61.4) after 12 months. 
Yet, the change was not statistically significant. BAP increased significantly from 19.0±6.5 to 
21.3±7.7 (P=0.007). There was insignificant small reduction in TRAP5b and CTX levels 
during follow up. Osteocyte markers (sclerostin and DKK1) were stable during follow up. 
After performing Bonferroni correction, the increase in sclerostin levels between 6 and 12 
months was found to be statistically significant (p=0.019). Depletion of most of CD19 B cells 
following baseline with increase at 6th month then continued to decrease following the second 
course of rituximab. After 12 months, BMD slightly decreased at all sites. However, the 
reduction was statistically significant only at total hip (p=0.041). There was significant 
positive independent association of BMD L2-L4 at 12 months with CD19 B-lymphocytes at 
baseline. 
 
Conclusion 
Based on results obtained from bone markers, B cell depletion using rituximab increased bone 
formation and slightly reduced bone resorbtion markers. However, sclerostin slightly 
increased from 6th to 12 month. BMD results were inconsistent with bone markers findings, as 
there was a reduction in all sites mostly at total hip. Furthermore, CD19+ B cells were found 
to have a direct positive association with BMD at LS suggesting that B cell depletion is not 
protective for bone metabolism as previously expected.  
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 1 
INTRODUCTION AND RATIONALE 
Osteoporosis is a disease of increased bone fragility leading to increased risk of fracture (1). 
Decreased bone mineral density is the hallmark of the disease. However, micro architectural 
alterations represent a major pathogenic factor leading to what is called fragility fractures 
(low trauma fractures). Women are more commonly affected than men with 50% of women 
above the age of 50 years are at risk of fracture compared to 20% for men (2, 3). 
 
RA is a chronic inflammatory joint disease that may lead to various extra-articular symptoms. 
While there has been progress in defining the etiology and pathogenesis of RA, these are still 
incompletely understood. There is synovial inflammation, subsequent pannus formation and 
intra-articular bone erosions, resulting in joint destruction. Joint damage is the major reason 
for disability in RA patients. In addition, the disease can affect the whole musculoskeletal 
system including bones, cartilage, ligaments and tendons. The bone system is particularly 
affected resulting in localized, peri-articular bone loss as well as generalized bone loss (4-9). 
 
An intricate interaction between the immune system and the skeleton is evidenced by the 
significant bone loss shown in RA (10). This interaction is thought to be occurring through 
the cell surface receptors, cytokines and signaling pathways. Furthermore, it is becoming clear 
that immune cells influence bone remodeling and vice versa. It is thought that there is a direct 
interaction between immune cells and bone cells due to their proximity in the bone marrow. 
The role of T cells is well established in inflammatory bone resorption and osteoclastogenesis 
(12). T cells have the ability to regulate bone turnover through direct cell-cell interaction with 
bone cells and indirectly through the production of inflammatory and other cytokines that 
modulate osteoclastogenesis. Osteoblasts and osteoclasts can express major histocompatibility 
complex (MHC) class II molecules under inflammatory conditions. Therefore, it is plausible 
that T cell:bone cell interaction may contribute to the autoimmune response as well as 
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accentuate bone turnover.  
 
On the other hand, the role of B-lymphocytes in osteoclast (OC) formation is controversial 
(13). B-lymphocytes can inhibit and stimulate osteoclastogenesis by their ability to secrete 
different cytokines (13). B lymphocytes produce pro-osteoclastogenic cytokines including 
receptor activator of NF-kappa-B ligand (RANKL), as well as cytokines that inhibit osteoclast 
differentiation from the progenitor cells, such as osteoprotegerin (OPG), transforming growth 
factor-β (TGF-β) and interleukin (IL)-7. Furthermore, B cells can stimulate the activation of 
other immune cells including T cells leading to further bone loss. Additionally, a subset of B 
cells named “regulatory” B cells can inhibit the inflammatory response and down-regulate the 
function of T cells (14).  
 
Therefore, the net effect of B cell depletion on bone turnover may depend on the relative 
depletion of effector versus regulatory B cell subsets. Studies have shown that B-lymphocytes 
stimulate osteoclastogenesis; while others have shown that B cells inhibit bone resorption 
(15). Knocking out B cells in mice led to severe osteoporosis indicating that B cells have an 
important role in bone metabolism (12). 
 
This thesis is to study the effects of rituximab, a B cell depleting monoclonal antibody, on 
bone turnover in RA patients in the UK. NICE has licensed rituximab for use in patients with 
RA who are unresponsive to treatment with second-line anti-rheumatic medication and a 
TNF-inhibitor. Rituximab proved its efficacy in controlling RA disease activity in many 
studies. This success has demonstrated that B cells play a key role in perpetuation of the 
disease.  
 
The study builds on pilot data obtained from RA patients, which suggested that B cell 
depletion has a beneficial effect on bone turnover in RA. The pilot study demonstrated a 50% 
decrease (p<0.001) in beta-crosslaps (CTX), a biochemical marker of bone resorption, and a 
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small but statistically significant increase in P1NP, a biochemical marker of bone formation, 
in sera of 46 RA patients 6 months after a single treatment course of rituximab (11).  
 
However, the pilot study had limitations as it was mainly based on assessment of serum levels 
of biochemical markers of bone turnover but not bone mineral density (BMD) measurements. 
Furthermore, the serum samples were collected for a different study aim and were randomly 
collected during the day and non-fasting. We therefore set up a new prospective clinical study 
(named ‘Horus trial’) to investigate bone mineral density measurements and markers of bone 
formation, resorption and osteocytes, in addition to markers of inflammation and disease 
activity in RA patients treated with rituximab. 
 
This multicenter, open-label, single treatment arm, prospective clinical trial aimed to 
determine the effects of B cell depletion using rituximab on bone density and biochemical 
markers of bone turnover in RA patients.  
 
We postulated that the presumed bone-protective effects of rituximab on bone density and 
turnover may be either due to a direct effect of B cell depletion on osteoclastogenesis, or due 
to reduction of disease activity, modulation of autoreactivity or all of the above (11). 
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AIM OF THE WORK 
This study is based on a multicenter prospective clinical trial aiming to assess the effects of B 
cell depletion using rituximab on disease activity, BMD and biochemical markers of bone 
turnover including bone formation markers, bone resorption markers and osteocyte markers in 
RA patients. We aim to determine whether this effect is related to remission of disease 
activity by the drug or a direct effect of B cell depletion on bone turnover. Additionally, we 
wanted to determine the effect of changes in disease activity on bone metabolism in RA. 
STUDY OBJECTIVES 
Primary Goal 
To determine the effect of B cell depletion using rituximab treatment on bone mineral density 
(BMD) measurements, disease activity and bone turnover (biochemical markers of bone 
resorption and formation) in RA patients. 
 
Secondary Goals 
To correlate changes in bone density with changes in biochemical markers of bone turnover; 
changes in biomarkers of inflammation and changes in circulating B cells. Additionally, we 
wanted to determine the effect of changes in disease activity on bone metabolism in RA. 
STUDY HYPOTHESIS 
B cell depletion has a beneficial effect on bone loss resulting from RA. We hypothesize that 
RTX is able to stop bone resorption and enhance bone formation by blocking inflammation 
and a possible direct effect on bone cells.
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CHAPTER 1. RHEUMATOID ARTHRITIS 
1.1. EPIDEMIOLOGY 
RA is a common disease affecting between 0.5-1% of the adult population worldwide (4). 
Osteoporosis is a leading co-morbidity in RA. Almost one third of women with RA will 
develop a fracture within 5 years of their diagnosis. These data clearly show that bone loss in 
RA is a significant public health problem (6). 
1.2. RISK FACTORS 
The cause of RA is still unknown. Risk factors for RA include female sex, positive family 
history for RA, presence of the shared epitope HLA DR beta chains most commonly HLA 
DR4 and DR14, smoking, increased BMI, infection, presence of other autoimmune diseases 
and the presence of auto-antibodies rheumatoid factor (RF) and anti-citrullinated peptide 
antibodies (ACPA). Other risk factors include heavy alcohol consumption, artificial-feeding 
and low socioeconomic status (7, 9, 14). 
1.3. PATHOGENESIS 
Despite the fact that the cause of RA is not completely understood, some data on RA 
pathogenesis exist. Environmental factors such as infections and smoking stimulate the 
immune system in the genetically susceptible patients to initiate the disease. This activation of 
the immune response leads to the production of citrullinated peptides. These peptides activate 
the production of anti-citrullinated peptides antibodies (ACPA) leading to immune complexes 
formation, which in turn activate the complement system. This activation of the immune 
system attracts further antigen presenting cells (APC), T and B cells into the joints through 
different mechanisms. These cells produce many pro-inflammatory cytokines including IL-1, 
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IL-6 and TN-α. These cytokines further aggravate the inflammatory response in the joint 
space causing synovial inflammation (7). 
Synovial neovascularization helps recruit the inflammatory cells into the joint space 
producing more pro-inflammatory cytokines. These cytokines stimulate the expression of 
adhesion molecules on the surface of endothelial cells leading to diapedesis of further 
inflammatory cells into the synovial space. This inflamed synovium start to creep under the 
cartilage destroying it and eroding the subchondral bone and ligaments through the production 
of proteases. (9, 16) (Figure 1).  
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Figure (1) pathogenesis of RA. 
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1.4. CLINICAL FEATURES  
1.4.I. Articular manifestations 
Although RA is a systemic disease and can affect all systems of the human body, it tends to 
present with inflammation of the joints leading to swelling, redness, hotness and loss of 
function of the affected joints. RA has an insidious onset in most of the patients. It usually 
starts with arthritis of the metacarpophalangeal (MCP), proximal interphalangeal (PIP), wrists 
and metatarsophalangeal (MTP) joints. Then it may affect larger joints like elbows, shoulders, 
ankles and knees (17-19). 
RA may have an acute onset with body aches, fatigue, low-grade fever, weight loss and 
depression. In other cases, it may present with polymyalgia rheumatica features such as pain 
in the shoulder and hip girdles associated with morning stiffness. Characteristic RA features 
may develop later. Intermittent disease with mono- or oligo-arthritis for few hours or days 
then settle down for weeks or months can also be a presenting feature. This picture is 
suggestive of palindromic rheumatism which some consider as an early phase of RA (17-19).  
Typically, the arthritis tends to be symmetrical affecting mainly the small joints of the hands 
sparing the DIPs. Morning stiffness for more than 1 hour is a common complaint in active 
disease. According to the diagnostic criteria, these symptoms should be present for at least 6 
weeks (20).  
1.4.II. Extra-articular manifestations 
Extra-articular manifestations might be a presentation of RA. Furthermore, RA can be 
complicated by other rheumatic diseases such as Sjogren syndrome, vasculitis, Felty’s 
syndrome, amyloidosis, serositis, splenomegaly, neuropathy, renal, lung, bone, muscle, skin 
and eye diseases (21). 
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1.4.II.A- Muscle disorders 
RA can affect the muscles by different mechanisms including synovitis, inflammatory 
myositis, vasculitis, and steroid induced myopathy. Disuse weakness and atrophy resulting 
from chronic arthritis is common. For example, chronic knee arthritis leads to weakness and 
atrophy of the quadriceps muscle. This leads to joint instability and further damage (22).  
Infiltration of inflammatory cells is common in muscles of RA patients leading to muscle 
necrosis. Moreover, some patients may suffer from frank polymyositis (23, 24).  
1.4.II.B- Skin manifestations  
Skin lesions in RA may include rheumatoid nodules, mucocutaneous ulcers, corticosteroid 
induced skin atrophy and rarely pyoderma gangrenosum and rheumatoid neutrophilic 
dermatosis (25). 
1.4.II.C- Vasculitis 
RA vasculitis is an unusual but serious complication. It may present as digital or skin ulcers, 
mononeuritis multiplex, myositis, retinal vasculitis, purpura, coronary, pulmonary, renal, and 
gastrointestinal tract (GIT) vasculitis. It may also mimic polyarteritis nodosa. Some risk 
factors are known for RA vasculitis. These include long standing erosive disease, high titer of 
RF and systemic disease. Rheumatoid nodules are common on patients with vasculitis. It is 
thought that both conditions are of the same pathogenesis (26).  
1.4.II.D- Eye disorders  
Eye manifestations in RA may include dry eyes, episcleritis and rarely scleritis. However, RA 
can also cause uveitis, keratitis and corneal melt (27). 
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Eye dryness is not related to RA disease activity. However, other conditions such as scleritis 
and corneal melts usually occur in active systemic disease (27). 
1.4.II.E- Pulmonary manifestations 
RA commonly affects the pleura presenting as pleuritis or pleural effusion that can be either 
asymptomatic or may present with chest pain, fever and dyspnea (28).  
Lungs could also be affected in RA leading to ILD. The most common presentations are usual 
interstitial pneumonia and non-specific interstitial pneumonia. Other forms of ILD that are 
less common include cryptogenic organizing pneumonia, lymphocytic and desquamative 
interstitial pneumonia. Symptoms can be fever, dyspnea, cough, malaise and weight loss (29). 
Pulmonary infections represent a major cause of morbidity and mortality in RA. Rheumatoid 
nodules may occur in the lungs. When associated with pneumoconiosis is called Kaplan 
syndrome. Pulmonary vasculitis maybe a part of RA vasculitis (30). 
1.4.II.F- Cardiac manifestations  
RA is a significant independent risk factor for coronary heart disease. Cardiac involvement 
includes pericarditis, myocarditis, myocardial infarction, arrhythmias, heart failure and 
sudden death. Pericarditis is common in RA patients with active systemic disease and high RF 
titer. Myocarditis and heart failure are less common (31). 
1.4.II.G- Peripheral vascular disease  
RA is also a significant independent risk factor for atherosclerosis and peripheral vascular 
disease in the same way as the coronary artery disease (32).  
1.4.II.H- Renal manifestations  
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RA can cause glomerulonephritis (GN), renal vasculitis and secondary AA amyloidosis 
leading to nephrotic syndrome that may occur in patients with longstanding active RA. 
Iatrogenic renal compromise is the most common cause of renal affection in RA by the 
medications used in the treatment of RA such as gold, penicillamine, cyclosporine and non-
steroidal anti-inflammatory drugs (NSAIDs) (33).  
1.4.II.I- Sjogren Syndrome 
Sjogren syndrome (SS) is characterized by dryness of the mucous membranes such as dry 
eyes and dry mouth. It is also named sicca syndrome. It can be either primary or secondary. 
Primary SS occur when there is no underlying disease while secondary SS occur in patients 
with pre-existing rheumatic diseases such as RA. SS is manifested as gritty or foreign body 
sensation in the eyes and difficulty in swallowing of dry food with dental caries and oral 
candidiasis (34). 
1.4.II.J- Neurological manifestations  
Entrapment neuropathies are the most common form of neurological disease in RA. Carpal 
tunnel syndrome is the most common entrapment neuropathy found in RA. Peripheral nerves 
can also be affected by joint damage, pannus formation and rheumatoid vasculitis. 
Neuropathies may include ischemic neuropathy, mono-neuritis multiplex and peripheral 
neuropathy. Spinal cord affection due to atlanto-axial subluxation is a life-threatening 
complication of longstanding active disease.  
Rheumatoid vasculitis may rarely affect the CNS as a part of the systemic condition leading to 
stroke, seizures, or intracranial hemorrhage. The risk of CNS ischemic events generally 
increases in RA as a result of the enhanced atherosclerosis (35-37). 
1.4.II.K- Hematologic manifestations  
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The most common hematologic abnormality in RA is anemia. It can be either normocytic 
normochromic due to chronic inflammation, microcytic hypochromic due to iron deficiency, 
macrocytic or hemolytic anemia. Hypersplenism and neutropenia in longstanding active RA 
represent the triad of Felty syndrome. 
Disease-modifying anti-rheumatic drugs (DMARDs) may also cause pancytopenia and 
leucopenia including methotrexate, sulphasalazine, gold and azathioprine. On contrary, 
leukocytosis and thrombocytosis occurs in active disease (38-40). 
1.4.II.L- Skeletal manifestations 
RA induced osteoporosis is multifactorial including increased inflammatory cytokines, 
immobility, and drugs such as corticosteroids, old age and low body mass index (41, 43).  
RA patients suffer from osteoporosis twice as much as age matched healthy individuals (43, 
44). RA patients lose 2.4% of their bone density at the spine and 4.3% at the hip (45). 
Additionally, the rate of vertebral and non-vertebral fractures in RA patients is higher than the 
age and gender matched healthy controls (46). 
Furthermore, patients with high disease activity had 2.1% decrease in BMD of the lumbar 
spine compared to 0.2% in patients with low disease activity (47). This section is discussed in 
further details in chapter 2. 
1.5. DIAGNOSIS  
RA should be suspected in any patient presenting with polyarthritis. For research purposes, 
diagnostic criteria have been set by the American college of rheumatology (ACR) in 1987 
(Table I). These criteria were also used in clinical practice to help diagnose RA. In 2010, new 
criteria for the diagnosis of RA were developed by the ACR and the EULAR (Table II). 
 
 12 
However, the old criteria of 1987 have the problem of omitting ACPA. While the new criteria 
omitted rheumatoid nodules and radiographic changes which are absent in early RA (48-50). 
The new criteria allow identification of early stages of RA, which allows early aggressive 
management of the disease to prevent its complications. This is in contrast to the old criteria 
that defined the disease late based on symmetrical arthritis, x-ray findings and rheumatoid 
nodules. The old criteria allowed only late diagnosis of well-established disease which 
delayed proper treatment.  
Table (1) showing the ACR classification criteria for diagnosis of RA (1987) (49) 
Diagnosis of RA is defined as having 4 or more out of the 7 following parameters: 
1- Morning stiffness: Morning stiffness in and around the joints, lasting at least one hour 
before maximal improvement.  
2- Arthritis of 3 or more joint areas: At least 3 joint areas (out of 14 possible areas; right 
or left PIP, MCP, wrist, elbow, knee, ankle, MTP joints) simultaneously have had soft- tissue 
swelling or fluid (not bony overgrowth alone) as observed by a physician.  
3- Arthritis of hand joints: At least one area swollen (as defined above) in a wrist, MCP, 
or PIP joint.  
4- Symmetric arthritis: Simultaneous involvement of the same joint areas (as defined 
above) on both sides of the body (bilateral involvement of PIPs, MCPs, or MTPs, without 
absolute symmetry is acceptable).  
5- Rheumatoid nodules: Subcutaneous nodules over bony prominences or extensor 
surfaces, or in juxta-articular regions as observed by a physician.  
6- Serum rheumatoid factor: Demonstration of abnormal amounts of serum rheumatoid 
factor by any method for which the result has been positive in less than 5 percent of normal 
control subjects.  
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7- Radiographic changes: Radiographic changes typical of rheumatoid arthritis on poster 
anterior hand or wrist radiographs, which must include erosions or unequivocal bony 
decalcification localized in, or most marked adjacent to, the involved joints (osteoarthritis 
changes alone do not qualify). 
Table (2) showing ACR/EULAR Criteria for diagnosis of RA (50) 
The ACR/EULAR 2010 criteria defined patients with definite RA who has arthritis of at least 
one joint and a total score of 6 or more out of 10 in four domains as follows: 
A. Number and site of inflamed joints 
1 point for 2 to 10 large joints such as the knees, the shoulders, the elbows, the ankles and the 
hips, 
2 points for 1 to 3 small joints such as PIP, MCP, wrist, MTP except of the big toe and the 
interphalangeal (IP) joint of the thumb. 
3 points for 4 to 10 small joints 
5 points for more than 10 joints including at least one small joint 
B. Serological abnormality including RF or ACPA 
2 points for low positive titer 
3 points for high positive titer 
C. Acute phase reactants 
1 point for elevated serum levels of ESR or CRP 
D. Symptom duration  
1 point for symptoms of at least 6 weeks  
 
1.6. ASSESSMENT OF SEVERITY/PROGRESSION  
1.6.I. Assessment of disease activity 
 
 14 
Active RA can cause major complications such as joint deformities, joint destruction, 
functional limitation and impaired activities of daily living. Accordingly, tight control of RA 
disease activity is mandatory to prevent such problems. Proper control of the disease starts 
with an accurate assessment of disease activity. The new strategy adopted by ACR and 
EULAR focuses on treat to target aimed at induction and maintenance of remission. 
Assessment of RA disease activity can be done using various tools which include tender joint 
count, swollen joint count, patient global assessment of disease activity and acute phase 
reactants such erythrocyte sedimentation rate (ESR) or CRP (51).  
Multiple indices have been developed using the above-mentioned parameters including the 
disease activity score (DAS), its modification DAS 28 joints (DAS28), simplified disease 
activity index (SDAI) and clinical disease activity index (CDAI). The DAS28 is currently the 
most commonly used index. Disease activity can be categorized in high disease activity 
(DAS28>5.1), moderate disease activity (DAS28 score between 3.2 and 5.1), low disease 
activity (DAS28 score between 2.6 to 3.2), and remission (DAS28<2.6) (51). 
1.6.II. Assessment of physical health status 
Functional impairment is a characteristic hallmark in RA. Hence, functional assessment is 
crucial in measuring treatment response in addition to DAS28, which is greatly affected by 
the acute phase reactants. This might be deceiving sometimes specially that these acute phase 
reactants rise in multiple conditions such as infections, malignancies…etc. (52).  
In many cases, patients have low acute phase response but suffer significant impairment of 
activities of daily living. So, assessment of functional capacity is as important as measuring 
the disease activity in RA follow-up. The health assessment questionnaire (HAQ) is the most 
commonly used in clinical trials. It consists of 20 questions divided into 8 categories dressing, 
rising, eating, walking, hygiene, reach, grip, and usual activities. Each question has a score 
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ranging from 0 to 3 with 0 = no difficulty; 1 = some difficulty; 2 = much difficulty; and 3 = 
inability to do (51).  
The score for each category is given to the question with highest score. Using an assistive 
device or help from another person increases the score to 2 unless it is 3, then it scores 3 as it 
is. The HAQ score is the mean of the eight categories ranging from 0 to 3 with 0 being the 
best health status and 3 is the worst (51). 
1.6.III. Response criteria 
Response criteria determine the change in disease activity in response to treatment. These 
criteria compare the disease activity between baseline and upcoming visits or the achievement 
of remission and low disease activity. The most common criteria are the ACR and EULAR 
response criteria. The ACR response criteria are ACR20, ACR50 and ACR70. ACR20 
improvement criteria is defined as at least 20% improvement in swollen and tender joint 
counts and three of the following five variables: Patient’s global assessment (by visual 
analogue scale [VAS]), Physician’s global assessment (by VAS), Pain assessment by the 
patient (by VAS), Functional assessment (by HAQ), Acute phase reactants (ESR or CRP).  
In the same way, ACR50 and ACR70 are at least 50% and 70% improvement in swollen and 
tender joint counts and three of the previously mentioned variables respectively (53, 54). 
The EULAR response criteria are based on DAS28 score. EULAR response can be either 
moderate or good response. For good response, there is a reduction of at least 1.2 in the 
DAS28 score and result in the achievement of low disease activity (DAS28 <3.2). While 
moderate response is a reduction of more than 1.2 but not reaching low disease activity or a 
reduction of DAS28 between 0.6 and 1.2 and achieving at least moderate disease activity 
(DAS28<5.1) (53, 54). 
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1.7. MANAGEMENT OF RA 
Management of RA includes pharmacological and non-pharmacological treatments. Care of 
RA patients should be done by a multidisciplinary team including rheumatologists, orthopedic 
surgeons, nurses, occupational therapists, orthotists and prosthetists. Treat to target is the 
general goal of RA treatment. The aim for management is inducing RA disease remission. 
This can be achieved by early diagnosis and introduction of traditional and biological 
DMARDs to control the disease activity. Prevention and early management of comorbidities 
such as deformities help patients cope with activities of daily life (55-60). 
1.7.I. Non-pharmacological management of RA 
Non-pharmacological management includes rest of inflamed joints and bed rest during flare-
ups; patient education about the nature of the disease and its treatments. Pacing and a relaxed 
schedule can be useful in patients complaining of fatigue. Physical therapy can ameliorate 
complications such as disuse atrophy, contractures and joint instability (60).  
Exercise is a crucial part of in the management of such patients. Isometric strengthening 
exercise can be helpful in preventing muscle weakness without worsening the joint damage 
(55). 
Physical therapy is an important part of management of RA. It aims to decrease inflammation 
and pain, improve joints’ range of motion (ROM) and ameliorate the patients’ physical 
fitness. Different modalities can be used including superficial heat such as hot packs and 
infrared; deep heat such as short wave diathermy, ultrasound; electrical stimulation to 
strengthen weak muscles and reduce the joint effusion. Last but not least, exercise is a crucial 
part of physical therapy including aerobics; isometric strengthening and stretching exercises 
(56, 57). 
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Assistive devices including orthoses and prostheses play a key role in correction of 
deformities and improving the function of the affected limb (56, 57). These help patients to 
better perform activities of daily living without pain. Occupational therapy has a major role in 
helping patients cope with their daily activities including jar opener, key holder, appliances 
for reach, and built up utensils (57).  
1.7.II. Pharmacological management of RA 
The strategy of RA treatment is currently based on the early introduction of disease modifying 
drugs to stop joint damage and disease progression. Medications include painkillers, non-
steroidal anti-inflammatory drugs (NSAIDs), corticosteroids and DMARDs. Supplementation 
with vitamins such as calcium and vitamin D is of great importance to protect against RA 
induced osteoporosis (60). 
Different management strategies have been set to stop RA disease progression but they all 
aim to induce remission of the disease. For instance, NICE advised that a combination of 
traditional DMARDs should be started immediately after confirmation of diagnosis including 
methotrexate and at least one other DMARD, in addition to bridge therapy with 
corticosteroids for three months in order to inhibit the disease activity quickly till DMARDs’ 
effect can be obtained (60). 
Biological DMARDs should only be started in patients who fail to respond to at least two 
traditional DMARDs including methotrexate or side effects cannot be tolerated. Traditional 
DMARDs have to be tried for at least 6 months, unless side effects limited their use. Disease 
activity should be assessed on two different visits 1 month apart. Recently, NICE introduced 
many options as first line biological therapies such as TNF-α inhibitors, abatacept and 
tocilizumab. The choice of drug is based according to the patient and physician’s preferences. 
Methotrexate should be continued with biological DMARDs whenever tolerated. If patients 
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fail to respond to a biological agent, an alternative biological agent can be tried. Patients 
should continue using the biological drug only if DAS28 score improved by at least 1.2 after 6 
months of initiation of the drug. In patients failing to respond to at least one TNFα inhibitor 
can be shifted to rituximab. Rituximab should be used in combination with methotrexate and 
should only be continued in a similar way to the above-mentioned biological DMARDs (60).  
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CHAPTER 2. BONE METABOLISM 
2.1. OVERVIEW 
Bone is a metabolically active organ and is in continuous turnover during our life. 
Interestingly, 20% of bone tissue is renewed every year (61). Bone turnover starts with bone 
resorption by osteoclasts. Bone deposition by osteoblasts follows. The terminally 
differentiated osteoblasts lie in lacunae forming osteocytes. Many factors orchestrate bone 
remodeling. These include hormones, cytokines, systemic diseases, drugs, age, sex and 
nutritional status. All these factors can affect bone metabolism through regulating the activity 
of different bone cells (10).  
In normal circumstances, there is a balance between bone resorption and formation. Abnormal 
bone architecture results from uncoupling of this balance resulting in low bone quality. 
Osteoporosis occurs in conditions where there is increased bone resoprtion compared to bone 
deposition leading to increased bone fragility resulting in increase in fracture risk (62). 
Fragility fracture is the most feared complication of osteoporosis. Osteoporotic fractures are 
common especially in postmenopausal women (62). Treatment of osteoporotic fractures is a 
significant economical problem with medical costs estimated at £1.8 billion in the UK in 
addition to the costs resulting from turning active community members into disabled patients 
(63). Osteoporosis is more prevalent in females than males and incidence increases with age 
(64, 65).  
World Health Organization (WHO) defined osteoporosis as a decrease of BMD equal to or 
more than 2.5 standard deviations (SD) below the mean peak bone mass of a young adult of 
the same sex and ethnicity (T-score ≤ -2.5 SD) (66).  
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BMD is currently the gold standard for diagnosis of osteoporosis worldwide. However, BMD 
should not be the sole element used in treatment decision due to the lack of sensitivity. BMD 
for example gives false negative results in patients with spondylosis. Furthermore, BMD is a 
good estimate of bone mass but not bone quality and does not provide data on the rate of bone 
turnover i.e. whether bone resorption exceeds formation or vice versa (67). 
2.2. BONE PROPERTIES 
Bone quality depends on three factors including mineralization, bone proteins and activity of 
bone cells. Bone should be strong but resilient at the same time to allow for weight bearing 
without being fractured (10).  If the bone is stony hard, then it will fail to adsorb shocks and 
will fracture. This happens in a disease called osteopetrosis. On the contrary, if bone is soft 
and flexible, this will also end up with a fracture such as in rickets in children and 
osteomalacia in adults. Bone also should be light in weight to allow easy mobility of the body 
(10). 
2.2.1. Bone structure  
Two types of bone are present in the human body. The outer cortical bone forms three 
quarters of bone mass while the inner trabecular bone represents one quarter of the bone mass. 
Compact bone consists of osteons made up of lamellae of bone tissue surrounding the central 
haversian canal which hosts the nerves and blood vessels. Between the osteons lie the 
interstitial lamellae and lacunae containing osteocytes (68). Hematopoiesis takes place in the 
bone marrow. Cancellous bone lines the cortex of long and flat bones. It looks like a sponge 
with pores to give lightness and resilience to bone structure (10).  
2.2.1.I. Matrix  
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Bone matrix contains mainly collagen type I with almost 90% of the matrix in addition to 
proteoglycan, osteocalcin and osteonectin representing the remaining 10%. Osteoblasts, the 
bone forming cells, produce pro-collagen which is then converted to collagen. Collagen fibers 
are made up of fibrils grouped together. Each fibril contains two α-1 chains and one α-2 chain 
connected together forming a triple helix (10). 
2.2.1.II.  Minerals  
Bone minerals are mainly calcium hydroxyapatite lying among the matrix collagen fibers. 
Bone mineralization is the main determinant of bone strength. In utero, primary 
mineralization happens fast within days producing most of the matrix minerals; while 
secondary mineralization is slower and occurs within months producing the mature calcium 
crystals (69). 
2.2.1.III.  Cells  
There are three types of bone cells: osteoclasts, osteoblasts and osteocytes. Osteoclasts are the 
bone resorbing cells; osteoblasts are the bone forming cells; mature osteoblasts transform into 
osteocytes after they end up with bone formation. Thus, osteoclasts and osteoblasts are only 
present in areas with active bone turnover; while osteocytes are the main cells in stable bone 
(69).  
2.3. MECHANISM OF PHYSIOLOGICAL BONE TURNOVER AND ITS 
DETERMINANTS 
Under physiological conditions, there is a balance between bone formation by osteoblasts and 
bone resorption by osteoclasts. Many factors including hormones, cytokines, immune 
signaling and bone cells maintain this balance. An imbalance in bone turnover cycle result in 
abnormal bone that predispose to fractures and deformities (68).  
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2.3.A.  Role of osteocytes 
Osteocytes, the fully differentiated osteoblasts, lie in lacunae in the mineralized matrix and 
the osteoid tissue of bone. Osteocytes are thought to be able to regulate their own proliferation 
through their ability to control the differentiation of their derivative osteoblasts. However, the 
exact mechanism of osteocytogenesis is still largely unknown (68). 
Over the last decades, research has focused on the role of osteoclasts and osteoblasts in 
osteoporosis. Osteocytes have been found to have a potential key role in the regulation of both 
bone formation and resorption. Osteocytes are able to detect changes in bone morphology 
particularly micro-fractures through their sensitivity to detect mechanical strain acting like 
bone mechanoreceptors (69).  
They act accordingly by regulation of bone turnover through direct physical contact with 
other bone cells and their ability to produce various factors such as dentin matrix protein 1 
(DMP1), sclerostin and dickkopf-related protein 1 (DKK1). In vivo studies showed that 
osteocyte depletion results in profound loss of trabecular bone mass. The authors thought that 
these results might be due to the enhanced activity of osteoclasts and inhibition of osteoblasts 
(70).  
In a different model, reduction of bone mechanical pressure resulted in increased osteocyte 
expression of osteopontin (OPN) known also as bone sialoprotein I (BSP-1), which is an 
important osteoclastogenic cytokine. OPN is thought to be responsible for the activation and 
development of osteoclasts promoting them to acquire their ruffled border (71). Moreover, 
bone resorption by osteoclasts is directed by the site of osteocyte apoptosis in a different 
model (72).  
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These results suggest the close interaction between osteocytes and the other bone cells and 
highlight their role in bone turnover regulation. The osteocyte markers can be used in vitro as 
markers of osteocyte function for research purposes but yet to be validated for daily clinical 
application for the monitoring of treatment response in osteoporosis and inflammatory 
arthritis. DMP1 is a secreted protein present on the surface of osteocytes and to lesser extent 
osteoblasts (73).  
DMP1 deficiency led to decreased mineralisation of bones with increased mineral crystals 
formation in a murine model that suggests that it is essential for mineralisation and osteocyte 
maturation (74). Additionally, phosphate homeostasis is determined by DMP1 through its 
ability to modify its renal reabsorption (75).  
Matrix extracellular phosphoglycoprotein (MEPE) is a protein markedly expressed by 
osteocytes (76). Like DMP1, MEPE is also capable of regulating phosphate homeostasis and 
hence affect bone mineralisation (77). Deletion of MEPE from osteoblasts in mice resulted in 
inhibition of bone formation (78).  
The wingless-int(Wnt)/beta-(β-)catenin signalling pathway has been studied thoroughly over 
the past few years as many factors have been found to target this pathway to affect bone 
formation by osteoblasts. The Wnt proteins bind to the frizzled (Fz) receptors and the low-
density lipoprotein receptor-related protein 5 (LRP5) and 6 (LRP6) co-receptors on the 
surface of osteoblasts. This interaction activates the dishevelled family proteins that lead to 
the phosphorylation of β-catenin. On the other hand, the activated dishevelled proteins inhibit 
the activity of the complex axin, and the protein APC that inhibits the β-catenin signalling. 
The last step is critical to stabilize the β-catenin which then diffuses from the cytoplasm to the 
nucleus to interact with T cell factor/lymphoid enhancer binding factor (TCF/LEF) 
transcription factors to promote the effects of Wnts on gene transcription (79) (Figure 2).  
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More interestingly, Wnt signalling pathway was found to affect the osteoblastic expression of 
both OPG and RANKL (80). Another study showed that the activation of Wnt signalling 
pathway increased the bone mass in mice, while β-catenin ablation resulted in marked 
osteoporosis in mice due to inhibited osteoblast proliferation and activity (81, 82). Research 
focused on treatments targeting the Wnt signalling pathway in the management of 
osteoporosis and related bone diseases (83).  
DKK1 is a secreted osteocyte marker acting as an inhibitor to the Wnt signalling pathway 
through binding to LRP5/6 and hence blocking the Wnt effects on osteoblasts decreasing bone 
formation (83). Murine studies showed that DKK1 deletion increased Wnt signalling leading 
to activation of osteoblasts and increased both trabecular and cortical bone mass (84). In a 
human model with thalassemia-induced osteoporosis, Serum DKK1 levels increased in these 
patients and correlated with the disease severity. Furthermore, DKK1 levels were suppressed 
following administration of zoledronic acid suggesting its role in bone formation in addition 
to the already known mechanism in bone resorption (85).  
DKK1 has been also found to have a role in the pathogenesis of post-menopausal and steroid 
induced osteoporosis as well as bone loss in malignant diseases. The implication of DKK1 
levels as a valid bone marker for clinical practice is challenging and needs to be validated due 
to its variable ranges among different enzyme-linked immunosorbent assay (ELISA) methods 
as well as its variability according to physical effort. Also, DKK1 needs to be further tested in 
response to other factors that might affect its levels in blood such as diet and diurnal 
variations (86, 87).   
Sclerostin is another inhibitory protein of bone formation secreted by osteocytes. It is the 
product of the SclerOSTin (SOST) gene located on the chromosome 17 (88). It acts in a 
relatively similar way as DKK1 by blocking the Wnt signalling pathway. Sclerostin bind to 
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LRP5/6 on the osteoblasts preventing the coupling of the Fz/LRP complex and hence 
inhibiting osteoblast activation (89). Mice expressing high levels of human SOST gene 
suffered from osteoporosis (90). While ablation of the SOST gene resulted in increased bone 
mass in another mice model (91).  
Parathyroid home (PTH) is capable of decreasing sclerostin formation that explains the 
mechanism of how PTH is able to stimulate bone formation as part of its mode of action in 
the treatment of bone loss related conditions. This has directed the researchers that targeting 
sclerostin can be a therapeutic option in the treatment of osteoporosis. However, the use of 
serum sclerostin levels for monitoring of osteoporosis and patient compliance to treatment in 
daily practise is still questionable and needs to be validated (92). 
 
Figure (2) showing the mechanism of blockade of the Wnt signaling pathway by osteocytes.  
Osteocytes detect changes in bone morphology through their sensitivity to mechanical forces, 
thereby regulating bone turnover through direct physical contact with osteoblasts. Osteocytes 
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produce OPN, DMP, MEPE, sclerostin and DKK-1. DKK-1 and sclerostin act as inhibitors of 
the Wnt signalling pathway through binding to LRP5 and 6 and hence blocking the Wnt 
effects on osteoblasts decreasing bone formation (83). 
DKK-1: dickkopf-related protein-1; DMP: dentin matrix protein 1; FZ: frizzled protein; LRP 
5/6: low density lipoprotein receptor-related proteins 5/6; MEPE: matrix extracellular 
phosphoglycoprotein; OB: osteoblast; OCY: osteocyte; OPN: osteopontin; SCL: sclerostin. 
2.3.B.  Role of Osteoblasts 
Osteoblasts are specialized stromal cells responsible for the production and mineralization of 
the bone osteoid matrix. Collagen type I is the main protein found in the osteoid matrix 
together with other proteins such as OPN, osteonectin, osteocalcin and bone sialoprotein. 
Furthermore, osteoblasts are the main regulators of osteoclastogenesis by virtue of their 
ability to produce the pro-osteoclastogenic RANKL and IL-6 and the anti-osteoclastogenic 
cytokine OPG. (10) 
Osteoblasts are derived from the pool of mesenchymal stem cells (MSC) that reside on the 
outer surfaces of blood vessels and sinusoids in the bone marrow and periosteum (93). MSC 
tend to migrate to areas of bone formation (94).  
The interaction between Wnt/β-catenin in osteoblasts and osteocytes and other growth factors 
such as transforming growth factor-beta (TGF-β) are critical for osteoblastic differentiation 
and hence bone deposition. The canonical Wnt signaling pathway is now established as the 
main mechanism of osteoblastic differentiation. Wnts are a group of secreted glycoproteins 
essential for embryonic development, determination of cell polarity and cellular 
differentiation (95).  
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These glycoproteins are involved in three signaling pathways of osteoblast maturation; the 
Wnt/β-catenin, the bone morphogenetic proteins (BMP’s) and the transcription factor RUN 
X2 signalling pathways. Wnt/β-catenin, another name for the canonical Wnt signalling 
pathway, starts with binding of the Wnt proteins to the frizzled family of receptors (Sfrps) and 
to LRP5/6 leading to the activation of a part of the Wnt receptor complex called disheveled 
protein and resulting in the inhibition of glycogen synthase kinase-3b (GSK-3). This inhibits 
the phosphorylation and degradation of the β-catenin intracellular signaling molecule leading 
to an increase in the amount of β-catenin in the nucleus, which interacts with transcription 
factors of the TCF/LEF family (96). 
BMPs are a group of growth factors essential for bone homeostasis; they belong to the tumor 
growth factor superfamily. BMPs act by binding to their cell surface receptors resulting in 
activation of the signaling cascade; this interaction initiates the phosphorylation of the Smads 
that are cytoplasmic signaling molecules. These phosphorylated molecules migrate to the cell 
nucleus leading to transcription of BMP response genes inducing bone and cartilage 
formation (97).  
Dkk family members (Dkk1 and Dkk2) and secreted Sfrps are families of extracellular 
proteins that bind to LRP-5/6, resulting in suppression of the Wnt signaling pathway; Sfrps 
bind directly to Wnts and prevent their association with LRP and Fzd receptors (98).  
Whereas, Dkk1 sequesters the LRP5/6 receptors with the transmembrane protein Kremens 
(Kringle-containing protein marking the eye and the nose) and destroys these receptors with 
lysosomal enzymes; hence decreasing their binding to Wnt proteins (99). 
Sclerostin secreted by osteocytes has a negative metabolic effect on osteoblast development 
by blocking the LRP5/6 receptors thus blocking the Wnt signaling pathway (99). 
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Bone formation by osteoblasts is regulated by several factors including hormones, BMP’s, 
growth factors, cells, cytokines, and mechanical forces. Many hormones can affect 
osteoblastic function and differentiation and are essential in certain concentrations for the 
development of the skeleton; these include cortisol, sex hormones such as estrogen and 
testosterone, PTH, calcitriol, calcitonin, growth hormone (GH), thyroid hormones, insulin and 
leptin (100-107).  
Additionally, estrogen is now an established regulator of both the skeletal and immune 
systems (108). The osteoblast-stimulating factor (OSF-1) also known as pleiotrophin (PTN); 
is chemotactic for the osteoprogenitor cells and stimulates mature osteoblast activity (109).  
Fibroblast growth factors (FGFs), platelet-derived growth factor (PDGF), insulin-like growth 
factors (IGFs) and epidermal growth factor all promote the renewal of MSC’s and hence 
stimulate bone formation by osteoblasts (110-113).  
Many inflammatory cells are capable of affecting osteoblastic activity, particularly activated 
T cells exerting their effects directly or indirectly either by cytokines (114) or by their 
interaction with dendritic and B cells (115). 
Bone cells can also regulate osteoblastogenesis. Osteocytes can produce this effect by either 
direct cross talking by gap junctions or via signaling pathways (116).  
Osteoclasts were also found to be able to stimulate alkaline phosphatase (ALP) expression by 
osteoblasts. Mechanical stress is also one of the most powerful inducers to osteoblastic 
differentiation via different signaling pathways and activation of the transcription factor 
RUNX2 (117). 
2.3.C.  Role of Osteoclasts 
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Osteoclasts are multinucleated giant cells specialized in bone resorption, derived from the 
hematopoietic progenitor cells of the monocyte/ macrophage cell lineage in the bone marrow. 
Bone resorption starts with binding of osteoclasts to bone through various mediators including 
integrins, OPN, fibronectin, collagen and bone sialoprotein. The next step involves 
polarization of osteoclasts to form the specialized ruffled border. This step is crucial for 
increasing the surface area for bone resorption. The ruffled border then releases acidic 
hydrogen ions, lysosomal enzymes such as cathepsin K and matrix metalloproteinases 
(MMPs) to dissolve the bone. Tartrate-resistant acid phosphatase (TRAP) further digests the 
bone matrix degradation products (Figure 3) (118) 
 Calcitonin inhibits bone resorption by osteoclasts. The macrophage colony-stimulating factor 
(M-CSF) produced by osteoblasts and the RANKL are the major cytokines stimulating 
osteoclastogenesis. RANKL binds to its receptor RANK on the surface of osteoclast 
precursors to promote their growth and maturation. OPG is the natural decoy receptor of 
RANKL. Osteoblasts and stromal cells primarily produce it. OPG acts by blocking the bond 
between RANKL and its receptor RANK to regulate bone turnover. Other regulators of 
osteoclastogenesis include different cytokines, vitamins, hormones and other molecules (118).   
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Osteoclastogenesis regulators mostly act by regulating the activity of RANKL and its decoy 
OPG as follows: 
 
Figure (3) showing the mechanism of bone turnover and the origin of biochemical markers of 
bone formation and resorption. The bone remodeling cycle indicating the origin of markers of 
bone turnover that express the metabolic activity of either osteoclasts (resorption) or 
osteoblasts (formation) and cell to cell communication between the two. BAP: bone specific 
alkaline phosphatase; CTX: carboxy-terminal cross-linked telopeptides of type 1 collagen; 
DPD: deoxypyridinoline; NTX: amino-terminal cross-linked telopeptide of type 1 collagen; 
OPG: osteoprotegerin; OC: osteocalcin; PICP: procollagen type 1 carboxy-terminal 
propeptide; PINP: procollagen type 1 amino-terminal propeptide; PYD: pyridinoline; RANK: 
receptor activator of nuclear factor kappa B; RANKL: receptor activator of nuclear factor 
kappa B ligand; TRAP: tartrate resistant acid phosphatase. 
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Stimulators of RANKL production are IL-1β, IL-6, IL-7, TNF-α, 1, 25-
dihydroxycholecalciferol (1.25(OH)2D3); PTH and glucocorticoids (GCs); activated T cells, 
and leptin. On the other hand, RANKL inhibitors include interferon-γ and OPG stimulators 
such as lipopolysaccharide (LPS) released by fibroblasts; estrogens and tumor growth factor 
(TGF). Osteoclast precursor cells migrate to the endosteal and periosteal surfaces of bones to 
proliferate and differentiate into osteoclasts. Three signal pathways may be involved in 
osteoclastic development; including the cyclic adenosine monophosphate (cAMP) mediated 
pathway, the glycoprotein130 (gp130) mediated pathway and the 1.25(OH)2D3 receptor 
mediated pathway (119).  
Osteoblasts and marrow stromal cells also play a critical role in the regulation of osteoclast 
activity and differentiation either by direct cell-cell contact or through their ability to express 
the main inducers of osteoclastogenesis. Osteoclasts are principally activated by the canonical 
pathway, which is mediated mainly by RANKL and M-CSF. RANKL is a member of the 
TNF superfamily; it binds to its receptor activator of nuclear factor kappa B (RANK) on the 
surface of osteoclasts inducing bone resorption. RANKL is essential for normal bone 
development and its deficiency results in osteopetrosis due in part to a breakdown in the 
crosstalk between osteoblasts and osteoclasts. Under normal conditions, a balance between 
RANKL and its antagonist (OPG) maintain bone homeostasis. OPG is a soluble decoy 
receptor of RANKL and is becoming the main physiological inhibitor of osteoclastogenesis. It 
acts by competing with RANKL to bind with RANK thus blocking the RANK-RANKL 
interaction (120). 
RANK-RANKL interaction recruits TNF receptor-associated factor (TRAF) proteins which in 
turn activates nuclear factor of kappa B (NF-кB) and nuclear factor of activated T cells, 
cytoplasmic, calcineurin-dependent 1 (NFATc1) leading to an increase in intracellular 
calcium (Ca2+) and tyrosine phosphorylation (120).  
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RANKL activates the immuno-receptor tyrosine-based activation motif (ITAM) bearing co-
stimulatory molecules DNAX activation protein 12 (DAP12) and Fc receptor gamma chain 
(FcRγ). Deficiency of DAP12 & FcRγ in mice led to a marked impairment of 
osteoclastogenesis, resulting in severe osteopetrosis (121). RANKL is responsible for 
formation of mature osteoclasts, stimulating their bone resorption activity and suppressing 
their apoptosis. (122).  
M-CSF is a cytokine involved in the proliferation and differentiation of osteoclasts. M-CSF 
binds to its osteoclast transmembrane receptor, colony-stimulating factor 1 receptor (c-fms), 
leading to the activation of spleen tyrosine kinase (Syk) and osteoclast activation (123).  
Additionally two other inducers of osteoclastogenesis are known; osteoclast-associated 
receptor (OSCAR) and triggering receptor expressed on myeloid cells 2 (TREM-2). OSCAR 
is a collagen receptor involved in osteoblast-osteoclast interaction and is critical for the 
formation and function of osteoclasts. RANKL increases the expression of OSCAR which 
acts as a co-stimulatory molecule of the FcRγ-associated pathway and by binding to specific 
motifs involved in osteoclast maturation, results in enhanced osteoclastogenesis (124).  
TREM-2 plays a central role in regulating the function of myeloid cells; it is expressed on 
macrophages, microglia and pre-osteoclasts and has been found to be essential for 
osteoclastogenesis (125).  
New evidence has revealed that osteoclastogenesis can also occur in a RANKL independent 
manner, referred to as non-canonical osteoclastogenesis. Five of these RANKL substitutes 
have recently been described which are capable of osteoclast differentiation and activation; a 
proliferation inducing ligand (APRIL); B cell activating factor (BAFF); nerve growth factor 
(NGF) and insulin like growth factor (IGF) I and II, although their role in pathological bone 
resorption has yet to be established. BAFF also known as B lymphocyte stimulator (BLyS) is 
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a protein that belongs to the tumor necrosis factor superfamily, which is expressed on a 
variety of cells predominantly leukocytes. BAFF is a potent activator of B cell proliferation 
and differentiation and an essential step in their maturation (126).  
Other well-documented surrogates include TNF-α (127), LIGHT, (homologous to 
lymphotoxins exhibiting inducible expression and competing with herpes simplex virus 
glycoprotein D for herpes virus entry mediator) HVEM, is a receptor expressed by T 
lymphocytes (TNFSF14), IL-6 and TGF-β (128-130).  
Additionally, it has been demonstrated that β-catenin and Wnt signaling can inhibit osteoclast 
differentiation; however, its negative regulatory role on osteoclasts is due to modulation of 
RANKL/OPG ratio in the osteoblasts and osteocytes (131).  
Another critical modulator of osteoclastogenesis is the large zinc finger protein ZAS3 
encoded by the HIVEP3 gene. ZAS3 has been shown to both inhibit osteoblast differentiation 
and stimulate osteoclastic activity and differentiation (132). 
Osteoclasts express a specific marker named TRAP; its role is still unknown but its deficiency 
in mice leads to decreased osteoclastic activity and osteopetrosis (133). It is hypothesized that 
TRAP is capable of dephosphorylating OPN and bone sialoprotein and the production of 
oxygen radicals leading to osteoclast differentiation. Integrins expressed by osteoclasts are 
now confirmed to be essential for bone resorption of calcified matrix (134).  
Resorption of bone starts with osteoclastic recognition of the target matrix, followed by 
cellular morphological changes including polarization and organisation of podosomes forming 
a tight sealing ring. Podosomes are formed of a shell of vinculin, talin, actinin, fimbrin, 
gelsolin and vimentin and contain a cytoskeleton core of F-actin. Adherence of osteoclasts to 
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the bone surface is followed by secretion of vesicles containing proteinases leading to bone 
resorption (135). 
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CHAPTER 3. BONE LOSS IN RA 
Bone loss resulting from RA has been extensively studied over the last years. However, its 
mechanism is still poorly understood. Moreover, trials to prevent its progression are still 
unsatisfactory as they only aim to treat it rather than prevent it. It has been well established 
that RA leads to increased bone resorption, but it has more recently been demonstrated that 
there is also substantially reduced bone formation.  
3.1. The role of Cytokines  
The increased bone resorption in RA has been explained by the increased osteoclastic activity 
under the effect of various inflammatory cytokines. Both the canonical and non-canonical 
osteoclastogenesis pathways are thought to play a role in the increased bone turnover in RA. 
Overproduction of RANKL by a wide range of cells, including osteoblasts, endothelial cells, 
T cells and B cells is a characteristic feature of RA (136). 
RANKL binds to its receptor RANK on the osteoclasts activating their proliferation and 
stimulating osteoclastogenesis. Human studies revealed that RANKL play a crucial role in the 
pathogenesis of bony erosions and peri-articular osteoporosis in RA. Synovial levels of 
RANKL positively correlate with RA disease activity and bone resorption in RA patients. The 
source of RANKL in synovium is thought to be mainly due to synovial fibroblasts and T cells 
(136).  
Moreover, higher serum levels of RANKL were found in patients with high bone resorption 
markers and low bone mineral density of hips.  Also, levels of serum RANKL was able to 
predict joint destruction (137).  
In another study, it was suggested that both increased RANKL and decreased OPG in 
peripheral blood is the main mechanism of osteoporosis in RA (138) 
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Interestingly, many other cytokines such as TNF-α, IL-1, IL-4, IL-6, IL-7, IL-10, IL-11, IL-
12, IL-13, IL-17, IL-18, IFN-γ and GM-CSF have variable effects on bone turnover and act 
via different mechanisms. TNF-α is a key player in RA osteoclastogenesis by both RANKL-
dependent and independent mechanisms. TNF-α blocking agents have recently been proven to 
reduce the local and generalized bone loss in RA (139).  
Moreover, TNF-α is thought to inhibit bone formation by increasing Dkk-1 expression, 
thereby inhibiting bone formation by blocking the Wnt signaling pathway and leading to 
apoptosis of osteoblasts through induction of the Fas-FasL system (140).  
IL-1 is capable of increasing bone resorption by increasing the release of MMPs and other 
degradative products and by promoting osteoclast differentiation and activation (141). In 
addition to their ability to stimulate bone cells to secrete RANKL, IL-6 and IL-11 can also 
induce bone loss by a RANKL-independent mechanism (142).  
IL-6 induces osteoclastogenesis via the activation of TH cells to secrete RANKL and IL-17 
(143). IL-17 is a major inducer of osteoclastic activity in inflammatory arthritis secreted by 
TH17 cells (144). 
IFN-γ functions as a modulator of bone turnover as it has a dual effect on osteoclasts; IFN-γ 
can block the formation of osteoclasts directly by inhibiting the differentiation of osteoclast 
precursors, but can also stimulate osteoclastogenesis indirectly by activating the T cells to 
produce RANKL and TNF-α, however, the end result is bone loss (145). 
In contrast other cytokines, such as IL-4, IL-10, IL-12, IL-13, IL-18, IFN-γ and GM-CSF are 
protective of bone by either inhibiting osteoclastogenesis, or stimulating bone formation by 
osteoblasts. As explained earlier, IL-4 inhibits the osteoclastogenic cytokines TNF-α, IL-1, 
IL-6, and IL-11 in RA, additionally IL-4 and IL-13 can stimulate osteoblasts and suppress 
prostaglandin E2 (PGE2) synthesis (146).  
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IL-10 is secreted by many cells, primarily monocytes and to a lesser extent by lymphocytes 
and is known to have an immunoregulatory effect in RA. It is presumed that it may have an 
anabolic effect on bone turnover by decreasing the production of TNF-α, IL-1, GM-CSF and 
the expression of HLA class II by monocytes (147).  
Moreover, IL-10 is able to suppress the inflammatory effects of TH17 cells and promote the 
immunoregulatory Treg formation in RA patients (148). GM-CSF has been thought to inhibit 
osteoclast formation and activity; nevertheless, in vivo studies are contradictory (149).  
IFN-γ has been found to play a pivotal role in bone formation in vivo. IFN-γ knockout mice 
developed osteoporosis and suffered from a marked decrease in both osteoblast and osteoclast 
numbers (150).  
IL-12 is capable of inhibiting osteoclastogenesis through its ability to stimulate immune cells 
particularly T cells and dendritic cells to secrete IFN-γ (151).  
IL-18 is capable of inhibiting osteoclast formation by the ability to stimulate the release of 
GM-CSF by TH cells (152). Additionally, it has been recently found to inhibit TNF-α 
mediated osteoclastogenesis in vivo by a T cell independent mechanism (153).  
RA patients showed increased OSCAR expression in peripheral blood monocytes (PBMC’s) 
compared to healthy controls leading to enhanced differentiation of these monocytes into 
osteoclasts. Additionally, there was a positive correlation between OSCAR expression and 
disease activity suggesting an increased activity of osteoclastogenesis co-stimulatory signals 
in RA (154). 
On the other hand, decreased bone formation in RA has been suggested to be mainly due to 
increased expression of Dkk-1. This causes blocking of the LRP-5 and LRP-6 receptors on the 
surface of osteoblasts, thereby inhibiting the Wnt signaling pathway (98). 
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In a mouse model of RA, inhibition of Dkk-1 by a neutralizing antibody led to a reversal of 
bone erosion and resulted in new bone formation but no change in markers of inflammation 
was noted (98).  
IL-1, TNF-α and IFN gamma are also capable of suppression of bone formation by inhibiting 
osteoblast collagen formation (155). LIGHT also increases in RA patients suggesting that it 
may play a role in the pathogenesis of RA localized and systemic bone loss (156).  
3.2. The role of T cells  
T cells are involved in most of the autoimmune diseases including RA. For many decades RA 
was considered to be a T-cell dependent disease as evidenced by large numbers of CD4+ T 
cells infiltrating the synovial tissues of RA patients (157). T cells are activated by antigen 
presenting cells via MHC class II and trigger the immune response by secreting a wide range 
of inflammatory cytokines and thereby activating the whole immune system. T cells are a 
major source of RANKL and TNF-α and are therefore capable of regulating bone turnover in 
RA by activating osteoclastogenesis (158).   
On the other hand, T cells may have an inhibitory effect on osteoclastogenesis by increasing 
OPG production by a mechanism that involves increased vitamin D3 activity (159).  
TH1 cells produce IFN- γ and IL-2 and activate the cell-mediated immune response, whereas 
the TH2 subset produces IL-4 and stimulates humoral immunity (160). Imbalance between 
these two subsets results in inappropriate production of their respective cytokines and was 
found to correlate with disease activity (161).  
Despite the inflammatory effects of T cells in RA, there is also a protective subset named 
regulatory T cells or Tregs that have anti-inflammatory effects. They act by regulating both 
TH1 and TH2 cells (162). However, in RA it is still not established if there is a defect in the 
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number or function of these Tregs. Interestingly, TNF-α has been found to suppress the Tregs 
response and this might be another mechanism by which TNF blocking agents act to control 
the disease activity in RA (163). Notably, both Tregs and CD8+ T cells have anti-
osteoclastogenic effects (164).  
A third type of helper T cells, the TH17 cells, has recently also been implicated in RA bone 
loss. TH17 cells secrete IL-17 that is capable of inducing osteoclastogenesis resulting in 
damage to cartilage and bones (165). T cells are also capable of interacting either directly 
with osteoblasts and osteoclasts or indirectly via dendritic cells and B cells (166).  
3.3. Effects of anti-rheumatic medication 
RA predisposes to both localized and generalized bone loss and increased fracture risk. This 
bone loss is multi factorial. Some of the drugs used to treat the condition can themselves 
cause bone loss such as glucocorticoid. Corticosteroids have been considered the cornerstone 
of the treatment of RA and most of the autoimmune diseases. Long-term use of 
corticosteroids is an established cause of generalized bone loss in RA. Nowadays, 
corticosteroid use has been minimized with the tendency to more aggressive use of DMARDs 
and the development of biological therapy (167). 
RA can be significantly disabling leading to marked reduction in mobility and even loss of the 
patient’s ability to feed themselves which results in disuse atrophy of the muscles and a 
consequent reduction in bone mass. Muscle atrophy and joint destruction will also increase 
falls risk. Inflammation and autoimmunity are the main mechanisms of osteoporosis in RA. 
Chronic systemic inflammation leads to generalized osteoporosis and localized inflammation 
with regional osteoporosis. It was therefore presumed that treating inflammation would be 
sufficient to stop bone loss in RA, but this view is now thought too simplistic (167). 
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With the introduction of biological drugs, the rate of generalized and localized bone loss has 
been markedly reduced specially with the use of TNF blockers that are effective in controlling 
the disease activity and inhibiting osteoclastogenesis directly (168).  
In a study of 102 RA patients, the use of infliximab for 1 year resulted in a stable BMD of the 
spine and hip but decreased BMD of the wrists. These results were supplemented with a 
significant decrease of serum levels of CTX and RANKL without a significant change in 
osteocalcin and osteoprotegerin (OPG) (168).  
Another study showed prevention of bone loss in the spine and hips after 1 year of treatment 
with adalimumab (169). More recently, treatment for more than 3 years with infliximab 
resulted in an increase of 2.55% of the spine BMD and a slight decrease of -0.12% of the hip 
BMD (170).  
Moreover, Schett et al showed that TNF blockers are able to decrease bone resorption induced 
by RANKL and to increase bone formation by reducing the levels of the Wnt signaling 
pathway inhibitor DKK1 (171). 
3.4. The role of B cells  
This will be discussed in details in chapter 4.
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CHAPTER 4. B CELLS 
4.1. B cells in RA 
B cell development 
B cells are formed in the bone marrow where hematopoietic stem cells differentiate initially 
through the pro-B to pre-B cell stage and later transform into immature B cells then complete 
their maturation in the spleen through three developmental stages; transitional type 1; type 2; 
then mature B cells (172). Mature B cells then differentiate into antibody secreting plasma 
cells, also known as effector B cells.  B cells are subdivided into two main types; B1 cells are 
characterized by expressing mainly immunoglobulin M (IgM) and present in low numbers in 
the lymph nodes and spleen and more abundantly in the peritoneal and pleural cavities; while 
B2 cells are present in the peripheral circulation and the bone marrow. Recent studies also 
indicate the coexistence of a distinct B cell subset called B regulatory cells (Bregs), they can 
down-regulate the immune system and consequently are protective against autoimmune 
diseases (173).  
 
Regulation of B cell function 
B cell regulation in physiological and pathological conditions is a complex mechanism under 
the influence of many cells. T cells are thought to play a major role in the activation of B cells 
by two mechanisms. The first through direct cell to cell contact in which the primary signal is 
the B cell receptor (BCR) binding to antigen and then presenting the antigen via MHC class II 
to the T cell receptor (TCR) on the surface of T cells, these in turn provide the B cells with the 
secondary signal via co-stimulatory binding of CD40L on T cells to CD40 on B cells to 
complete the B cell activation. The antigen-presenting function of B-lymphocytes is thought 
to be relevant mainly in the late phase of infections and in secondary immune responses, due 
to the low number of clonogenic antigen-specific B cells that are present in homeostatic 
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conditions. The second mechanism by which T cells regulate B cell activity is by the release 
of lymphokines acting as growth factors for B cells (174, 175).  
B cells have multiple functions in the pathogenesis of RA; they secrete autoantibodies such as 
rheumatoid factor (RF) and the highly specific anti-cyclic citrullinated peptides antibodies 
(ACPA). RFs are antibodies directed against the Fc portion of IgG, thus leading to formation 
of immune complexes. 
 Additionally, B cells are involved in processing and presentation of autoantigen and 
activation of T cells (176).  B cells are also able to secrete different pro-inflammatory 
cytokines and promote differentiation of follicular dendritic cells in secondary lymphoid 
organs (177).  
In RA, effector B cells for example secrete TNFα, IL-6, IL-12 and IFNγ (178-180). TNFα 
plays a critical role in the pathogenesis of RA and its inhibition is currently one of the most 
successful treatments available for this disease. TNFα has a wide variety of functions; 
including complement activation and stimulation of synovial fibroblasts and macrophages to 
secrete pro-inflammatory cytokines such as IL-6 (181), prostaglandin E2 (PGE2) and matrix 
metalloproteinases (MMPs) (182), inducing inflammation, cartilage and bone damage, in 
addition to transforming growth factor-beta (TGF-β), granulocyte/monocyte-colony 
stimulating factor (GM-CSF) and other growth factors that induce neovascularization and 
promote pannus formation characteristic of RA.  
IL-6, another major pro-inflammatory mediator secreted by many cells including B cells, has 
a pivotal role in RA. IL-6 shares many effects with TNF-α, including stimulation of 
neovascularization, promotion of acute phase response, infiltration of inflammatory cells, 
synovial hyperplasia and damage to cartilage and bone (183).  
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B cells also produce IL-12 that stimulates the release of IFN-γ by T lymphocytes and natural 
killer (NK) cells and activates the T cell immune response leading to cellular infiltration, 
inflammation, cartilage and bone destruction (184). 
IL-12 levels in serum and in synovium correlate with disease activity in RA revealing the 
definite role of this mediator in RA pathology (187). On the other hand, IFN-γ is found to 
have a dual action on chronic inflammation as it is capable of both inducing chronic 
inflammation and regulating the immune responses (185). 
Interestingly, B cells can also secrete anti-inflammatory mediators such as IL-4 and IL-13. IL-
4 inhibits the activity of pro-inflammatory TNF-α, IL-1, IL- 11 and IL-6, in addition to up-
regulating the inhibitory mediator IL-1 receptor antagonist in RA (186).  IL-13, similar to IL-
4, is capable of suppressing the inflammation in RA (187). 
Recently, a new subtype of regulatory B-lymphocytes known as Bregs has been reported to 
regulate the immune system by producing the inhibitory cytokine IL-10. IL-10 has pleiotropic 
effects in immuno-regulation and inflammation. It down-regulates the proliferative responses 
and pro-inflammatory cytokine production by T helper cells, MHC class II antigen expression 
and co-stimulatory molecules on macrophages. Moreover Bregs can promote differentiation 
of T cells into regulatory IL-10 producing T cells and hence permit vigorous immune 
suppression (188).  
Despite these anti-inflammatory effects, IL-10 has also been found to be an activator of B cell 
proliferation and antibody production. Moreover, Bregs were found to have other potential 
inhibitory mechanisms including secretion of the inhibitory cytokine TGF-β, interactions with 
Tregs and production of regulatory antibodies (189). 
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4.2. B cells and bone 
Crosstalk between bone cells and B-lymphocytes is bidirectional, in that bone cells can 
regulate the development and maturation of B cells and B cells can regulate both osteoblastic 
and osteoclastic activity. The mechanisms that underlie these interactions are only partially 
understood, as is the precise role of B cells in bone turnover.  
B cells have the capacity to both stimulate and inhibit bone turnover by direct and indirect 
mechanisms. Additionally, B cells appear to be capable of affecting bone formation and 
resorption under different physiological and pathological conditions.  
4.2.A. B cells and RANK-RANKL-OPG system 
Mature B cells secrete a number of different cytokines including RANKL, the key cytokine of 
bone breakdown and its inhibitor OPG, this mechanism works correctly under normal 
physiological conditions.  
The bone protective role of B cells is mainly achieved through OPG production. In RA, this 
balance is disturbed by the increased B and T cell activity, leading to a marked increase in the 
production of RANKL by both cells in addition to other pro-inflammatory cytokines such as 
TNF-α. This shifts the bone turnover balance towards bone loss.   
In an RA human model, the cytokine messenger-RNA expression by CD4 and CD8 T cells, B 
cells, macrophages and neutrophils were evaluated to identify the source of RANKL in the 
synovial fluid and peripheral blood. They found that B cells were the major source of 
RANKL in RA (190).  
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4.2.B. B cells and cytokines 
In addition to the bone specific cytokines mentioned above, other cytokines secreted by B 
cells can affect bone turnover positively or negatively. TNF-α, IL-6 and IFN-γ for example 
are pro-osteoclastogenic while TGF-β, IL-4, IL-10, IL-12 and IL-13 promote bone formation 
(191). 
4.2.C. B cells and osteoclasts  
 B cells are able to stimulate, both directly and indirectly, the conversion of monocytes to 
active osteoclasts. More interestingly, studies have shown that osteoclasts and B-lymphocytes 
may both arise from pro-B cells. Pro-B cells from osteopetrotic mice for example expressed 
markers from the B-lymphoid (CD19, CD43 and CD5) and the myeloid (F4/80) lineages. 
When stimulated with RANKL and M-CSF, these cells could grow into osteoclasts, while 
they were able to differentiate into B cells when stimulated by IL-7 (192).  
Furthermore, B cells have been found capable of transforming into osteoclasts. Recently it has 
been found in a murine model that a subset of CD19+ B lymphocytes named B1 cells, can 
differentiate into mononuclear phagocytes forming osteoclast-like multinucleated giant cells. 
These cells express RANK and the macrophage colony-stimulating factor receptor (M-CSFR) 
and when stimulated with RANKL and M-CSF, these cells transformed into tartrate resistant 
acid phosphatase (TRAP) positive osteoclasts and have osteoclastic properties leading to 
formation of lacunae when allowed to grow on a calcium phosphate analog. Deficiency of B1 
cells resulted in failure of bone resorption. Moreover, reconstitution of these cells resulted in 
regaining of osteoclastogenesis (193).  
In a human model of multiple myeloma, nuclei of malignant B cells were found in osteoclasts 
that might suggest that myeloma cells can differentiate into osteoclasts explaining the 
mechanism of increased osteoclastogenesis in these patients (194).  
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Additionally, deletion of any of the transcription factors Ebf-1, paired box protein 5 (Pax5) 
and PU.1, which are essential for B cell development, resulted in marked changes in bone 
turnover in vivo. The transcription factor PU.1 is a protein encoded by the SPI1 gene, it is a 
specific factor for gene expression during myeloid and B-lymphoid cell development (195, 
196).  
Levels of PU.1 positively correlated with osteoclastic differentiation in vitro and deletion of 
PU.1 in vivo led to the arrest of osteoclast and macrophage differentiation. More recently, 
reduction in PU.1 activity resulted in impaired B-cell development (195, 196).  
Ebf-1 deficiency in mice, another key regulator of B cell development, led to increased 
osteoclastogenesis and impaired B cell development, but despite this there was an overall 
increased bone mass. The authors explained that the mechanism of increased bone formation 
was related to increased numbers and activity of osteoblasts. However, there is a hypothesis 
that B cell depletion may share in this anabolic effect on bone (197).  
4.2.D. B cells and estrogen 
Estrogens are known to be important regulators of both the skeletal and immune systems. 
Estrogen is able to inhibit the autoimmune disturbances in RA evidenced by decreased disease 
activity during pregnancy and a flare up after delivery. Accordingly, estrogens are capable of 
affecting the disease course and bone density in RA. Replacing estrogen deficiency is an 
established treatment for postmenopausal osteoporosis.  
Estrogen has the ability to both inhibit the cellular immune response by T cells and stimulate 
the humoral response by B cells. In fact in postmenopausal women, it has been found that 
down regulation of estrogen receptor 1 (ESR1) and mitogen activated protein kinase 3 
(MAPK3) in B cells, regulates secretion of factors leading to either increased 
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osteoclastogenesis or decreased osteoblastogenesis, while estrogen deficiency stimulates the 
hematopoietic synthesis of B cells (198).  
Indeed, the increased osteoclastogenesis resulting from estrogen deficiency might be partly 
due to increased B cell proliferation and activity. The increased B cell numbers may either 
directly affect bone turnover, if B cell precursors are actually able to differentiate into active 
osteoclasts, or act indirectly through the release of different cytokines (199).   
Mouse studies showed that B cells are able to stimulate the conversion of monocytes to active 
osteoclasts both indirectly through the production of RANKL and M-CSF and directly 
through their proximity in the bone marrow. However, the mechanisms of direct stimulation is 
not clearly understood (200). Other studies suggested that osteoclasts and B-lymphocytes 
might both arise from pro-B cells (201).  
Pro-B cells from osteopetrotic mice for example expressed markers from the B-lymphoid 
(CD19, CD43 and CD5) and the myeloid (F4/80) lineages. When stimulated with RANKL 
and M-CSF these cells could differentiate into osteoclasts, while they were able to 
differentiate into B cells when stimulated by IL-7 (202).  
In a different study, depletion of a subset of B cells named B-1 cells in mice with induced 
periodontitis resulted in impaired osteoclastogenesis and bone resorption. However, 
reconstitution of B-1 cells in these mice led to increased bone resorption to near normal 
values. This subtype of B cells express RANK and M-CSFR. Stimulation of B cells with 
RANKL and M-CSF transformed these cells into functional TRAP positive osteoclast-like 
multi-nucleated giant cells (203).  
These cells express RANK and the macrophage colony-stimulating factor receptor (M-CSFR) 
and when stimulated with RANKL and M-CSF, these cells differentiated into tartrate resistant 
acid phosphatase (TRAP) positive osteoclasts, which formed lacunae when allowed to grow 
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on a calcium phosphate analog. Deficiency of B1 cells resulted in failure of bone resorption in 
these mice (203). Moreover, reconstitution of these cells resulted in restoration of 
osteoclastogenesis.  
Other mice studies showed that deletion of any of the transcription factors Ebf-1, paired box 
protein 5 (Pax5) and PU.1, which are essential for B cell development, resulted in marked 
changes in bone turnover. Expression of Pax5, for example, is restricted to B-lymphocytes 
(203).  
In Pax5 depleted mice, B cell development was stopped at the pro-B cell stage. These mice 
developed severe osteoporosis, with 60% bone loss compared to baseline. The diminished 
bone mass was explained by doubling of the numbers of osteoclasts together with a mild 
reduction in osteoblast numbers. The result was a marked decrease in bone volume, 
specifically trabecular bone in tibiae and femur. However, the authors suggested that the bone 
loss was not due to B cell depletion, because a similar effect could not be found in other 
strains of B cell-deficient mice (203).  
The transcription factor PU.1 is a protein encoded by the SPI1 gene; it is a specific factor for 
gene expression during myeloid and B-lymphoid cell development. Levels of PU.1 positively 
correlated with osteoclastic differentiation in vitro and deletion of PU.1 in mice led to the 
arrest of osteoclast and macrophage differentiation. More recently, reduction in PU.1 activity 
resulted in impaired B-cell development (204, 205).  
Ebf-1 deficiency in mice, another key regulator of B cell development, led to increased 
osteoclastogenesis and impaired B cell development, but despite this there was an overall 
increased bone mass. The authors explained that the mechanism of increased bone formation 
was the concomitant increase in the numbers and activity of osteoblasts. However, there is a 
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hypothesis that B cell depletion may share in this anabolic effect on bone (197). These data 
support the close connection between B cells and osteoclasts development. 
In another murine model, quantification of OPG in the bone marrow using ELISA and real 
time PCR showed that B cells are responsible for the production of 64% of total BM OPG. In 
the same study, depletion of B cells in these mice developed osteoporosis due to the 
deficiency of OPG in the bone marrow. Moreover, reconstitution of B cells in these mice 
reversed the bone loss (206).  
In humans with multiple myeloma, examining the bone sections revealed the presence of 
osteoclasts which contain transcriptionally active nuclei of malignant myeloma-B cells. These 
hybrid cells are thought to either develop from the fusion of osteoclasts and malignant B cells 
or due to the conversion of the malignant B cells into functioning osteoclasts in multiple 
myeloma patients. This explains the marked increase of osteoclastogenesis in these patients 
(190). Whether this mechanism is found only in malignant B cells or stimulated healthy B 
cells are capable of attaining the same capabilities needs to be further investigated.  
In summary, literature review confirms the presence of a close interaction between B cells and 
bone cells. However, the results are conflicting. Additionally, there is a clear lack of evidence 
of these effects in humans and the underlying mechanisms behind them.   
4.3. B cell depletion in RA osteoporosis  
In one study, 31 active RA patients with long-standing disease treated with rituximab were 
assessed at baseline and after 12 weeks using DAS 28 & HAQ as well as laboratory 
parameters using ESR, CRP, RF levels in addition to flow cytometry of CD19, CD27, CD38 
and CD45 in peripheral blood and bone marrow. Results showed a significant improvement of 
disease activity indices and RF concentrations. RTX markedly reduced CD19+ B cells in 
peripheral blood and to a lesser extent in the bone marrow.   Additionally, it was found that 
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there was a significant decrease in CD19+CD27+ memory B cells in both compartments in 
patients who had a good response to RTX treatment compared to increased or stable levels of 
memory cells in the ones who did not have a favorable clinical response (207).     
In another study, 13 active RA patients were assessed every 3 months over 1 year post RTX 
treatment. Samples were tested for Type I C-terminal collagen propeptide (CICP) and tartrate 
resistant acid phosphatase isoform 5b (TRAP 5b), Osteoprotegerin (OPG) and total sRANKL, 
Bone-specific alkaline phosphatase. The authors found no significant effect of RTX on the 
measured biomarkers. However, the sample was small and there were no bone mineral density 
measurements to support the results (208). 
28 patients with active RA treated with RTX were assessed by X-ray of hands and feet at 
baseline and after 1 year of treatment using the Sharp–van der Heijde score (SHS), 
immunohistochemistry and immunofluorescence of synovial biopsies, serum levels of bone 
markers including OPG, RANKL, osteocalcin and cross-linked N-telopeptides of type I 
collagen (NTx) were measured by ELISA obtained at baseline and 16 weeks after treatment. 
There was an improvement in the mean (SD) of SHS of 1.4 (10.0) after 1 year (209).  
After 16 weeks of treatment, there was a decrease of 99% in RANK-positive osteoclast 
precursors and a decrease of 37% of RANKL expression in the synovium associated with 
25% reduction in synovial OPG expression. In serum, both OPG and RANKL levels were 
significantly reduced by 20% and 40% respectively after 16 weeks, but the OPG/RANKL 
ratio increased by 157% (209).  
Additionally, osteocalcin levels increased but not significantly while NTx concentrations did 
not change. It was concluded from this study that B cell depletion reduces the synovial 
osteoclast precursors and RANKL expression and increases bone formation by increasing the 
OPG/RANKL ratio in serum (210).  
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CHAPTER 5. BONE TURNOVER ASSESSMENT 
The identification of cellular components of bone matrix led to development of specific 
markers to aid the management of osteoporosis. Bone biomarkers are formation markers, 
resorption markers or the newly discovered osteocyte markers. Though, this distinction is not 
clear cut as some markers may represent both processes e.g. osteocalcin. Some of these 
biomarkers are now reliable, sensitive, specific and cost-effective methods to detect bone 
turnover. These markers have been used in research for a long time. Currently, there are great 
efforts to improve their accuracy to allow them to be used in clinical practice. During recent 
years, methods of detection of these markers have greatly improved and become reliable in 
measuring these markers.  
These bone markers can be found in blood or urine. Under physiological conditions, bone-
remodeling processes are coupled. Measurement of a combination of formation and resorption 
markers is crucial to be able to determine the metabolic activity of bone cells. However, these 
markers are not disease specific, yet they can give a good idea of what is going on in bone 
turnover processes (211). 
Unfortunately, some bone markers are really not bone-specific and can change in non-skeletal 
diseases as well. Accordingly, translation of their levels should be with great caution in 
coordination with the clinical picture of the patient (211). 
5.1. MARKERS OF BONE FORMATION 
Markers of bone formation are either by-products of active developing osteoblasts or enzymes 
generated by osteoblasts during their activity. The most popular markers of bone formation 
nowadays are serum bone specific alkaline phosphatase (BAP), osteocalcin and the carboxy- 
and amino-terminal propeptides of type 1 collagen (P1CP, P1NP). BAP is a component of the 
cellular membrane of osteoblasts. During bone mineralization, BAP is cleaved by 
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phospholipase and enters the circulation. BAP activity and concentration can both be 
measured in serum with almost similar results (212).  
Osteocalcin is the second most abundant protein in the bone matrix after collagen. It is 
produced by osteoblasts during bone deposition and can also be found in the serum that can 
be measured. Interestingly, osteocalcin is also released during bone resorption and is therefore 
considered a marker of bone turnover rather than pure marker of bone formation. The half-life 
of osteocalcin in serum is very short lasting about few minutes; then it is rapidly cleared in the 
urine (213, 214).  
Type 1 collagen is manufactured in bone, skin, dentin, cornea, fibrocartilage and tendons 
(211). It is synthesized by fibroblasts and osteoblasts from pro-collagen. This collagen 
derivative is cleaved by proteases. The peptides released by the cleavage of pro-collagen are 
P1CP and P1NP as the C-terminal or the N-terminal propeptides respectively. Both markers 
are derivatives of collagen formation; hence they can be used as markers of bone formation. 
Both peptides are metabolized by the liver. In clinical trials, P1NP is more commonly used 
than P1CP (215-217). 
5.2. MARKERS OF BONE RESORPTION 
On the contrary, all bone resorption markers are derived from type I collagen degradation 
except TRAP. The collagen triple helix is stabilized by cross-links that bind the neighboring 
collagen molecules. Two major cross-links are present: pyridinoline (PYD) and 
deoxypyridinoline (DPD). They are formed extra-cellularly after collagen is deposited in bone 
matrix. During bone collagen degradation, these cross-links are released into the circulation 
and are excreted in the urine. DPD is more specific for bone than PYD, which is also found in 
type II collagen (218).  
 
 53 
These cross-links are released in the circulation in the form of CTX and NTX. Both CTX and 
NTX are produced by cathepsin K activity. Both markers can be detected by specific 
immunoassays. Though, CTX is more widely used. Increase in serum levels of CTX and NTX 
indicate acceleration of bone resorption rate (214). 
TRAP is an acid phosphatase expressed by different tissues and cells in the body. It is cleaved 
by proteases into two subunits 5a and 5b. TRAP5a is expressed by macrophages and TRAP5b 
is present in the ruffled border of osteoclasts. Activated osteoclasts secrete TRAP5b, which 
leads to degradation of type 1 collagen (219). 
 The OPG/ RANKL system is a major determinant of bone turnover. RANKL is produced by 
osteoblasts in response to signals, which induce osteoclastogenesis, such as pro-inflammatory 
cytokines (220).  
RANKL binds to RANK receptors found on the surface of osteoclasts leading to their 
activation and proliferation. On the other hand, OPG, the RANKL decoy receptor, is also 
produced by osteoblasts. However, it inhibits osteoclastogenesis by binding to RANKL 
preventing its effects on osteoclasts. Laboratory methods used to measure OPG and RANKL 
are available but their results need to be validated before they can be used in clinical practice 
(221). 
5.3. OSTEOCYTE MARKERS 
Osteocytes play a key role in the regulation of bone turnover. Osteocytes are fully 
differentiated osteoblasts and lie in lacunae in the mineralized matrix and osteoid tissue of 
bone (222).  
Osteocytes are capable of regulating their own proliferation through their ability to control the 
differentiation of their derivative osteoblasts; however, the exact mechanism of 
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osteocytogenesis is still largely unknown. Osteocytes are able to detect changes in bone 
morphology, particularly micro-fractures through their sensitivity to mechanical forces, acting 
like bone mechanoreceptors (223), thereby regulating bone turnover through direct physical 
contact with other bone cells. In vivo studies have shown that osteocytes directly inhibit the 
activity of osteoclasts and stimulate the activity of osteoblasts, their depletion therefore results 
in profound loss of trabecular bone mass (224-226). 
Moreover, the site of osteocyte apoptosis directs osteoclasts recruitment. On the other hand, 
increased osteocyte activity resulted in increased bone resorption by osteoclasts through the 
enhanced expression of osteopontin by active osteocytes. Additionally, osteocytes produce 
various factors, which affect bone balance such as DMP1, MEPE, sclerostin and DKK1. 
Research has focused on the Wnt signaling pathway in the management of osteoporosis and 
related bone diseases. DKK1 is a secreted osteocyte marker acting as an inhibitor to the Wnt 
signaling pathway through binding to LRP5/6 and hence blocking the Wnt effects on 
osteoblasts decreasing bone formation (227).  
The use of DKK1 as a bone marker for clinical practice needs to be validated due to both its 
analytical and biological variability. In addition, its response to other factors such as diet and 
diurnal variations needs to be explored. Sclerostin is another inhibitory protein of bone 
formation, secreted by osteocytes. It is the product of the SOST gene located on the 
chromosome 17 (228). It also blocks the Wnt signaling pathway by binding to LRP5/6 on 
osteoblasts, preventing the coupling of the Fz/LRP complex and thus inhibiting osteoblast 
activation (229).  
PTH decreases sclerostin formation explaining in part how exogenous PTH is able to 
stimulate bone formation in the treatment of bone loss conditions. This has targeted research 
into the application of sclerostin as a therapeutic option for the treatment of osteoporosis. 
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However, its use as a diagnostic marker or for monitoring patient compliance to treatment is 
still under investigation (230). 
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CHAPTER 6. PATIENTS AND METHODS 
6.1. INTRODUCTION 
The study aims were investigated in a multicentre, open-label, single treatment arm, 
prospective clinical trial. The effect of RTX on bone turnover was investigated in patients 
with RA eligible to start RTX for the first time during their lifetime according to NICE 
guidelines. Changes of B cell numbers, bone densitometry, bone markers and changes in 
disease activity were assessed in these patients to determine whether RTX has any effect on 
bone turnover similar to anti-TNF blockers and if present, whether the mechanism is indirect 
through inhibition of disease activity or there is a direct effect of B cell depletion on bone 
cells.  
6.2. STUDY SAMPLE  
Forty-five adult RA patients were recruited into the study between the period of August 2011 
and September 2012. Patients were recruited on the basis of being RA patients eligible for 
starting rituximab (RTX) treatment.  
 
According to NICE guidelines, RTX is a second line biological agent; which means that most 
of these patients failed at least one TNF blocking agent unless it was contraindicated or not 
tolerated. We excluded any patient who was using treatment for osteoporosis such as 
bisphosphonates, strontium ranelate, raloxifene, denosumab or teriparatide within three 
months prior to joining the study.  
 
However, patients using calcium and vitamin D were allowed to join our study. This is 
because according to NICE guidelines, any patient using long-term corticosteroids should be 
prescribed calcium and vitamin D. Additionally; these supplements do not affect the functions 
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of bone cells so are considered as replacement of deficiency of these elements. We also 
excluded patients who used RTX or any other B cell depleting agent before joining the study. 
6.3. Methods 
Eligible patients were invited to join the study and were given the study patient information 
leaflet (PIL). Patients were allowed 2-4 weeks to read the PIL and discuss it with their 
physician and relatives. All patients who accepted to be enrolled in the study signed an 
informed consent of approval. 
6.3.A.  Clinical assessment 
Patients who fulfilled the eligibility criteria described above were assessed on 3 monthly 
bases for one year from starting RTX. At baseline, a full patient history and detailed physical 
examination were done. History involved basic demographic data, duration of RA, disease 
activity, comorbidities and detailed drug history. Past history of past surgeries, 
hospitalizations, previous fractures, risk factors for osteoporosis. Family history of RA and 
osteoporosis (either a definite diagnosis or a low trauma hip fracture in a first degree relative), 
smoking, excess alcohol consumption (defined as greater than 21 units per week).  
 
Detailed list of medications and other medical conditions were taken. Recorded data included 
intake of calcium, alfacalcidol, calcitriol, warfarin, corticosteroids, anticonvulsants or 
testosterone supplementation. Subjects were checked if they suffered from asthma, epilepsy, 
kidney disease, hyperthyroidism, eating disorders, coeliac disease, liver disease, gastrectomy, 
inflammatory bowel disease or other concomitant diseases. Subjects were asked if they had 
any of the secondary causes of osteoporosis such as long-term immobilization, gastrectomy, 
liver disease, inflammatory bowel disease, coeliac disease, anorexia nervosa and 
hypogonadism. 
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History involved clinical assessment of disease activity using DAS28 score. Health 
assessment questionnaire (HAQ) was completed by the patient in each visit to measure the 
functional and disability status.  
 
6.3.B.  Laboratory assessment 
 
Underlying causes of osteoporosis were excluded by questionnaires, medical history, physical 
examination and blood tests. All blood was taken in the morning (9 am) to avoid diurnal 
variations of bone markers. Blood investigations included: full blood count, ESR, biochemical 
profile, thyroid function tests (thyroid stimulating hormone (TSH) and free thyroxin), 
parathyroid hormone (PTH), serum testosterone, estradiol (E2), SHBG, gonadotropins 
(follicular stimulating hormone (FSH), and luteinizing hormone (LH)) and serum and urine 
electrophoresis. Biochemical investigations included bilirubin, total protein, albumin, 
globulin, corrected calcium (adjusted according to albumin levels), phosphate, alanine 
aminotransferase (ALT), alkaline phosphatase (ALP) and creatinine. 
 
For the purposes of this study, steroid therapy was defined as the use of oral corticosteroids 
for at least three months. The use of corticosteroids during this study was considered 
unavoidable as patients were in RA flare. This was considered appropriate at the time of the 
study design. Regarding the risk of corticosteroid induced osteoporosis; the Royal College of 
Physicians of London stated that corticosteroid use for more than three months is considered 
to increase the risk of fractures (Royal College of Physicians of London, 2002). 
Hypogonadism was considered a diagnosis in the presence of low serum sex hormones and 
inappropriately raised or decreased gonadotropins. A past history of any gastric surgery or use 
of anticonvulsants was also regarded as a potential risk factor for osteoporosis. 
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6.3.C.  BMD assessment 
 
BMD was measured in lumbar spine L2-L4, both hips (total and neck of femur) and both 
wrists using DXA at baseline and after 12 months. All 12 months visit scans were done using 
the same DXA machine that was used in the baseline scan. DXA scanning was performed 
using GE lunar prodigy advance compact scanner in the following hospitals: James Cook 
University hospital  (Middleborough), City Hospital Sunderland (Sunderland), North 
Tyneside General Hospital (Northumbria), Darlington Memorial Hospital (Darlington), 
Warwick hospital (Warwick) and Cannock Chase Hospital (Cannock). While Hologic 
Discovery QDR 2000 machine (Hologic Instruments, Waltham, MA, USA) was used in 
University Hospital of North Tees (North Tees), Queen Elizabeth Hospital (Gateshead) and 
Dewsbury and district hospital (Dewsbury). The machines had a coefficient of variation 
(CV%) of 1.0-1.5% at lumbar spine, total hip, forearms (UD) and 1.5-2.0% at femoral neck. 
 
BMD results were obtained as an area density in g/cm2, but T and Z scores were also 
recorded.   The T-score is the number of standard deviation units above or below the mean for 
a healthy 30-year-old adult of the same sex and ethnicity, whilst the Z-score is the number of 
standard deviation units above or below the normal mean of the same age, sex and ethnicity 
(calculated using the manufacturer’s standard normal reference database). 
 
6.3.D.  General assessment 
 
Further assessment of the patients was done using X-ray of the hands and feet to detect 
erosions and joint deformities. Laboratory assessment of the patients included routine follow-
up investigations such as full blood count, ESR, electrolytes, liver and kidney function tests. 
Additionally, we tested the parameters that may affect bone turnover such as serum levels of 
parathyroid hormone, sex hormones and vitamin D levels. Immune profile for each patient 
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was done and included rheumatoid factor (RF), anti-nuclear antibodies (ANA), and 
immunoglobulins. 
 
6.3.E.  Flow cytometric analysis 
 
Whole blood samples were analyzed using flow cytometry to determine the numbers of 
CD19+ B cells and its subsets CD24+, CD27+ and CD38+ cells on each visit to correlate the 
changes in the different B cell subsets with the changes of bone markers and markers of 
disease activity. FACS analysis of the patients’ samples was done using FACSCanto 1 
machine in the instritute of cellular medicine, the medical school, Newcastle university. 
 
6.3.F. Bone markers assessment 
 
All samples were taken fasting because of the effects of food intake and the diurnal variation 
of markers on bone turnover. Serum and plasma samples were stored in -80 C  within 1 hour 
of collection till the end of the study. These samples were used for assessment of the markers 
of bone formation (Bone specific alkaline phosphatase, P1NP), markers of bone resorption 
(bCTX, TRAP5b) and markers of osteocyte functions (sclerostin and DKK1). The following 
biochemical markers were quantified in human serum by a manual solid phase, monoclonal 
antibody immunoenzymatic assay: BAP (ImmumoDiagnostics, IDS), sclerostin (Biomedica, 
Austria, CAT. NO. BI-20492), DKK1 (Biomedica, Austria, CAT.NO. BI-20412) and 
TRAP5b The BoneTRAP® Assay Kit (IDS, Inc., UK), while P1NP and CTX were quantified 
in plasma by an electrochemiluminescence immunoassay on an automated analyser, Roche - 
Elecsys 2010. Evaluation of the manual ELISA kits was done my myself and my colleague 
Gill Wheater during the study. However, these assays were completed by Ms Wheater alone 
after the end of follow-up period in December 2013. 
 
 
 61 
 
6.3.G.  Determination of the Sample Size 
 
The determination of the sample size was based on the comparison of the BMD at baseline 
and 12 months. Assuming the true change in BMD of the lumbar spine is 0.01 g/cm2 (based 
on previous unpublished data from Dr S Tuck) and that the DXA scan is reproducible with a 
standard deviation of 0.02 g/cm2 (based on data from the manufacturer); then the study 
should have 80% power to detect a statistically significant difference (at the 5% confidence 
level) with 33 patients in the final analysis. A meta-analysis on anti-resorptive agents in 
osteoporosis concluded that a 1% gain in bone density of the spine was associated with a 
statistically significant reduction of 8% in non-vertebral fractures and a study in a large 
population cohort showing a decline of bone density over time in RA patients not treated with 
anti-resorptive agents (13,14). To allow for 25% dropout (based on the treatment criteria of 
NICE which mean some patients will discontinue therapy early due to treatment failure or 
complete disease resolution or incompliance with the study) 45 patients were needed based on 
a one sample T-test. 
A 2.77% increase in bone density in lumbar spine and total hip and 3% increase in femoral 
neck would show that RTX improved BMD based on the minimum coefficient of variation of 
the DXA machines as provided by the participating centers (1-1.5% for LS and total hip and 
1.1-2% for femoral neck). The calculation of the least significant change (LSC) is calculated 
as 2.77xCV% (ISCD). 
 
6.3.H. Analysis plan: 
Our study subjects were grouped into a single study group. Descriptive statistics were used to 
quantitatively summarise the distribution, central tendency and dispersion of data. Normality 
testing for each data set was done to determine whether median (95%CI) or means (SD) to be 
used. The primary endpoint; change in BMD of the lumbar spine and secondary endpoints; 
 
 62 
changes in BMD of the hips (total hip and femoral neck) and forearms; bone turnover 
markers; inflammatory markers and disease activity between baseline and 12 months were 
investigated using one-way ANOVA if normally distributed or Freidman test if not normally 
distributed among the five visits. 
 
Pearson’s and spearman correlation coefficient were used to correlate the changes in BMD 
with changes in biochemical markers of bone turnover, changes in biomarkers of 
inflammation and changes in circulating B-cells. 
Multivariate regression analyses were done to determine the best predictors at baseline of 
BMD and its changes after 12 months.  
 
Patients were divided into two groups at baseline according the presence or absence of 
erosions and BMD was compared between the subgroups using T-test. 
 
P values <0.05 were considered statistically significant, P values <0.01 were considered 
highly significant and a trend towards significance were defined as p<0.10. 
 
6.3.I. Accrual: 
Fifty-two patients were assessed for eligibility. Five patients were excluded as they did not 
meet eligibility criteria and 2 patients were excluded due to being on bisphosphonates. Forty-
five patients were enrolled in the study group (Figure 4). Patients’ enrolment took place in 
ten participating centers in England. 
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Figure (4) showing the study consort flow diagram. 
Patients were treated with 2x 1,000 mg rituximab i.v. after a bolus of i.v. methylprednisolone 
100 mg in accordance with NICE-guidelines. Patients who responded to the first course 
received a second course at 6 months unless they have attained a state of low disease activity, 
in accordance with clinical practice. Retreatment was delayed in patients with low disease 
activity at 6 months until a state of moderate disease activity has been documented in 2 
consecutive visits one month apart. 
 
The dose of NSAIDs was adjusted during the study if deemed necessary, e.g. because of a 
flare, but the dose of DMARDs and corticosteroids remained stable over the study period. We 
aimed for attainment of a state of low disease activity as measured by DAS score less than 
3.2. All patients who fulfilled the eligibility criteria were assessed in 5 visits with 3 months 
interval as follows: 
6.4. BASELINE EVALUATION 
o Comprehensive medical patient’s history with particular attention to RA specifics, 
treatment history. 
o Detailed physical and rheumatologic examinations. 
52 patients were assessed for eligibility 
5 patients did not meet eligibility criteria 
2 patients were on bisphosphonates 
 
45 patients were eligible 
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o Disease activity and health assessment indices (DAS28 and HAQ). 
o Anthropometric measures (weight, height and body mass index [BMI]). 
Laboratory assessment: 
• Acute phase response: ESR and CRP. Normal reference ranges: Males ESR 2-10 
mm/hr; Females ESR 3-15 mm/hr; CRP 0-5 mg/L. 
• Chemistry: PTH and 25OHD. Normal manufacturer’s reference range for 25OHD: 
Deficient <25; Insufficient 25-50; Adequate 50-75; Optimum >75 nmol/L; PTH 12 - 72 ng/L. 
• Immunology: serum immunoglobulins including IgM RF and ACPA. Normal 
reference range RF <20 IU/mL; ACPA = <7U/mL 
The following bone biochemical markers were quantified in human serum by a manual solid 
phase, monoclonal antibody immunoenzymatic assay:  
§ BAP (ImmumoDiagnostics, IDS). Reference range based on manufacturer for 
premenopausal females 2.9-14.5 µg/L; Postmenopausal females 3.8-22.6 µg/L; Males >50yrs 
3.7-20.9 µg/L). 
§ P1NP and CTX were quantified in human serum by an electrochemiluminescence 
immunoassay on an automated analyzer, Roche - Elecsys 2010. Manufacturer’s reference 
ranges (Premenopausal females P1NP 15.1-58.6 µg/L, βCTx 25-573 ng/L; Postmenopausal 
females; P1NP 16.3-73.9 µg/L, βCTx 104-1008 ng/L; Males >50yrs; P1NP 15.1-58.6 µg/L, 
βCTx 0-854 ng/L,). 
§ TRAP5b (The Bone-TRAP® Assay Kit IDS, Inc., UK; CV = 9% to 13%). Normal 
manufacturer’s range is for premenopausal females 1.0-4.2 U/L; Postmenopausal females 1.5-
4.9 U/L; Males >50yrs 1.9-4.8 U/L. 
§ Sclerostin (Biomedica CAT. NO. BI-20492). Normal range according to 
manufacturer: Females (21.6-68.1) pmol/L), Males (26.4-68.0) pmol/L. 
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§ DKK1 (Biomedica CAT.NO. BI-20412). Normal range according to manufacturer: 
Females (12.4-72.2 pmol/L), Males (15.5-80.8) pmol/L. 
Serum samples were cryopreserved at -80 degrees for biomarker studies till the end of the 
study. Because of the effects of food intake and the diurnal variation of markers of bone 
turnover, morning fasting blood samples were collected. 
6.5. FOLLOW-UP EVALUATION 
o Follow-up was performed at 3, 6, 9, 12 months after baseline. 
o Patient’s history, concomitant medication, detailed physical and rheumatologic 
examinations. 
o DAS28 and HAQ. 
o ESR and CRP. 
o Biochemical markers of bone turnover (BAP, P1NP, TRAP5b, CTX, sclerostin and 
DKK1). 
6.6.  STUDY PROCEDURE  
The treatment protocol followed the routine clinical practice. No change in DMARDs or 
steroids dose were allowed during the stduy. The studied patients were followed up over one 
year. Patients were subjected to full history taking and thorough clinical examination 
(systemic and articular). Full laboratory investigations were done to confirm the diagnosis and 
to rule out patients with any of the exclusion criteria. Clinical assessments included DAS28 
and HAQ at baseline, 3, 6, 9, and 12 months were recorded. Height and weight were recorded 
at baseline for all subjects. All patients were aimed for tight control of disease activity using 
traditional and biological DMARDs. 
 
 66 
A comprehensive analysis of the changes in bone markers in serum was done using CTX and 
TRAP5b as markers of bone resorption; on the other hand, BAP, P1NP and the osteocyte 
markers (sclerostin and DKK1) levels in serum as markers of bone formation. 
Changes in biomarkers and disease activity were analysed using descriptive statistics in both 
groups. Results of biomarkers measurements were correlated with disease activity parameters 
including CRP, ESR, PtGA, PhGA, DAS28, and HAQ.  
BMD was measured in lumbar spine L2-L4, both hips (total and neck of femur) and both 
wrists using DXA scan at baseline and after 12 months. All 12 months visit scans were done 
using the same DXA machine that was used in the baseline scan. The first baseline scan was 
done on 8th of August 2011 and the last baseline scan was done on the fourth of September 
2012. 
6.7.  ADMINISTRATIVE AND ETHICAL CONSIDERATIONS  
The National Research Ethics Service (NRES), United Kingdom (UK) have approved the 
study. All documents related to the study have been prepared according to Good Clinical 
Practice (GCP) standards including PIL, consent forms, case record forms (CRF), standard 
operation procedures (SOP).  
Research and development (R&D) department approval have been granted in participating 
centers. An electronic and a hard copy master file have been made. The study database has 
been made to include all patients’ data from different centers.  
Each study subject was anonymized by an ID made of four digits, where the first two digits 
represent the center’s ID and the second two digits represent the patient’s number.  
6.8. DATA MANAGEMENT AND STATISTICAL ANALYSIS  
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Upon completion of data collection, variables included in each data collection sheet were 
organized and tabulated then coded prior to computerized data entry using Microsoft Excel 
software. The data were then imported into Statistical Package for the Social Sciences (SPSS 
version 20.0) software for statistical analysis. 
6.9. TIME PLAN 
 
 
 
 
 
 
Figure (5) Time plan of the study. 
6.10. Bone markers methods evaluation 
6.10.A) DKK1 & sclerostin assays 
Sclerostin (Biomedica, Austria, CAT. NO. BI-20492) and DKK1 (Biomedica, Austria, 
CAT.NO. BI-20412) manual ELISA kits were used to analyze 24 healthy control samples (12 
females & 12 males) within 24 hours from being taken and 10 samples (males and females) 
stored in -80 C for 2 weeks. The aim was to evaluate these kits and to check the difference in 
detection between fresh and stored samples. Additionally, we wanted to evaluate the 
difference in serum levels of these markers among males and females. The full details of the 
methods used are attached in the index. 
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Males had higher levels of DKK1 compared to females using fresh samples with mean (SD) 
37.3(21.3) pmol/l and 32.7(21.7) pmol/l respectively. Though, the difference was not 
statistically significant (P value = 0.68). Similarly, serum levels of sclerostin were higher in 
males compared to females with levels 24.3(5.7) pmol/l and 17.2(6.6) pmol/l respectively. 
The difference was statistically significant (P=0.01). Sclerostin levels were almost similar in 
both fresh and stored samples. Although there was a slight difference between fresh and 
stored samples for DKK1, the difference was not statistically significant (P=0.1). 
Table 3 showing results of serum levels of DKK1 and sclerostin in 24 healthy control 
samples (12 females & 12 males) within 24 hours from being taken and 10 samples (males 
and females) stored in -80 C for 2 weeks. 
 
Sclerostin 
Mean (SD) 
DKK1 
Mean (SD) 
Male 24.3 (5.7) 37.3 (21.3) 
Female 17.2 (6.7) 32.7 (21.7) 
Fresh 20.8 (7.0 39.3 (21.0) 
Stored 20.5 (5.2) 36.0 (8.9) 
 
6.11. Pilot study to compare serum levels of osteocyte markers among seropositive 
versus seronegative RA patients 
Rationale 
It is well established that plasma cells, a subset of B cells, are the main producer of 
autoantibodies such as RF and ACPA. However, the effect of hyperactive B cells and disease 
activity on bone turnover markers is still controversial. So, the aim of this study was to 
determine the effect of positivity of RF and the effect of RA disease activity on serum levels 
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of osteocyte markers such as sclerostin and DKK1 in RA patients. The availability of serum 
samples of RA patients from a prior study provided us with a unique opportunity to determine 
the effect of pathological autoantibodies and disease activity on bone turnover. 
Methods 
Our group (Myself and my colleague Gill Wheater) used stored serum samples of 291 RA 
patients collected during a previous study aiming to evaluate the reliability of self-reported 
smoke exposure in comparison with serum cotinine measurement for identifying smokers 
among patients attending the JCUH outpatient department. We analyzed the serum levels of 
osteocyte markers (sclerostin and DKK1) in these samples using Sclerostin (Biomedica, 
Austria, CAT. NO. BI-20492) and DKK1 (Biomedica, Austria, CAT.NO. BI-20412) manual 
ELISA kits. RF IgM levels were similarly analyzed using manual ELISA (Immunodiagnostics 
(IDS)). Manual ELISA assays were done in the research laboratory, JCUH. While CRP levels 
were analyzed in the clinical pathology department, JCUH using Roche automated analyzer. 
Results 
We divided our samples into two groups according to their CRP levels. Patients with CRP 
levels higher than 20 mg/l were considered to be having high disease activity while patients 
with CRP levels lower than 20 mg/l were considered to have low disease activity based on 
previous unpublished data from our group. Descriptive statistics were done to compare 
between the two groups. 162 patients had high disease activity were tested for sclerostin while 
45 patients had low disease activity. 84 samples were excluded from analysis, as the amount 
of serum was not enough for analysis. Patients with high disease activity had higher levels of 
sclerostin but the difference was not statistically significant (P=0.418). For DKK1, 220 
patients had high disease activity compared to 65 patients with low disease activity. 6 samples 
were excluded due to deficient amount of serum left. DKK1 was significantly higher in 
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patients with high disease activity compared to the patients with low disease activity and the 
difference was statistically significant (P=0.02). 
Table 4 shows the serum levels of sclerostin and DKK1 among patients with high and low 
disease activity 
Bone marker 
High disease activity 
Mean (SD) 
Low disease activity 
Mean (SD) 
P value 
Sclerostin 35.8 (17) 38.8 (23) P=0.418 
DKK1 36 (14.5) 31.7 (15.7) P=0.02 
 
Furthermore, we divided our patients into two groups according to their RF level. We 
categorized them as patients with seronegative RA (RF IgM < 20U/l) versus patients with 
seropositive RA (RF IgM > 20 U/L). 
Table 5 shows the bone markers levels in seronegative RA and seropositive RA patients. 
Bone marker 
Seronegative patients  
Mean (SD) 
Seropositive patients  
Mean (SD) 
P value 
Sclerostin 37.7 (23.3) 38.3 (21.1) P=0.862 
DKK1 30.2 (11.9) 35.0 (16.4) P=0.014 
 
Descriptive statistics were used to compare the sclerostin and DKK1 levels between the two 
groups. For sclerostin analysis, 69 patients had seronegative RA; 138 patients had 
seropositive RA and 84 samples were excluded due to insufficient amount of serum available 
for testing. Sclerostin levels were similar in the two groups with mean (SD) levels 37.7(23.3) 
and 38.3(21.1) respectively (P=0.862). For DKK1, 86 patients had seronegative RA, 199 
patients had seropositive RA. 6 samples were excluded from analysis due to lack of amount of 
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serum available for testing. DKK1 was found to be higher in the seropositive (35 pmol/l) 
compared to the seronegative RA patients (30.2 pmol/l) (P=0.014). 
Discussion 
Our results are consistent with a previous study that suggested that serum levels of DKK-1 
were significantly higher in patients with RA than in healthy controls and those with other 
rheumatic diseases. Moreover, lower serum levels of DKK1 were found in patients receiving 
treatment with TNF inhibitors and IL-1 Ra compared to patients receiving traditional 
DMARDs. However, the mechanism for this is still under investigation (237-239). 
Conclusion from the pilot study 
Patients with higher disease activity (CRP>20 mg/l) tend to have significantly higher levels of 
DKK1 compared to patients with low disease activity (CRP<20 mg/l). Moreover, RA patients 
with positive RF have significantly higher levels of DKK1 compared to RA patients with 
negative RF. However, sclerostin levels were similar in these groups. This suggests that 
patients with high disease activity and patients with positive RF had inhibited bone formation 
through increased production of DKK1 by osteocytes compared to patients with low disease 
activity and patients with seronegative RA respectively. This may suggest that hyperactive 
plasma cells, a subset of B cells, as well as increased inflammation may inhibit bone 
formation through increasing DKK1 production by osteocytes. This may explain part of the 
mechanism of bone loss in RA. 
Limitations of the pilot study 
In this study, we used stored serum samples that were collected for a different aim so samples 
were randomly taken during the day and non-fasting. We did not have data about the 
medications taken by these patients. So, we presume some of these patients might be using 
bisphosphonates or other drugs that may affect the bone markers levels. 
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CHPATER 7. RESULTS 
This multicenter, open-label, single treatment arm clinical study was designed to investigate 
bone density measurements using DEXA scan, disease activity using DAS28 and bone 
turnover using changes in serum levels of bone formation (BAP and P1NP), bone resorption 
(TRAP5b and CTX) and osteocyte biomarkers (sclerostin and DKK1) in patients with 
rheumatoid arthritis treated with rituximab over one year follow-up. 
 
This chapter will examine changes in BMD, disease activity, flow cytometric analysis of B 
cells and bone markers in response to rituximab treatment over 1 year of treatment . 
 
As presented in table 6, the mean age of patients was 59.3±12.1 years. Concerning the gender, 
36 (80%) of the patients were females. 26 (57.8%) females were postmenopausal. 43 (95.6%) 
subjects were from white origin while 2 patients were Asians. The mean body mass index was 
29.6±7.5. Fifteen subjects (33.3%) were current smokers, 16 (36%) were ex-smokers and the 
rest were non-smokers. Our patients had a severe active disease at baseline DAS28=6.1±1.3 
as per the indication for rituximab according to NICE guidelines. Several comorbidities were 
recorded for the study participants, including diabetes mellitus (1 patient, 2.2%), thyroid 
diseases (8 patients, 17.8%), hypertension (18 patients, 40.0%) and CVD (19 patients, 
42.2%). Nodules were found in 17 (37.8%) of participants. 
 
Out of the 45 patients who joined the study, 9 patients had an early withdrawal from the 
study; three patients had to start bisphosphonates for being found to have osteoporosis at 
baseline as decided by their treating physician.  Three patients had inappropriate response to 
RTX and were shifted to other biological therapies. One patient developed chronic 
lymphocytic leukemia (CLL), another patient developed secondary renal amyloidosis and a 
third patient had to be withdrawn due to non-compliance with 2 consecutive study visits. The 
 
 73 
baseline characteristics included all patients who joined the study, while other comparative 
and follow-up analyses included only the 36 patients who successfully completed the study. 
Thirty-two patients received their second course of RTX as planned at the 6th month while 
four patients were postponed. Three patients were having DAS28 score less than 3.2; so we 
agreed with their treating physicians that it would be appropriate to postpone their second 
RTX course and one patient refused to take the second course based on a discussion with her 
treating physician that she was feeling well and she wanted to postpone it. All study 
participants have never used any treatment for osteoporosis during their lifetime. Missing data 
at any timepoint were excluded from analysis at all visits.  
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Table 6. Baseline characteristics of the study participants 
 
Baseline characteristics No. (%) 
Age (mean±SD, range) 59.3± 12.1 (33-86) 
Gender   
Female  36(80.0%) 
Male  9(20.0%) 
Ethnicity   
White  43(95.6%) 
Asian  2(4.4%) 
Smoking status   
Non-smoker  16(35.6%) 
Current smoker 15 (33.3%) 
Ex-smoker 14(31.1) 
Post-menopausal – n(%)  
No 10(22.2%) 
Yes  26(57.8%) 
BMI (Kg/m2) (mean±SD) 29.6 ±7.5 
Baseline DAS28 (mean±SD) 6.1 (1.3) 
Diabetes  1(2.2%) 
Thyroid  8(17.8%) 
Hypertension  18(40.0%) 
CVD 19(42.2%) 
Nodules  17(37.8%) 
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Serum levels of vitamin were sub-grouped as follows: Deficient <25; Insufficient 25-50; 
Adequate 50-75; Optimum >75 nmol/L. It was found that 68.9% of patients had low 25OHD 
(25 hydroxyvitamin D). These included patients deficient in 25OHD with levels <25 nmol/L 
and patients with insufficiency who had levels between 25-50 nmol/L at baseline. At baseline, 
the median (95% CI) for vitamin D3 was 31.15 (21.5-44.76). The median PTH at baseline 
was 34.0 (95%CI=34.6-46.4) ng/L as shown in table 7.  
 
Table 7. Baseline PTH and 25OHD results of the study participants. 
 Mean SD 
PTH (ng/L) (Normal 12-72 ng/L) 
Median (95%CI) 
34.0 (34.6-46.4) 
25OHD (nmol/L) 
Median (95%CI) 
31.15 (21.50-
44.76) 
Normal (50-125 nmol/L) (No., %) 14 (31.1%) 
Low 25OHD (Deficiency <25 nmol/L) + (Insufficiency 25-50 nmol/L) 
(No., %) 
31 (68.9%) 
 
At baseline, 33.3% of the study participants were using prednisolone during the study with a 
mean dose of (SD)=11.2(9.8) mg. We tried to keep the dose of steroids stable during the study 
unless decided inappropriate by the treating physician. 
 
Table 8. Steroids use by the study participants. 
Variables Study subjects (N=45 patients) 
Prednisolone 15(33.3%) 
Prednisolone dose (mg) (mean ± SD, range) 11.2±9.8 (5-40) 
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7.1. DISEASE ACTIVITY 
CRP data were not normally distributed. Accordingly, Friedman test was used to compare 
CRP values among the five visits. Although there was a noticeable reduction of median CRP 
from 12.6 (95%CI = 6.3-27.1) mg/dl at baseline to 8.0 (95%CI = 3.4-13.1) mg/dl at 12 
months, the change was not statistically significant (p=0.0698). Disease activity measure 
DAS28 was tested using one-way ANOVA as data were normally distributed. DAS28 score 
decreased significantly from highly active disease 6.08 (SD=1.298) at baseline to moderate 
disease activity score 4.66 (SD=1.417). It is clear that both measures improved after 1 year of 
rituximab treatment. Yet, improvement of DAS28 components tender joints count, swollen 
joints count, patient’s global assessment, physicians’ global assessment and ESR were more 
remarkable than the improvement of CRP in response to treatment.  
Table 9. Changes of disease activity during follow-up 
Variables Baseline 3 months 6 months 9 months 12 months P value 
CRP 
(mg/dl) 
Median 
(95% CI) 
12.6 
(6.3-27.1) 
8.9 
(4.9-14.7) 
9.5 
(5.3-17.8) 
11.5 
(6.7-15.4) 
8.0 
(3.4-13.1) 
0.0698*** 
DAS28 
Mean 
(SD) 
6.08(1.298) 5.05(1.221) 4.95(1.583) 4.55(1.667) 4.66(1.417) *<0.001**** 
*Highly significant at p<0.01, **Statistically significant at p<0.05, *** Friedman test, 
****one way ANOVA 
CRP=C-reactive protein; DAS28=disease activity scale using 28 joints 
After performing Bonferroni corrections, none of pairwise comparisons between CRP levels 
among different visits was statistically significant.  
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Figure 7. Changes of CRP values during the follow up period post-rituximab 
The central box represents the values from the lower to upper quartile (25 to 75 percentile). The 
middle line represents the median. There are two sets of horizontal lines; the narrow horizontal lines 
represent the 95% confidence interval of the median, the wide horizontal lines extend from the 
minimum to the maximum value, excluding "far out" values which are displayed as separate points. A 
far out value is defined as a value that is smaller than the lower quartile minus 3 times the interquartile 
range, or larger than the upper quartile plus 3 times the interquartile range (wide horizontal lines set). 
These values are plotted with a different colour marker. 
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Figure 8. Changes of DAS28 score over 12 months post rituximab 
The central box represents the values from the lower to upper quartile (25 to 75 percentile). The 
middle line represents the median. There are two sets of horizontal lines; the narrow horizontal lines 
represent the 95% confidence interval of the median, the wide horizontal lines extend from the 
minimum to the maximum value, excluding "far out" values which are displayed as separate points. A 
far out value is defined as a value that is smaller than the lower quartile minus 3 times the interquartile 
range, or larger than the upper quartile plus 3 times the interquartile range (wide horizontal lines set). 
These values are plotted with a different colour marker. 
 
7.2. BONE MARKERS 
A) Bone formation markers 
Bone formation markers P1NP and BAP increased after one year of rituximab treatment. 
Median P1NP levels increased from 41.9 (95%CI=34.1-46.4) µg/L at baseline to 47.7 
(95%=42.0-61.4) µg/L at the end of the study. However, the rise was not statistically 
significant (p=0.066) as was tested by Freidman test (data were not normally distributed). On 
the other hand, the mean BAP level increased from 18.996 (SD=6.496) µg/L at baseline to 
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21.256 (7.733) µg/L at 12 months. The change was statistically significant as tested using 
one-way ANOVA (p=0.022). As shown in figures 9 and 10, there is an increasing trend in 
both formation markers. This indicates that bone formation rate has improved during the 
study period in response to rituximab. Whether this is due to inhibition of inflammation and 
disease activity or due to a direct effect of B cell depletion on bone needs further analysis. 
 
Table 10. Changes of bone formation markers (BAP and P1NP) during follow-up 
 
Variables Baseline 3months 6months 9months 12months P value 
P1NP (µg/L) 
Median 
(95%CI) 
41.9 
(34.1-46.4) 
49.9 
(44.3-57.0) 
49.4 
(40.3-59.7) 
48.9 
(40.5-58.0) 
47.7 
(42.0-61.4) 
0.066** 
BAP (µg/L) 
Mean (SD) 
18.996 (6.496) 20.967(8.481) 20.331(6.451) 20.274(6.939) 21.256(7.733) *0.022*** 
 
*Significant p-value <0.05, **Friedman test, ***one way ANOVA 
P1NP=amino-terminal pro-peptide of type I pro-collagen; BAP=bone-specific alkaline 
phosphatase; µg/L= microgram per liter.  
After performing Bonferroni corrections, none of pairwise comparisons between serum P1NP 
levels among different visits was statistically significant.  
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Figure 9. Changes in P1NP levels over 12 months follow-up post-rituximab. 
The central box represents the values from the lower to upper quartile (25 to 75 percentile). The 
middle line represents the median. There are two sets of horizontal lines; the narrow horizontal lines 
represent the 95% confidence interval of the median, the wide horizontal lines extend from the 
minimum to the maximum value, excluding "far out" values which are displayed as separate points. A 
far out value is defined as a value that is smaller than the lower quartile minus 3 times the interquartile 
range, or larger than the upper quartile plus 3 times the interquartile range (wide horizontal lines set). 
These values are plotted with a different colour marker. 
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Figure 10. Changes in BAP levels over 1 year follow-up of rituximab treatment. 
The central box represents the values from the lower to upper quartile (25 to 75 percentile). The 
middle line represents the median. There are two sets of horizontal lines; the narrow horizontal lines 
represent the 95% confidence interval of the median, the wide horizontal lines extend from the 
minimum to the maximum value, excluding "far out" values which are displayed as separate points. A 
far out value is defined as a value that is smaller than the lower quartile minus 3 times the interquartile 
range, or larger than the upper quartile plus 3 times the interquartile range (wide horizontal lines set). 
These values are plotted with a different colour marker. 
 
 
 82 
7.3. BONE RESORPTION MARKERS 
Serum levels of TRAP5b and CTX were not normally distributed. So, testing the change 
between the five visits was done using Freidman test. Although there was a reduction in both 
resorption markers as median TRAP5b decreased from 3.07 (95%CI=2.765-3.470) U/L at 
baseline to 2.88 (95%CI=2.756-3.464) U/L after 12 months; while median CTX decreased 
from 436.0 (95%CI=373.4-503.5) ng/L at baseline to 391.0 (299.0-469.7) ng/L after 12 
months following treatment with rituximab. However, this reduction was not statistically 
significant (p=0.676, p=0.800 respectively). 
Table 11. Changes of bone resorption markers in respone to rituxmab (TRAP5b and CTX) 
during follow-up: 
 
Variables Baseline 3months 6months 9months 12months P value** 
TRAP5b (U/L) 
Median 
(95%CI) 
3.07(2.765-
3.470) 
3.27 (2.884-
3.441) 
3.11 (2.783-
3.620) 
3.04 (2.795-
3.458) 
2.88 (2.756-
3.464) 
0.676 
CTX (ng/L) 
Median 
(95%CI) 
436.0 
 (373.4-
503.5) 
368.0 
(271.5-
446.7) 
405.0 
(309.5-
471.2) 
 
379.0 
(302.0-
428.7) 
391.0 
(299.0-
469.7) 
0.800 
*Significant p-value <0.05, **Friedman test 
TRAP5b=tartrate-resistant acid phosphatase 5b; CTX=cross-linked carboxy-terminal telo-
peptide of type I collagen; U/L= unit per liter; ng/L= nanogram per liter. 
After performing Bonferroni corrections, none of pairwise comparisons between neither 
TRAP5b nor CTX levels among different visits was statistically significant.  
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Figure 11. Changes in serum levels of TRAP5b during the follow up period. 
The central box represents the values from the lower to upper quartile (25 to 75 percentile). The 
middle line represents the median. There are two sets of horizontal lines; the narrow horizontal lines 
represent the 95% confidence interval of the median, the wide horizontal lines extend from the 
minimum to the maximum value, excluding "far out" values which are displayed as separate points. A 
far out value is defined as a value that is smaller than the lower quartile minus 3 times the interquartile 
range, or larger than the upper quartile plus 3 times the interquartile range (wide horizontal lines set). 
These values are plotted with a different colour marker. 
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Figure 12. Changes in serum levels of CTX during 3 monthy intervals. 
The central box represents the values from the lower to upper quartile (25 to 75 percentile). The 
middle line represents the median. There are two sets of horizontal lines; the narrow horizontal lines 
represent the 95% confidence interval of the median, the wide horizontal lines extend from the 
minimum to the maximum value, excluding "far out" values which are displayed as separate points. A 
far out value is defined as a value that is smaller than the lower quartile minus 3 times the interquartile 
range, or larger than the upper quartile plus 3 times the interquartile range (wide horizontal lines set). 
These values are plotted with a different colour marker. 
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7.4. OSTEOCYTE MARKERS 
 
The significance of osteocyte markers DKK1 and sclerostin is that they are inhibitors of the 
Wnt-βcatenin pathway of bone formation. So, we predicted that there might be a reduction in 
their levels as part of the mechanism of increased bone formation rate evidenced by the rising 
bone formation markers shown above. However, there was no change in both osteocyte 
markers. This shows that there is another mechanism involved in osteoblastic activation other 
than the Wnt-βcatenin pathway.  
 
Data of DKK1 and sclerostin was not normally distributed. So, Freidman test was used to 
compare their levels among the five visits. There was no significant change among the five 
visits (p=0.226 and p=0.944 respectively). Median sclerostin level started with 54.50 
(95%CI=48.437-58.802) pmol/L at baseline and ended the study with 55.65 (95%CI=50.630-
62.368) pmol/L. While that of DKK1 started with 52.80 (95%CI=44.276-57.726) pmol L at 
baseline and ended with 51.45 (95%CI=41.191-65.719) pmol/L at 12 months. 
 
Table 12. Changes of osteocyte markers (sclerostin and DKK1) during follow-up 
 
Variables Baseline 3months 6months 9months 12months P value**  
Sclerostin (pmol/L) 
Median (95%CI) 
54.50 
(48.437-
58.802) 
53.10 
(49.528-
57.397) 
51.50 
(48.727-
54.836) 
54.20 
(45.366-
59.128) 
55.65 
(50.630-
62.368) 
0.226 
DKK1 (pmol/L) 
Median (95%CI) 
52.80 
(44.276-
57.726) 
51.80 
(46.684-
55.741) 
48.80 
(37.684-
54.812) 
51.10 
(40.421-
59.137) 
51.45 
(41.191-
65.719) 
0.944 
*Significant p-value <0.05, **Friedman test 
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After performing Bonferroni corrections, the increase in sclerostin levels between 6 and 12 
months was found to be statistically significant (p=0.019). While pairwise comparisons 
between DKK1 levels among different visits was statistically significant. 
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Figure 13. Changes of Sclerostin levels during follow up. 
The central box represents the values from the lower to upper quartile (25 to 75 percentile). The 
middle line represents the median. There are two sets of horizontal lines; the narrow horizontal lines 
represent the 95% confidence interval of the median, the wide horizontal lines extend from the 
minimum to the maximum value, excluding "far out" values which are displayed as separate points. A 
far out value is defined as a value that is smaller than the lower quartile minus 3 times the interquartile 
range, or larger than the upper quartile plus 3 times the interquartile range (wide horizontal lines set). 
These values are plotted with a different colour marker. 
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Figure 14. Changes of DKK1 levels during the 3 monthly follow-up visits 
The central box represents the values from the lower to upper quartile (25 to 75 percentile). The 
middle line represents the median. There are two sets of horizontal lines; the narrow horizontal lines 
represent the 95% confidence interval of the median, the wide horizontal lines extend from the 
minimum to the maximum value, excluding "far out" values which are displayed as separate points. A 
far out value is defined as a value that is smaller than the lower quartile minus 3 times the interquartile 
range, or larger than the upper quartile plus 3 times the interquartile range (wide horizontal lines set). 
These values are plotted with a different colour marker. 
 
Flow cytometric analysis (FACS) of CD19 B cells including subsets was done for 23 patients 
every follow-up visit to determine the efficacy of rituximab in depleting B cells and 
correlating their blood levels with disease activity and serum levels of bone markers. Five of 
these patients had an early withdrawal from the study.  
Table 13 shows changes of absolute counts of CD19 B cells and their subset CD24hiCD38hi. 
We were mostly interested in this subset as they were assumed to represent the regulatory B 
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cells (B-regs). Flow cytometric analysis was done for 18 patients only from both 
Middlesborough and Newcastle upon-Tyne centers. There was a highly significant decrease in 
both CD19 B-lymphocytes (p<0.00001) and their subset CD24hiCD38hi (p<0.001) absolute 
counts through the follow up period with an increase in their count at the 6th month then 
continued to decrease later on. This can be explained by the administration of the second 
course of rituximab at 6 months. Interestingly, as shown in figure 15, CD24hiCD38hi cells 
were the first to reappear at 3 and 6 months among the CD19 B cell subsets. 
Table 13. Absolute counts of CD19 B cells and their subset CD24hiCD38hi (n=18) 
Variables Baseline 3months 6months 9months 12months P value** 
CD19 B lymphocytes 
(cells/µl) 
Median	(95%CI)	
18.575 
(13.916-
23.330) 
0.044 
(0.0341-
.0626) 
0.126 
(0.996-
2.919) 
0.028 
(0.023-
0.055) 
0.070 
(0.050-
0.134) 
<0.00001* 
CD24hiCD38hi  
(cells/µl) 
Median	(95%CI) 
0.797 
(0.177-
1.100) 
0.008 
(0.001-
0.012) 
0.022 
(0.014-
1.562) 
0.009 
(0.002-
0.012) 
0.006 
(0.002-
0.018) 
<0.00001* 
*Highly significant p-value <0.01, **Freidman test 
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Figure 15. Changes of CD19 B cells over 3 monthly intervals in response to rituximab 
The central box represents the values from the lower to upper quartile (25 to 75 percentile). The 
middle line represents the median. There are two sets of horizontal lines; the narrow horizontal lines 
represent the 95% confidence interval of the median, the wide horizontal lines extend from the 
minimum to the maximum value, excluding "far out" values which are displayed as separate points. A 
far out value is defined as a value that is smaller than the lower quartile minus 3 times the interquartile 
range, or larger than the upper quartile plus 3 times the interquartile range (wide horizontal lines set). 
These values are plotted with a different colour marker. 
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Figure 16. Changes of CD24hiCD38hi B cells over 1 year in response to rituximab. 
The central box represents the values from the lower to upper quartile (25 to 75 percentile). The 
middle line represents the median. There are two sets of horizontal lines; the narrow horizontal lines 
represent the 95% confidence interval of the median, the wide horizontal lines extend from the 
minimum to the maximum value, excluding "far out" values which are displayed as separate points. A 
far out value is defined as a value that is smaller than the lower quartile minus 3 times the interquartile 
range, or larger than the upper quartile plus 3 times the interquartile range (wide horizontal lines set). 
These values are plotted with a different colour marker. 
7.5. BMD 
Despite the promising results obtained from the bone turnover markers, BMD results obtained 
from DXA scans were relatively inconsistent with those findings. BMD of lumbar spine, 
femoral neck , total hip and forearms all decreased after 12 months in response to rituximab. 
Yet, the reduction was variable among the different regions. Median BMD of lumbar spine 
assessed at L2-L4 showed a slight decrease from 1.138 (95%CI=1.069-1.223) g/cm^3 at 
baseline to 1.137 (95%CI=1.067-1.216) g/cm^3 at 12 months. Femoral neck, total hip and 
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both ultra-distal radius were measured independently and the mean of both sides was used for 
every patient. However when a patient had a metal implant in one side, the affected side was 
excluded and the BMD of the other side was used for that particular site for this patient. A 
slight insignificant reduction (p=0.656) when tested using paired T-test was also noted at the 
femoral neck mean starting with 0.883 (SD=0.140) g/cm^3 and ending the study with 0.878 
(SD=0.157) g/cm^3 (p=0.656). BMD of total hip showed a significant decrease from median 
BMD 0.964 (95%CI=0.914-1.001) g/cm^3 at baseline to 0.946 (95%CI=0.907-0.978) g/cm^3. 
The change was statistically significant as tested using Wilcoxon signed rank test (p=0.041). 
Median BMD of means of (UD) radius also decreased from 0.372 (95%CI=0.346-0.395) 
g/cm^3 at baseline to 0.353 (0.326-0.394) g/cm^3 after 12 months from initiation of 
rituximab. Yet this change was statistically insignificant (p=0.055) using wilcoxon signed 
rank test. 
Table 14. Changes of BMD from baseline to 12th month following RTX 
Total subjects = 35 patients 
Variables Baseline 12months P value** 
BMD L2-L4 
Median (95% CI) 
1.138 (1.069-1.223) 1.137 (1.067-1.216) 0.101** 
BMD Neck femur (mean 
Rt&Lt) 
Mean (SD) 
0.883 (0.140) 0.878 (0.157) 0.656*** 
BMD Total Hip (mean Rt&Lt) 
Median (95% CI) 
0.964 (0.914-1.001) 0.946 (0.907-0.978) *0.041** 
BMD Radius (UD) (mean 
Rt&Lt) 
Median (95% CI) 
0.372 (0.346-0.395) 0.353 (0.326-0.394) 0.055** 
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*Significant p-value <0.05, **Wilcoxon signed rank test, Paired T-test*** 
 
 
 
Figure 17. Changes in BMD at different sites in response to RTX over 1 year follow-up  
The central box represents the values from the lower to upper quartile (25 to 75 percentile). The 
middle line represents the median. There are two sets of horizontal lines; the narrow horizontal lines 
represent the 95% confidence interval of the median, the wide horizontal lines extend from the 
minimum to the maximum value, excluding "far out" values which are displayed as separate points. A 
far out value is defined as a value that is smaller than the lower quartile minus 3 times the interquartile 
range, or larger than the upper quartile plus 3 times the interquartile range (wide horizontal lines set). 
These values are plotted with a different colour marker. 
 
Correlation analysis was done to examine any relationship between values on each visit and 
changes from baseline for the following: DAS28, bone makers, BMD at different sites and 
absolute counts of CD19+ B cells. Unfortunately, there was no significant correlation between 
each other on different visits not their changes from baseline (p>0.05) except that there was a 
significant negative correlation between CRP and each of BMD lumbar spine (-0.43, p= 
 
 94 
0.011) on one hand and neck of femur (rho=-0.37, p=0.033) on the other hand. Also, total hip 
BMD showed a significant negative correlation with age (rho= -0.41, p=0.012), CRP (rho=-
0.36, p=0.041) and a positive correlation with absolute counts of CD19 B lymphocytes 
(rho=0.44, 0.007) at 12 months. Radius BMD showed a significant negative correlation with 
age (rho=-0.37, p=0.035) and a positive one with BMI (rho= 0.43, p=0.013). 
 
Table 15. Correlation between BMD L2-L4 and different parameters at 12th month visit 
 
 BMD Lumbar 2-4  
 rho P value 
Age 0.11 0.511 
BMI 0.11 0.507 
DAS 28 0.28 0.104 
CRP  -0.43 0.011* 
CD19.B lymphocyte  0.27 0.347 
CD24hiCD38hi  -0.24 0.398 
* Statistically significant at p<0.05 
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Table 16. Correlation between BMD Neck of Femur and different parameters at 12th month 
visit 
 
 BMD  
 rho P value 
Age -0.297 0.079 
BMI 0.20 0.254 
DAS 28 0.27 0.123 
CRP  -0.37 0.033* 
CD19.B lymphocyte  0.147 0.632 
CD24hiCD38hi  0.34 0.238 
* Statistically significant at p<0.05 
 
 
Table 17. Correlation between BMD Total Hip and different parameters at 12th month visit 
 BMD Total Hip 
 rho P value 
Age -0.41 0.012* 
BMI 0.62 <0.001 
DAS 28 0.27 0.118 
CRP  -0.36 0.041* 
CD19.B lymphocyte  0.44 0.007* 
• Statistically significant at p<0.05 
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Table 18. Correlation between BMD radius and different parameters at 12th month visit 
 BMD radius 
 rho P value 
Age -0.37 0.035* 
BMI 0.43 0.013* 
DAS 28 -0.162 0.376 
CRP  0.29 0.102 
CD19.B lymphocyte  -0.12 0.692 
CD24hiCD38hi  -0.29 0.318 
* Statistically significant at p<0.05 
 
Based on the results from the correlation analysis, multivariate linear regression models were 
performed (backward procedure). Independent association between age, body mass index, 
CRP, Vitamin D, DAS28, CD19 B cells, PTH and CD24hiCD38hi B cells at baseline with 
BMD of different sites at 12 months was done in order to detect factors which may affect 
BMD after 12 months. There was a significant negative independent association between 
BMD L2-L4 at 12 months and each of age (standardized β=-0.577, p=0.013) and 
CD24hiCD38hi B cells (standardized β=-1.365, p=0.062) at baseline; while there was 
significant positive independent association of BMD L2-L4 at 12 months with CD19 B-
lymphocytes (standardized β=1.467, p=0.049) and vitamin D levels (standardized β=1.085, 
p<0.001) at baseline (table 19). On the other hand, there was no significant association 
between the actual change in BMD after 12 months of treatment and the other parameters. 
This can be explained by that the change was very small to detect any significant association. 
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Table 19. Independent predictors of BMD L2-L4 
 
Unstandardized 
Coefficients 
Standardized 
Coefficients 
t P value  
95.0% Confidence Interval 
for B 
B Std. Error Beta 
Lower 
Bound Upper Bound 
(Constant) 1.414 0.143  9.908 <0.001 1.091 1.737 
Age  -0.008 0.003 -0.577 -3.095 0.013 -0.014 -0.002 
CD19 B-lymphocyte 0.578 0.253 1.467 2.279 0.049 0.004 1.151 
CD24hiCD38hi -1.858 0.871 -1.365 -2.132 0.062 -3.829 0.113 
Vitamin D 0.004 0.001 1.085 5.702 <0.001 0.003 0.006 
 
 
Table 20 shows that there was a significant negative independent association between BMD 
neck femur at 12 months and each of age (standardized β=-0.872, p=0.007), and PTH levels 
(standardized β=-0.630, p=0.035) at baseline.  
Table 20. Independent predictors at baseline for BMD neck femur at 12 months 
 
Unstandardized 
Coefficients 
Standardized 
Coefficients 
t P value  
95.0% Confidence Interval 
for B 
B Std. Error Beta 
Lower 
Bound Upper Bound 
(Constant) 1.548 0.186  8.34 <0.001 1.135 1.962 
Age  -0.009 0.003 -0.872 -3.38 0.007 -0.015 -0.003 
PTH -0.030 0.012 -0.630 -2.44 0.035 -0.057 -0.003 
 
As presented in table 21, there was an independent association between BMD total hip at 12 
months and each of age (standardized β=-0.985, p=0.001), and PTH (standardized β=-0.459, 
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p=0.061) at baseline. In other words, the higher the age at baseline, the lower the BMD of 
total hips at 12 months.  
 
Table 21. Independent predictors at baseline for BMD total hip at 12 months 
 
Unstandardized 
Coefficients 
Standardized 
Coefficients 
t P value  
95.0% Confidence Interval 
for B 
B Std. Error Beta 
Lower 
Bound Upper Bound 
(Constant) 1.846 0.207  8.923 <0.001 1.385 2.307 
Age  -0.013 0.003 -0.985 -4.531 0.001 -0.020 -0.007 
PTH -0.029 0.014 -0.459 -2.111 0.061 -0.059 0.002 
 
Table 22 shows there were a significant negative independent association between BMD 
radius at baseline and DAS28 at baseline (standardized β=-0.597, p=0.031); while there was a 
highly significant positive association between BMD radius at 12 months and Vitamin D 
levels at baseline (standardized β=0.718, p=0.013). 
 
Table 22. Independent predictors of BMD radius 
 
Unstandardized 
Coefficients 
Standardized 
Coefficients 
t P value  
95.0% Confidence Interval 
for B 
B Std. Error Beta 
Lower 
Bound Upper Bound 
(Constant) 0.016 0.126  0.128 0.901 -0.264 0.297 
DAS28 - 0.059 0.024 - 0.597 - 2.514 0.031 - 0.007 - 0.111 
Vitamin D 0.003 0.001 0.718 3.024 0.013 0.001 0.005 
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The presence of plain x-ray hands and feet reports was a great opportunity to study the effect 
of presence of erosions on BMD results. Patients were divided into two groups according to 
the presence of erosions in their report or their absence. Reports with vague terms such as 
(RA changes) were excluded from analysis. Group 1 refers to patients without erosions while 
group 2 refers to patients with erosions. Difference in numbers between both groups was not 
statistically significant. The mean (SD) BMD total hip for group 1 was 1.040 (0.145) 
compared to 0.871 (0.158) in group 2. The difference between both groups was highly 
significant (p=0.009). For femoral neck BMD, Group 1 mean BMD (SD) was 0.963 (0.134) 
compared to 0.838 (0.162) in group 2. Comparing both groups revealed a significant 
difference (p=0.043). To summarize these results, patients with erosions have lower BMD 
compared to patients without erosions in our sample. 
Table 23. BMD difference between patients without and with erosions. 
  Group 1 (12 subjects)  Group 2 (14 subject) P value 
Total hip BMD 1.0403 (0.1452) 0.8711 (0.1577) 0.009 
Femoral neck BMD 0.9634 (0.1338) 0.8376 (0.1621) 0.043 
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Figure 18. Total hip BMD difference between patients without and with erosions. 
 
The central box represents the values from the lower to upper quartile (25 to 75 percentile). The 
middle line represents the median. There are two sets of horizontal lines; the narrow horizontal lines 
represent the 95% confidence interval of the median, the wide horizontal lines extend from the 
minimum to the maximum value, excluding "far out" values which are displayed as separate points. A 
far out value is defined as a value that is smaller than the lower quartile minus 3 times the interquartile 
range, or larger than the upper quartile plus 3 times the interquartile range (wide horizontal lines set). 
These values are plotted with a different colour marker. 
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Figure 19. Femoral neck BMD difference between patients without and with erosions. 
 
The central box represents the values from the lower to upper quartile (25 to 75 percentile). The 
middle line represents the median. There are two sets of horizontal lines; the narrow horizontal lines 
represent the 95% confidence interval of the median, the wide horizontal lines extend from the 
minimum to the maximum value, excluding "far out" values which are displayed as separate points. A 
far out value is defined as a value that is smaller than the lower quartile minus 3 times the interquartile 
range, or larger than the upper quartile plus 3 times the interquartile range (wide horizontal lines set). 
These values are plotted with a different colour marker. 
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CHAPTER 8. DISCUSSION 
RA is a common disease affecting between 0.5-1% of the adult population worldwide (234). 
Osteoporosis is a leading co-morbidity in RA (235). Bone loss resulting from RA has been 
extensively studied over the last years. However, its mechanism is still poorly understood. It 
has been well established that RA leads to increased bone resorption, but it has more recently 
been demonstrated that there is also substantially reduced bone formation (236). 
The role of B-lymphocytes regarding bone turnover is controversial (237). The net effect of B 
cell depletion on bone turnover may depend on the relative depletion of effector versus 
regulatory B cell subsets. Studies have shown that B-lymphocytes stimulate 
osteoclastogenesis; while others have shown that B cells inhibit bone resorption (238). 
Knocking out B cells in mice led to severe osteoporosis indicating that B cells have an 
important role in bone metabolism (239). 
The study described in this thesis is based on a multicenter prospective clinical trial of 45 RA 
patients to assess the effects of B cell depletion using rituximab on bone density 
measurements using DEXA scan and bone turnover using changes in serum levels of bone 
formation (BAP and P1NP), bone resorption (TRAP5b and CTX) and osteocyte biomarkers 
(sclerostin and DKK1) over 12 months follow-up. 
 
Flow cytometric analysis of B cells including subsets was done to assess the direct effect of 
change in B cell numbers on different bone turnover parameters and disease activity. We 
aimed to confirm the effect of B cell depletion on BMD and bone turnover and to determine 
whether this effect is related to remission of disease activity by the drug or a direct effect of B 
cell depletion on bone turnover. Additionally, we aimed to determine the effect of changes in 
disease activity on bone metabolism in RA.  
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Patients were treated with 2x 1000 mg rituximab I.V. after a bolus of I.V. methylprednisolone 
100 mg in accordance with NICE guidelines. Patients who responded to the first course 
received a second course at 6 months unless they have attained a state of low disease activity, 
in accordance with clinical practice. Retreatment was delayed in patients with low disease 
activity at 6 months until a state of moderate disease activity has been documented in 2 
consecutive visits one month apart. 
The dose of NSAIDs was adjusted during the study if deemed necessary such as in a flare, but 
the dose of DMARDs and corticosteroids remained stable over the study period. We aimed at 
attainment of a state of low disease activity as measured by DAS28 score less than 3.2 
The results of this study showed contradictory results between bone turnover markers and 
BMD results. However, data obtained from bone turnover markers support the hypothesis that 
rituximab may have protective effects on bone. This study revealed a significant increase in 
bone formation markers in response to rituximab and a decrease in bone resorption, yet 
statistically insignificant along with steady levels of osteocyte markers over one year follow-
up. On the other hand, BMD results showed a small statistically insignificant reduction at 
lumbar spine, femoral neck and wrists; while the decrease was statistically significant for the 
total hip BMD after 12 months.  
Accordingly, we assume that B cell depletion by rituximab stimulated osteoblastic activity 
either directly through their proximity in bone marrow or indirectly through inducing disease 
remission more than affecting osteoclastogenesis. However, this effect may have not appeared 
at BMD results either due to precision error or small sample size. 
Rituximab is a B cell depleting agent. It is an anti CD20 antibody. It acts by inducing 
depletion of different B cell populations with exception of the pro B cells and plasma cells. 
This therapy can improve signs and symptoms as well as physical function and radiological 
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progression in RA (240, 241). However, a potential influence of rituximab on systemic bone 
remodeling in RA has not been so far investigated. The crosstalk between immune system and 
the cells participating in bone remodeling (osteoblasts and osteoclasts) is extremely complex, 
and few experimental data indicate possible unfavorable effects of B cell depletion on bone 
remodeling (242). 
The current study indicated that treatment with rituximab led to changes of disease activity 
during follow-up as our results showed that there was a significant decrease of mean (SD) 
DAS28 score from 6.08(1.298) at baseline to 4.66(1.417) at the end of the follow-up period. 
This reduction was highly significant (p<0.001). Concerning CRP, there was a decrease in 
CRP levels during follow-up compared to baseline values. Median (95%CI) CRP started with 
12.6 (6.3-27.1) and declined to 8.0 (3.4-13.1) after 12 months. Though, the difference 
between groups was statistically insignificant (p=0.0698). 
 
Regarding biochemical markers of bone turnover, this study revealed that changes of bone 
formation markers (BAP and P1NP) during follow-up showed an increasing trend. The 
median P1NP levels increase from 41.9 (95%CI=34.1-46.4) µg/L at baseline to 47.7 
(95%=42.0-61.4) µg/L at the end of the study. However, the rise was not statistically 
significant (p=0.066). On the other hand, the mean BAP level increased from 18.996 
(SD=6.496) µg/L at baseline to 21.256 (7.733) µg/L at 12 months. The change was 
statistically significant (p=0.022). 
On the other hand, there was a reduction in both resorption markers as median TRAP5b 
decreased from 3.07 (95%CI=2.765-3.470) U/L at baseline to 2.88 (95%CI=2.756-3.464) U/L 
after 12 months; while median CTX decreased from 436.0 (95%CI=373.4-503.5) ng/L at 
baseline to 391.0 (299.0-469.7) ng/L after 12 months following treatment with rituximab. 
However, this reduction was not statistically significant (p=0.676, p=0.800 respectively). 
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Median sclerostin level started with 54.50 (95%CI=48.437-58.802) pmol/L at baseline and 
ended the study with 55.65 (95%CI=50.630-62.368) pmol/L. While that of DKK1 started with 
52.80 (95%CI=44.276-57.726) pmol L at baseline and ended with 51.45 (95%CI=41.191-
65.719) pmol/L at 12 months. However, there was no change in both osteocyte markers 
(p=0.226 and p=0.944 respectively). 
Flow cytometric analysis (FACS) of CD19 B cells including subsets was done for 23 patients 
every follow-up visit to determine the efficacy of rituximab in depleting B cells and 
correlating their blood levels with disease activity and serum levels of bone markers. These 
patients were from Middleborough (The James Cook University hospital) and Newcastle upon 
Tyne (Freeman hospital) centers. Five of these patients had an early withdrawal from the 
study due to different reasons mainly starting bisphosphonates, inadequate response to 
rituximab and being diagnosed with other diseases, which may affect bone turnover (CLL). 
Additionally, one patient has been withdrawn due to non-compliance with the study visits.  
The analysis for changes of absolute counts of CD19 B cells and their subset CD24hiCD38hi 
was for 18 patients only. There was a highly significant decrease in both CD19 B-
lymphocytes (p<0.00001) and their subset CD24hiCD38hi (p<0.00001) absolute counts 
through the follow up period with an increase in their count at the 6th month then continued to 
decrease later on. This can be explained by the administration of the second course of 
rituximab at 6 months. This indicates that rituximab has successfully depleted almost all 
CD19 B cells and their subsets. 
Despite the promising results obtained from the bone turnover markers, BMD results obtained 
from DXA scans were relatively disappointing. BMD of lumbar spine, femoral neck , total hip 
and forearms all decreased after 12 months in response to rituximab. Yet, the reduction was 
variable among the different regions. Median BMD of lumbar spine assessed at L2-L4 
showed a slight decrease from 1.138 (95%CI=1.069-1.223) g/cm^3 at baseline to 1.137 
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(95%CI=1.067-1.216) g/cm^3 at 12 months (p=0.101). A slight insignificant reduction 
(p=0.656) was also noted at the femoral neck mean starting with 0.883 (SD=0.140) g/cm^3 
and ending the study with 0.878 (SD=0.157) g/cm^3 (p=0.656). BMD of total hip showed a 
significant decrease from median BMD 0.964 (95%CI=0.914-1.001) g/cm^3 at baseline to 
0.946 (95%CI=0.907-0.978) g/cm^3 (p=0.041). Median BMD of means of (UD) radius also 
decreased from 0.372 (95%CI=0.346-0.395) g/cm^3 at baseline to 0.353 (0.326-0.394) 
g/cm^3 after 12 months from initiation of rituximab. Yet this change was statistically 
insignificant (p=0.055). 
Although the reduction of total hip BMD was significant after 12 months of rituximab 
treatment, these changes were very small and less than the LSC calculated based on the CV% 
of DXA machines provided by each center. Accordingly, this change might be due to 
precision error rather than a real change in BMD. The presence of a control group could have 
been of great value for our study as it could detect such small changes. Another possible 
explanation is the short duration of the study, which may not be enough for the slow 
progression of BMD changes. Unfortunately, while reviewing the literature, some studies 
showed such small changes as significant without considering the precision error. 
A study with 31 RA patients was done to assess bone turnover. The mean (SD) age of the 
patients was 50.6 (6.8). Their DAS28 score was 5.8 (1.2). All patients used prednisone (7.5 
mg) and methotrexate 10 mg/week. 11 patients took concomitantly etanercept (25 mg 
twice/week) and 10 patients received infliximab 3mg/kg at 0, 2, 6 weeks then every 8 weeks. 
Ten patients receiving only prednisone and methotrexate were used as controls. BMD was 
assessed at baseline then after 6 months. BMD increased by 0.2% at LS and 0.1% at total hip 
in patients receiving TNF-alpha blockers compared to a reduction of 0.8% at LS and 0.6% at 
total hip in the control group. BMD changes were not significant similar to our study. 
However, the duration was very small to detect real BMD changes (243). 
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Femoral neck is well known by its sensitivity to minor position changes so very high 
precision is required to obtain accurate results. Though, femoral neck BMD may have slightly 
decreased in case of presence of persistent hip arthritis. Oppositely, BMD of total hip may 
have increased due to secondary osteoarthritis of the joint which may give false high BMD 
results.  
Combining the BMD results with the bone turnover markers results may lead us to the fact 
that BMD failed to show the improvement noticed in bone formation and no worsening of 
bone resorption. This might be due to the short duration of the study or the reasons explained 
earlier. On the other hand, the results of bone formation markers may be encouraging that 
there is an anabolic effect of B cell depletion using rituximab on bone, as it did increased 
opposite to what is expected with severe RA patients such as our subjects. Obviously, B cell 
depletion led to improvement of bone formation and a slight reduction of bone resoprtion. 
Notably, the one-year follow-up period may not be enough for BMD to build up significantly 
to find an obvious change.  
Correlation between different variables was tested to see if there was any significant 
association. Correlation was performed between mean change in DAS28 and changes in 
different parameters at follow up visits. Results revealed no persistent significant correlation 
between DAS28, bone markers, CD19+B cell numbers and BMD changes over 12 months. 
 
However, there was a significant correlation between CRP and each of BMD lumbar 2-4 (-
0.43, p= 0.011), BMD neck femur (rho=-0.37, p=0.033) and total hip CRP (rho=-0.36, 
p=0.041). Total hip BMD showed significant correlation with age (rho= -0.41, p=0.012). 
Radius BMD showed significant correlation with age (rho=-0.37, p=0.035) and BMI (rho= 
0.43, p=0.013).  
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The finding that there is a significant negative correlation between CRP and BMD supports 
the hypothesis that inflammation has a negative effect on BMD. Age also negatively 
correlated with BMD.  
 
Interestingly, we subdivided our patients based on the presence or absence of erosions on their 
hands and feet x-rays. We found a significant difference in BMD of total hip and femoral 
neck at baseline (p=0.009, p=0.043 respectively). Patients with erosions had much lower 
BMD than patients without erosions. This may partly explain the worsening of BMD and 
suggests that patients with erosions should be routinely surveyed for osteoporosis and treated 
accordingly. 
 
Interestingly, Depletion of CD19+ B cells led to worsening of BMD opposite to our 
hypothesis that the presence of B cells is pathogenic for bone homeostasis. So, this may 
suggest that not all B cells are harmful for bone. In fact, it might be the opposite, that the 
absence of B cells may lead to osteoporosis. This has been suggested in the literature by some 
studies. In a murine study, depletion of B cells resulted in development of osteoporosis. 
Moreover, reconstitution of B cells in these mice reversed bone loss (206). 
 
Furthermore, we divided our patients into 2 subgroups based on the presence or absence of 
erosions in their x-ray reports at baseline. We found a significantly lower total hip BMD in 
patients with erosions compared to patients without erosions 1.040 (0.145) versus 0.871 
(0.158). The difference between both groups was highly significant (p=0.009). Similarly, for 
femoral neck BMD, Group 1 mean BMD (SD) was 0.963 (0.134) compared to 0.838 (0.162) 
in group 2. Comparing both groups revealed a significant difference (p=0.043). Applying 
these results in clinical practice showed that for patients with erosions a vigilant and routine 
assessment of BMD should be done and osteoporosis should be treated accordingly if present. 
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Based on the results from the correlation analysis, multivariate linear regression models were 
performed (backward procedure). There was an independent association between age, body 
mass index, CRP, Vitamin D, CRP, DAS28, CD19 B-lymphocytes, PTH and CD24hiCD38hi 
B cell at baseline against BMD LS, total hip, femoral neck and wrist (UD) after 12 months. 
There was an independent association between BMD L2-L4 and each of age (standardized 
β=-0.577, p=0.013), CD19 B-lymphocytes (standardized β=1.467, p=0.049), CD24hiCD38hi 
B cells (standardized β=-1.365, p=0.062) and vitamin D (standardized β=1.085, p<0.001). 
The significant positive independent association found between CD19+ B cells and BMD 
lumbar spine at baseline suggests a direct effect of B cells on BMD. This may explain why 
BMD have slightly decreased in response to depleting B cells using rituximab. This suggests 
that rituximab may have a negative impact on BMD opposite to what we were expecting. The 
finding that CD24hiCD38hi B cells may have a noticeable but statistically insignificant 
negative independent association with BMD lumbar spine suggests that the presence of this 
subtype of B cells (previously considered as B-regs) is not actually protective but in fact may 
have a negative effect on BMD. Yet, these results were not found in BMD hips, femoral neck 
and forearms. 
 
 
CD24hiCD38hi B cells were assumed to be B regulatory cells named Bregs. A recent study 
by Mauri et al. showed that in patients with active RA, CD19+Cd24hiCD38hi b cells failed to 
convert T helper cells into functioning T regulatory cells and lost their ability to suppress 
TH17 cells. On the other hand, healthy controls and patients with low disease activity had 
normal activity of CD24hiCd38hi B cells. 
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In our study, there was an independent association between BMD neck femur and each of age 
(standardized β=-0.872, p=0.007), and PTH (standardized β=-0.630, p=0.035). There was an 
independent association between BMD total hip and each of age (standardized β=-0.985, 
p=0.001), and PTH (standardized β=-0.459, p=0.061). Lastly, there was a significant 
independent correlation between BMD radius and DAS28 (standardized β=-0.597, p=0.031) 
and Vitamin D (standardized β=0.718, p=0.013). 
 
These findings are in accordance with results obtained by multicenter, randomized, placebo-
controlled, double-blinded trial conducted to evaluate efficacy and safety of rituximab in 
patients with active, longstanding RA over 24 weeks. Patients were categorized into 2 groups; 
209 patients were randomized to placebo and 311 patients to receive rituximab I.V. 2x1000 
mg at baseline.  Mean DAS28 score and CRP levels were significantly decreased from 
baseline in rituximab-treated patients (P=0.0001, P < 0.0001 respectively) (244). 
Keystone et al., reported that therapy with B cell depletion using rituximab, for patients with 
progressive RA led to decreased inflammatory activity and limited joint destructive process. 
Yet, potential effects on bone remodeling have not been studied (241). 
Gough et al, reported that disease activity is consistently associated with low BMD. They 
concluded that generalized bone loss observed in RA is associated with disease activity as 
measured by CRP. So, suppression of the disease activity could stabilize this bone loss (241). 
Moreover, in a two-year follow up study, patients whose disease became inactive recovered 
partially from the initial bone loss. A similar relationship between sustained inflammation and 
BMD loss shown in ankylosing spondylitis, in which steroids are not used. Even in the 
general population, a mild elevation of CRP within the normal range increases non-traumatic 
fracture risk (246). 
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Results obtained by a prospective study conducted by Hein et al., on 13 patients with a 
follow-up of 3–15 months after administration of rituximab in dose of 2x1,000 mg revealed 
no significant change of the bone formation markers; BAP and c-terminal propeptide of 
collagen I, yet it revealed that rituximab had significant effect on bone resorption marker 
TRAP concentration after 15 months (247). 
This is in accordance with what was reported by Fardellone et al., as they concluded that 
Rituximab lowered osteoclast activity in RA patients proven by a significant decrease of the 
bone resorption marker deoxypyridinoline, which was significantly reduced 15 months after 
treatment (244). These findings are contradictory to our results that bone resorption markers 
TRAP5b and CTX remained stable post RTX over 1 year. 
A review of comparable studies that used infliximab to assess effects of TNF blockade on 
BMD revealed that dampening of inflammation and disease activity resulted in improvement 
of BMD (245-247). Earlier studies suggested also a beneficial effect of TNF blockade on 
osteoporosis among RA patients (246). 
In a multicenter study of the effects of infliximab on bone, Chopin et al. showed a decrease in 
serum ICTP and CTX associated with a favorable change in ratio between markers of bone 
resorption and bone formation (252). So they suggested beneficial systemic and local bone 
effects of infliximab in patients with RA. The study included 48 women with mean age of 
54.2 ±12.1 years old diagnosed with severe RA for 11.4±7.8 years. They all started infliximab 
after failure of other DMARDs. Assessment performed at baseline, 6, 22 and 54 weeks after 
initiating Infliximab therapy. The study results revealed that BMD remained stable over one 
year. Serum CTX-I levels decreased at week 6 and week 22 by 19% and 28%, respectively 
(p=0.032), returning to pre treatment levels at week 54. By contrast, ICTP levels declined 
progressively with a maximal decrease (25%) at week 54 (p=0.028). PINP levels remained 
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stable over time, leading to a 30-40% improvement in bone remodeling balance, as assessed 
by the ratios PINP/CTX and PINP/ICTP (p=0.05) (252). 
Seriolo et al. reported that treatment with TNFα blockers was shown to prevent structural 
bone damage and improve BMD in RA patients. Whether this is a direct effect of TNFα 
inhibition on bone cells or an indirect effect through reducing RA disease activity, this could 
not be confirmed (251). 
This is in accordance with Vis et al. who showed that patients with RA treated with infliximab 
could stop bone loss in both spine and hip, but not in hand bones. The outcome of their study 
also supported a relationship between clinical response, mirrored by reduced inflammatory 
activity, and bone loss changes of the spine, hip and hands. They conducted a cohort study on 
102 patients with RA treated with infliximab over one year. Uncoupling between bone 
destruction and bone formation was observed in RA. The bone formation markers P1NP and 
osteocalcin increased 2 and 6 weeks after initiation of infliximab. On the other hand, serum 
CTX-I and sRANKL decreased significantly (250).  
The BMD of the spine and hip using dual x ray absorptiometry and hands dual x ray 
radiogrammetry were measured before start of treatment and after one year. The BMD of the 
spine and hip were unchanged during treatment, whereas BMD of the hand significantly 
decreased by 0.8% (p=0.01). Serum RANKL and CTX were considerably decreased relative 
to baseline at all timepoints. The decrease in CTX was associated with the decrease in DAS28 
and CRP during the 0 to 14 weeks interval (250) 
Another study conducted on 20 patients with RA (infliximab and placebo group; 10 patients 
in each) with early active RA. BMD was assessed at hands; hips and lumbar spine (L2–4) by 
using DXA scan performed at baseline and after 12 months follow-up. The study revealed that 
BMD loss was reduced significantly in the infliximab group compared to placebo group at the 
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femoral neck (p=0.01) and total hip (p=0.03) but not at hands (p=0.82) or spine (p=0.71). 
Results revealed that the anti inflammatory effects of infliximab could arrest inflammatory 
bone loss at femoral neck and hip but could not at spine and hand (253)  
Results of this study revealed no statistically significant correlation between change in BMD 
and age, gender, and methylprednisolone. In contrast, a significant correlation was detected 
between BMD and body mass index. DAS28 was significantly correlated with BMD loss at 
the femoral neck; CRP was significantly correlated with BMD loss (253).  
Multivariate linear regression model was performed, the independent association between 
age, BMI, CRP, treatment groups, MRI synovitis and erosions with bone loss. An increase in 
CRP was found to be associated independently (standardised b=20.658, p=0.003) with hand 
bone loss. At the spine a high MRI synovitis score was found to be associated independently 
(standardized b=20.587, p=0.010) with bone loss. An increase in MRI erosions (standardized 
b=0.511, p=0.012) and CRP (standardized b=20.428, p=0.030) was found to be independently 
associated with bone loss at the femoral neck. Finally, at the total hip, MRI erosions were 
statistically significantly associated (standardized b=20.776, p=0.001) with bone loss (253). 
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Marotte and colleagues performed a case control study on 99 patients with RA treated with 
infliximab. After one year, patients receiving infliximab had preserved BMD of lumbar spine 
and femoral neck in contrast to bone loss of 3.9% and 2.5% observed at same sites, 
respectively, in the control group that was treated with methotrexate alone. Changes of 
biochemical markers of bone turnover either between the groups or from baseline were not 
statistically different. However, the trends in serum osteocalcin and serum CTX suggest 
greater decrease in bone remodeling activity among patients in infliximab group. Effects of 
infliximab on BMD appeared to occur independently of RA activity (254) 
This is also in accordance with what is reported by Lange and colleagues as they studied 26 
RA patients treated with 12 months of infliximab and observed a significant increase in BMD 
of spine and femoral neck of 2.7% and 1.3%, respectively. The study revealed a trend for a 
correlation between BMD changes and changes in DAS28 score but could not detect 
correlation between changes in BMD with bone markers changes (249). 
Wang et al. reported that osteocyte marker DKK-1 correlated with inflammation and bone 
erosions in RA. So, the changes in DKK-1 levels may serve as a biomarker of disease activity 
and bone erosions (255).  
Results obtained from the study conducted by Wang et al. on assessing osteocytes markers in 
patients with RA, revealed that serum levels of DKK-1 were significantly higher in patients 
with RA than in healthy controls and those with other rheumatic diseases (p<0.01). Serum 
DKK-1 level was correlated with levels of CRP (r = 0.488, p = 0.003) and ESR (r = 0.458, p = 
0.002) and radiologic changes (r = 0.449, p = 0.001) in RA. DKK-1 was found to be 
significantly decreased in RA patients treated with either TNF-α inhibitor (p < 0.01) or IL-
1Ra (p < 0.01) (255). 
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Blockade of Dkk-1 and sclerostin may serve to restore the balance between osteoblasts and 
osteoclasts and repair of bone erosions (252). This is in accordance with results obtained by a 
study conducted by Garnero et al. revealed that increased Dkk-1 levels were associated with a 
high risk of progression of bone erosions, independent of age, sex, baseline radiological 
damage, CRP, and disease activity in patients treated with etanercept (257).  
Nakou et al. conducted a study on patients with active RA who failed treatment with TNFα 
blockers. Patients received rituximab at dose of 1,000 mg on days 1 and 15. Peripheral blood  
(n = 11) and BM (n = 8) aspirates were then collected at baseline and at 3 months. They used 
triple-color flow cytometer to assess B cell and T cell populations. This study revealed that 
rituximab significantly decreased peripheral blood CD19+ B cells from 2% to 0.9%  (P = 
0.022) but reduction was not significant for BM CD19+ B cells (4.6% to 3.8%, P = 0.273). 
These effects were specific to rituximab and not for TNF blocking therapy (258). 
Results revealed no correlation between degree of peripheral B-cell reduction and clinical 
response. However, the authors denote that incomplete B-cell depletion could potentially be a 
reason for poor clinical response. This was noted in 4 out of 11 patients. It was found that 
responders to rituximab had a significant reduction of CD19+CD27+ memory B cells in 
peripheral blood and in BM. In non-responders, a similar reduction of memory B cells has not 
been found. 	Nevertheless, this group of RA patients had highly active disease refractory to 
previous treatments (258) 
Cohen et al. suggested HLA-DR+ B cells are important for B cell mediated T cell activation. 
They concluded that depletion of HLA-DR+ cells could represent an additional mechanism 
for the beneficial effects of rituximab in RA patients (248).  
Cohen et al. investigated the effects of rituximab on peripheral blood and BM lymphocyte 
subsets in patients with active RA. Results revealed that Rituximab therapy preferentially 
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depletes activated CD19+HLA-DR+ B cells in the peripheral blood and bone marrow, which 
was significant for only peripheral blood  (P=0.022). Clinical response to rituximab was 
associated with CD19+CD27+ memory B cells depletion in peripheral blood and BM of RA 
patients (244)  
That is also supported by results obtained from previous studies, which showed that rituximab 
was associated with complete depletion of CD19 B cells in the peripheral blood (259). The 
responses clearly support the hypothesis that B cells are main contributor to the 
immunopathogenesis of RA through several different potential mechanisms (260-262) 
Wijbrandts et al. suggested the importance of controlling inflammation on progression of 
bone loss in RA. They conducted an open label prospective clinical study on 50 patients with 
active RA who started adalimumab and followed-up for one year.  All patients used fixed 
dose of methotrexate and were allowed to use prednisone at ≤10 mg/day. The BMD of the 
lumbar spine and femur neck were measured before and one year after starting the treatment. 
Study results revealed that BMD of lumbar spine and femoral neck were correlated with 
disease activity and duration of RA at baseline. The mean BMD of femoral neck and lumbar 
spine remained unchanged after one year of adalimumab treatment. Actual increase in BMD 
of femoral neck (+2.5%) occurred in patients on prednisone in contrast to patients without 
concomitant prednisone (-0.7%). Lumbar spine also showed similar trend (263). 
Our study had several limitations. First, the study was designed with no control group. 
Control group could be precious regarding comparing results at each timepoint of sequential 
treatment. The lack of a control group is a major limitation for predicting true estimation of 
the effect of rituximab treatment on bone. However, we could not have a control group 
because in the UK, rituximab can only be prescribed in RA patients with severe disease 
activity not responding to traditional DMARDs and only after failure of TNFα blockers 
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according to NICE guidelines. So, there was no true control group that can match our study 
sample group in disease severity and duration.  
The short duration of the study was another weakness point in our study. Because in only one 
year, it might be difficult to detect a significant change in the bone reflected as change in 
BMD over 12 months. A longer evaluation and follow-up of patients after subsequent 
treatment courses is needed to confirm these results.  
Furthermore, our study had limited power to detect individual effects and interactions. 
Although all our study patients had high disease activity and fulfilled the criteria for treatment 
with rituximab, the group was heterogeneous, consisting of men, pre and postmenopausal 
women and different age groups.  
Additionally, more than two-thirds of our patients had low serum vitamin D levels, which 
may have a significant impact on our BMD and bone markers results. Also, one third of 
patients were using steroids during the study, this can also be a good reason why BMD did 
not improve as we anticipated. Although in the study mentioned earlier, steroids were 
beneficial for BMD. 
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SUMMARY AND CONCLUSION 
This multicenter, open-label, single treatment arm clinical study was designed to investigate 
bone density measurements using DEXA scan, disease activity using DAS28 and bone 
turnover using changes in serum levels of bone formation (BAP and P1NP), bone resorption 
(TRAP5b and CTX) and osteocyte biomarkers (sclerostin and DKK1) in patients with 
rheumatoid arthritis treated with rituximab over one year follow-up. Flow cytometric analysis 
of B cells was done to correlate these changes with changes in B cell numbers in blood during 
the study to determine whether B cells have any direct effect on bone turnover and the type of 
this effect whether it is towards bone formation or bone loss. We also tried to determine the 
reason behind this effect whether it is related to B cells themselves or it is the inhibition of 
inflammation and disease activity that caused this effect or a combination of both. 
 
Our patients had severe active disease at baseline DAS28=6.08±1.298 6.08 as per the 
indication for rituximab. All patients failed at least one TNFα unless contraindicated 
according to NICE guidelines. That is why we could not find a matching control group to our 
patients with severe longstanding disease.  
 
In our sample, we found that 68.9% of the patients had low vitamin D at baseline including 
patients with deficiency and insufficiency. Median PTH at baseline was 34.0 (95%CI=34.6-
46.4) ng/L (Normal reference range Normal 12-72 ng/L). This finding may explain why our 
patients did not have a significant improvement in their bone densitometry results. Also, this 
should drive clinicians’ attention that vitamin D supplementation might be required to all 
white patients with RA. This deficiency may also contribute to the generalized 
musculoskeletal pain despite the inhibition of disease activity. 
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Additionally, 15(33.3%) of the study participants were using prednisolone concomitantly as 
part of their routine clinical practice during the study with a mean dose of 11.2±9.8 mg. We 
could not avoid them to do this, as it would have been unethical if their treating physicians 
think that steroids should be part of their management.  
 
Mean DAS28 score decreased significantly from highly active disease 6.08 (SD=1.298) at 
baseline to moderate disease activity score 4.66 (SD=1.417). This reduction in disease activity 
was statistically significant (P<0.001). Although there was a noticeable reduction of median 
CRP from 12.6 (95%CI = 6.3-27.1) mg/dl at baseline to 8.0 (95%CI = 3.4-13.1) mg/dl at 12 
months, the change was not statistically significant (p=0.0698). These results indicate that 
rituximab is a successful treatment for management of severe resistant RA.  
 
In response to rituximab, there was almost depletion of all CD19+ B lymphocytes during the 
follow-up visits compared to baseline (p<0.00001) with an increase in their counts at the 6th 
month then continued to decrease later on. This is explained by the administration of the 
second course of rituximab at 6 months. Interestingly, CD24hiCD38hi B cells were the first to 
reappear at 3 and 6 months among the CD19+ B cell subsets. This B cell depletion was not 
associated with an increase in side effects such as infections during the study. 
 
There was improvement in bone formation during the study in response to rituximab. Median 
P1NP levels increased from 41.9 (95%CI=34.1-46.4) µg/L at baseline to 47.7 (95%=42.0-
61.4) µg/L at the end of the study with a median change of +12.16%. On the other hand, the 
mean BAP level increased from 18.996 (SD=6.496) µg/L at baseline to 21.256 (7.733) µg/L 
at 12 months with a median change of +10.63%. Interestingly, we found no correlation 
between DAS28 and any of the bone formation markers during all visits. This finding 
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suggests that there are other mechanisms for this anabolic bone effect other than inhibition of 
inflammation and disease activity. 
 
Although there was a reduction in both resorption markers as median TRAP5b decreased 
from 3.07 (95%CI=2.765-3.470) U/L at baseline to 2.88 (95%CI=2.756-3.464) U/L after 12 
months with a median change of -6.19%; while median CTX decreased from 436.0 
(95%CI=373.4-503.5) ng/L at baseline to 391.0 (299.0-469.7) ng/L after 12 months following 
treatment with rituximab with a median change of -10.32%. However, the reduction was not 
statistically significant (p=0.676, p=0.800 respectively). This indicated that on the contrary of 
the known fact that inhibition of inflammation and reduction of disease activity lead to 
stoppage of bone resorption. The rate of bone formation versus breakdown ratio was 
estimated by 1.178 using P1NP/CTX change ratio. Similarly, the change of BAP/TRAP5b 
ratio was estimated by 1.717. Accordingly, our study shows that inhibition of disease activity 
affects mainly bone formation rather than osteoclastogenesis. 
Osteocyte markers (sclerostin and DKK1) showed no significant change among the five visits 
(p=0.226 and p=0.944 respectively). Median sclerostin level started with 54.50 
(95%CI=48.437-58.802) pmol/L at baseline and ended the study with 55.65 (95%CI=50.630-
62.368) pmol/L. While that of DKK1 started with 52.80 (95%CI=44.276-57.726) pmol L at 
baseline and ended with 51.45 (95%CI=41.191-65.719) pmol/L at 12 months. 
 
Our primary endpoint showed no significant change in Median BMD of lumbar spine (1.138 
(95%CI=1.069-1.223) g/cm^3 at baseline to 1.137 (95%CI=1.067-1.216) g/cm^3 after 12 
months) with a median change of -0.088%. Similarly, BMD of femoral neck and radius (UD) 
showed no significant change after 12 months (p=0.656 and p=0.055). However, BMD of 
total hip showed a significant decrease from median BMD 0.964 (95%CI=0.914-1.001) 
g/cm^3 at baseline to 0.946 (95%CI=0.907-0.978) g/cm^3 (p=0.041) with a median change of 
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-1.87%. However, the changes were very small and lower than the coefficient of variation 
calculated at the start of the study. Accordingly, further larger scale studies are required to 
confirm these results especially with the promising results obtained from bone markers.  
 
Interestingly, we subdivided our patients based on the presence or absence of erosions on their 
hands and feet x-rays. We found a significant difference in BMD of total hip and femoral 
neck at baseline (p=0.009, p=0.043 respectively). Patients with erosions had much lower 
BMD than patients without erosions. This may partly explain the worsening of BMD and 
suggests that patients with erosions should be routinely surveyed for osteoporosis and treated 
accordingly. 
 
Based on results obtained from bone markers, B cell depletion using rituximab 
increased bone formation and slightly reduced bone resorbtion markers. However, 
sclerostin slightly increased from 6th to 12 month. BMD results were inconsistent with 
bone markers findings, as there was a reduction at all sites mostly at total hip. 
Furthermore, CD19+ B cells were found to have a direct positive association with BMD 
at LS suggesting that B cell depletion is not protective for bone metabolism as 
previously expected.  So, we believe that there is a direct effect of B cell depletion on 
bone cells that need to be further investigated. This effect is directed mainly to 
osteoblasts rather than osteoclasts as previously thought. 
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Recommendations for further work 
The results and conclusions presented suggest a number of areas where further work is 
required. 
1. There is a need for much larger studies with bigger sample size to confirm our results. 
There is also a strong need for a control group to compare the small changes we had with 
patients with similar circumstances. 
2. Future work on cross sectional studies to detect the prevalence of vitamin D deficiency 
in the northeast of England and compare vitamin D incidence in RA and non-RA patients. 
This will help develop new guidelines to mandate vitamin D supplementation to RA patients 
even without the need to test its levels.  
3. Newer biologic agents should be tested for ability to protect against RA induced 
osteoporosis as this information may make us prefer to use the biologic with the most bone-
protective ability in patients at risk to osteoporosis (postmenauposal women).  
4. The normative database, gender comparison, disease activity, bone markers and BMD 
have all shown promising results on the use of rituximab in RA. Therefore, further 
prospective studies with longer duration follow-up should take this into account with addition 
of fracture risk as well.  
5. Further studies should include different genders and ethnic groups to standardise these 
results. More work is required to investigate the efficacy of rituximab on controlling RA 
disease activity and bone turnover in different age groups as well.  
6. Further in-vitro studies are required to eliminate the other factors which may affect 
osteoporosis in RA patients to determine the precise effect of B cell depletion on bone 
turnover. This is important because some factors were unavoidable in our clinical study such 
as the use of steroids, vitamin D deficiency, age, sex …etc. 
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APPENDIX 
Study protocol 
Changes in bone density and bone turnover in patients with rheumatoid arthritis treated with 
rituximab, a B cell depleting monoclonal antibody. 
An investigator-led, industry supported multicenter, open-label, single treatment arm, 
prospective clinical trial. 
 
1.0 INTRODUCTION 
This multicenter, open-label, single treatment arm, prospective clinical trial aims to study the 
effects on bone turnover of rituximab, a B cell depleting monoclonal antibody, licensed for use 
in patients with rheumatoid arthritis who are unresponsive to treatment with second-line ant 
rheumatic medication and a TNF-inhibitor. The effectiveness of rituximab in rheumatoid 
arthritis has demonstrated that B cells play a key role in perpetuation of rheumatoid arthritis. 
Recent investigations have provided abundant evidence for an intricate interaction between the 
immune and skeletal systems (1). This interaction is demonstrated by the fact that a number of 
cell surface receptors, cytokines and signaling pathways serve a critical role both in the immune 
and skeletal systems. Furthermore, it is becoming clear that immune cells influence bone 
remodeling and vice versa. The close interaction between immune progenitors and skeleton is 
facilitated by their proximity in the bone marrow. The role of the immune system, especially 
activated T cells, in inflammatory bone resorption and osteoclastogenesis is well established (2). 
In addition to indirect effect on bone turnover through the production of inflammatory and other 
cytokines that modulate osteoclastogenesis, T cells can also regulate bone turnover through 
direct cell-cell interaction with bone cells. Indeed, it has been shown that both osteoblasts and 
osteoclast can express major histocompatibility complex (MHC) class II molecules under 
inflammatory conditions, therefore, it is plausible that T cell:bone cell interactions may 
contribute to the autoimmune responses as well as accentuate bone turnover. The role of B-
lymphocytes in osteoclast (OC) formation is controversial (3). Mature B-lymphocytes have the 
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capacity to both inhibit and stimulate osteoclastogenesis by virtue of their ability to secrete 
appropriate cytokines (3). B lymphocytes produce proosteoclastogenic cytokines including 
receptor activator of NFkappaB ligand (RANKL), as well as cytokines that inhibit osteoclast 
differentiation from the progenitor cells, such as osteoprotegerin (OPG), transforming growth 
factor-K (TGF-K) and interleukin (IL)-7. Furthermore, B cells can also activate autoreactive T 
cells and further aggravate bone loss through the mechanisms described earlier. It should be 
noted, however, recent data suggest that some B cells (often termed “regulatory” B cells) can 
modulate the function of CD4+ T cells to pathogens and autoantigens. Therefore, the net effect 
of B cell depletion on bone turnover and autoreactivity may depend on the relative depletion of 
effector versus regulatory B cell subsets. It is not therefore altogether surprising that while some 
in vitro studies have shown that B lymphocytes to stimulate osteoclastogenesis, others have 
shown that B cells are inhibitory. In vivo studies on the role of mature B cells in bone 
remodeling have been equally inconsistent (4). For instance, although estrogen withdrawal is 
associated with a significant expansion in mature B cell population, the role of these cells as 
mediators of ovariectomy-induced bone loss remains unclear. A further complicating factor is 
that ovariectomy-induced bone loss, which may be mediated by a variety of cytokines, has been 
shown to have selective effect on trabecular or cortical bone (5). B cell knockout mice are 
osteoporotic, but as these mice also lack plasma cells, it is unclear whether the osteoporotic 
phenotype can be ascribed to the absence of B cells (2).  
 
Given the pathogenetic role of B cells in RA, it is tempting to speculate that B cell depletion has 
a beneficial effect on bone loss. We have recently generated pilot data demonstrating a 50% 
decrease (p<0.001) in beta-crosslaps (CTX), a biochemical marker of bone resorption, and a 
small but statistically significant increase in P1NP, a biochemical marker of bone formation, in 
sera of 46 RA patients 6 months after a single treatment course of rituximab, but these data need 
to be confirmed in a new prospective study. Biochemical markers of bone turnover such as beta-
crosslaps are predictive of clinically relevant bone loss and future fracture risk. We anticipate 
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that some of these effects may be indirect through attenuation of systemic inflammation, while 
others may be direct as a result of the absence of B cells in osteoclasto- and osteoblastogenesis. 
An accurate assessment of bone metabolism is critical for determining the severity of metabolic 
bone disease in RA; it may be a reliable indicator of future disease course and potentially will 
give clinicians valuable information about individual patient’s response to treatment and gives 
insights into the pathophysiology of osteoporosis. 
2.0 STUDY RATIONALE 
This multicenter, open-label, single treatment arm, prospective clinical trial will investigate bone 
density and biochemical markers of bone turnover in RA patients treated with rituximab, a B-cell 
depleting monoclonal antibody. We have recently demonstrated in a retrospective study that 
rituximab-treatment results in a reduction of biochemical markers of bone resorption, and now 
want to confirm and extend these results in a new, prospective cohort of patients. It is postulated 
that the presumed bone-protective effects of rituximab on bone density and turnover may be 
either due to a direct effect of B cell depletion on osteoclastogenesis, or due to reduction of 
disease activity, modulation of autoreactivity or all of the above. 
3.0 STUDY OBJECTIVES 
3.1 Primary Goal 
To investigate the effects of rituximab treatment on bone turnover (biochemical markers of bone 
resorption and formation and bone mineral density (BMD) measurements in RA patients. 
3.2 Secondary Goals 
To correlate changes in bone density with changes in biochemical markers of bone turnover, 
changes in biomarkers of inflammation and of autoreactivity, and changes in circulating Bcells 
and B cell subsets in RA patients treated with rituximab. 
4.0 PATIENT ELIGIBILITY 
4.1 Inclusion criteria 
1. Minimum age 18 years. 
2. Diagnosis of rheumatoid arthritis according to ACR classification criteria. 
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3. Eligibility for treatment with rituximab according to NICE-guidelines 
4. First treatment course of rituximab within 6 weeks after screening 
5. Written informed consent 
4.2 Exclusion criteria 
1. Use of bisphosphonates 
2. Previous B-cell depleting therapy 
3. Poor compliance of the patient as assessed by the referring physicians. 
5.0 STUDY DESIGN 
Multicenter, open-label, single treatment arm, prospective clinical trial in patients with 
rheumatoid arthritis who are starting treatment with rituximab. 
6.0 STUDY ENDPOINTS 
6.1 Primary endpoint 
The primary endpoint is change in BMD of the lumbar spine as measured by DXA. 
6.2 Secondary endpoints 
• Changes in BMD of forearms and hips by DXA 
• Changes in biochemical markers of bone turnover (TNFQ, OPG, sRANKL, BAP, TRAP5b, 
P1NP, CTX) 
• Changes in biomarkers of inflammation (ESR, CRP) and autoreactivity (blood T cell responses 
against autoantigens) 
• Changes in clinical parameters of disease activity (DAS28), functional ability (HAQ-DI) 
• Number of new fractures 
• Duration of B cell depletion in blood and changes in absolute and relative numbers of 
circulating CD19+ B cells, including subsets (CD27+, CD24+, CD38+) by FACS 
• Changes in osteoclast differentiation (osteoclastogenesis assays on blood mononuclear cells) 
7.0 CONDUCT OF THE STUDY 
7.1 Patient Registration 
All patients who fulfill the eligibility criteria will be registered by fax to the study administration 
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office (SAO) – full contact details are on the cover of the protocol. 
7.2 Baseline Evaluation 
The following investigations will be completed and documented at baseline: 
- comprehensive patient’s history with particular attention to RA specifics, treatment history 
- detailed physical examination 
- DAS28 and HAQ-DI 
- X-rays of hands and feet if not done in past year 
- DXA lumbar spine, hips, forearms according to local protocol 
- laboratory examinations as part of usual care (except for those marked by *) 
Hematology: ESR, Hb, Hct, WBC with differential, platelet count, Chemistry: electrolytes, renal 
and liver function tests, serum electrophoresis, albumin, PTH, 25OH-vit D, TSH. LH/FSH 
(females), testosterone/PSA/SHBG (males). urinalysis 
Immunology FACS of peripheral blood CD19+ cells incl subsets*; immunoglobulins incl IgG, 
IgA, IgM; ANA, anti-CCP, IgM rheumatoid factor. 
Serum* (15 mL) and heparinised blood* (40 mL) to be cryopreserved for biomarker studies. 
Because of the effects of food intake and the diurnal variation of markers of bone turnover, 
fasting blood samples are collected (6,7). 
7.3 Outline of Study 
The duration of the study is one year for each patient, which includes 3-monthly study visits at 
baseline, 3, 6, 9 and 12 months after enrolment. Patients will be treated with 2x 1,000 mg 
rituximab i.v. after a bolus of i.v. methylprednisolone 100 mg in accordance with NICE-
guidelines. Patients who responded to the first course will receive a second course at 6 months 
unless they have attained a state of low disease activity, in accordance with clinical practice. 
Retreatment will be delayed in patients with low disease activity at 6 months until a state of 
moderate disease activity has been documented at 2 consecutive visits one month apart. 
The dose of NSAIDs may be adjusted during the study if deemed necessary, eg because of a 
flare, but the dose of DMARDs and corticosteroids should remain stable. The aim of treatment is 
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attainment of a state of low disease activity. Assessment of DAS28 and HAQ will be done by an 
independent research nurse. 
Blood samples for biomarkers will be stored at -80C. The following biochemical markers will be 
quantified in human serum by a manual solid phase, monoclonal antibody immunoenzymatic 
assay: 
OPG, BAP, TRAP5b and sRANKL, while P1NP and CTX will be quantified in human serum by 
an 
electrochemiluminescence immunoassay on an automated analyser, Roche - Elecsys 2010.  
BMD measurements of forearms, hips and spine will be performed by Dual Energy X-ray 
absorptiometry (DXA) according to local protocol. A number of studies have reported that the 
greatest reduction in bone density occurs at the foreram sites and that forearm bone density 
correlates with clinical features of disease activity and markers of bone turnover (8-12). 
To investigate the effects of B-cell depletion on osteoclastogenesis, cryopreserved mononuclear 
cell preparations will be cultured in vitro, and osteoclast numbers determined by morphology, 
TRAP staining, and immunochemical localisation of surface integrins. The in vitro osteoclast 
activity will be assessed using the Osteoclast Activity Assay Substrate (OAASTM) where both 
number and size of the resorption bits will be determined. 
7.4 Toxicity 
Rituximab is a B-cell depleting chimeric monoclonal antibody. It will be used within its licensed 
indication, and no unexpected toxicities other than reported in the SmPCs are therefore expected. 
7.5 Clinical Evaluations, Laboratory Tests and Follow-up 
The following assessments will be done at 3, 6, 9, 12 months after registration: 
- Patient’s history, concomitant medication, detailed physical examination 
- Adverse event recording according to RCTC vs 2.0 
- DAS28, HAQ-DI 
- Laboratory tests for hematology (ESR, Hb, HCT, WBC and differential, thrombocytes), 
chemistry (electrolytes, renal and liver function tests, proteins), urinanalysis, FACS 
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- serum and blood for biochemical markers of bone turnover and osteoclastogenesis assay (as 
baseline sample) 
DXA of lumbar spine, forearms, hips (total hip and femoral neck) will be repeated at 12 months. 
8.0 RECORDING AND REPORTING OF ADVERSE EVENTS 
8.1 Definitions of Adverse Events 
Adverse Event (AE) 
This is defined as any untoward medical occurrence or effect in a patient treated on a study 
protocol which does not necessarily have a causal relationship with the study treatment. An AE 
is therefore described as any unfavourable and unintended sign (including an abnormal 
laboratory finding), symptom or disease temporally associated with the use of the study 
treatment, whether or not related to the study treatment. 
Adverse Reaction (AR) 
This is defined as all untoward and unintended responses to a study treatment related to any dose 
administered. A causal relationship between the study treatment and an adverse event is at least a 
reasonable possibility, i.e. the relationship cannot be ruled out. 
Serious Adverse Event (SAE) 
This is defined as any untoward medical occurrence or effect in a patient treated on a study 
protocolwhich does not necessarily have a causal relationship with the study treatment, that also, 
at any dose: 
• Results in death 
• Is life threatening 
• Results in persistent or significant or disability/incapacity 
• Requires in-patient hospitalisation or prolongs existing hospitalisation 
• Results in a congenital anomaly or birth defect 
• Is otherwise medically significant (i.e. withdrawal reactions, all accidental or intentional 
overdoses whether they result in an adverse event or not, or any event which the investigator 
considers significant but which is not covered by the above.) 
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Suspected Serious Adverse Reaction (SSAR) 
This is defined as an adverse reaction, the nature or severity of which is consistent with the 
known study treatment information (e.g. Summary of Medicinal Product Characteristics 
(SmPC), Investigator Brochure (IB) or Investigator Medicinal Product Dossier (IMPD)). 
Suspected Unexpected Serious Adverse Reaction (SUSAR) 
This is defined as an adverse reaction, the nature or severity of which is not consistent with the 
known study treatment information. 
A serious event or reaction is not defined as a SUSAR when: 
• it is serious but expected 
• it does not fit the definition of an SAE, whether expected or not 
8.2 Procedures for Adverse Event Reporting 
All adverse events 
Adverse events and adverse reactions thought to be related to rituximab but not listed in its 
SmPC will be recorded. All serious adverse events that occur between the first study-related 
procedure (i.e. screening) and 30 days post the last study treatment (or after this date if the 
investigator feels the event is related to the study treatment) will be recorded and reported using 
the Serious Adverse 
Event Report form. 
Investigators must record in the CRF and the patient notes their opinion concerning details of 
nature, onset, duration, severity and any relationship to the investigational product. Medical 
terminology should always be used to describe any event. Investigators should avoid vague 
terms such as “sick”. 
Severity 
Severity for each adverse event, including any lab abnormality, will be determined by using the 
WHO Common Toxicity Parameters, wherever possible (appendix B). In those cases where 
these criteria do not apply, severity should be defined according to the following criteria: 
• Mild: Awareness of sign or symptom, but easily tolerated 
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• Moderate: Discomfort enough to cause interference with normal daily activities 
• Severe: Inability to perform normal daily activities 
• Life threatening: Immediate risk of death from the reaction as it occurred. 
Causality 
Relationship to study treatment will be determined as follows: 
• None: No relationship between the experience and the administration of the study treatment; 
related to other etiologies such as concomitant medications or patient’s clinical state. 
• Unlikely: The current state of knowledge indicates that the relationship is unlikely 
• Possible: A reaction that follows a plausible temporal sequence from administration of the 
study treatment and follows a known response pattern to the suspected treatment. The reaction 
might also have been produced by the patient’s clinical state or other modes of therapy 
administered to the patient. 
• Probable: A reaction that follows a plausible temporal sequence from administration of the 
study treatment and follows a known response pattern to the suspected treatment. The reaction 
cannot be reasonably explained by the known characteristics of the patient’s clinical state or 
other modes of therapy administered to the patient. 
• Definitely: An adverse event, which is listed as a possible adverse reaction and cannot be 
reasonably explained by an alternative explanation, e.g., concomitant drug(s), concomitant 
disease(s). 
Expectedness 
An expectedness assessment needs to be conducted for all Serious Adverse Events and recorded 
appropriately on the Serious Adverse Event Report form. Expectedness of the event to the 
medicinal product will be determined as follows: 
• Expected: The event is listed in the SmPC/IB or the study protocol as expected. 
• Unexpected: The event is not listed in the SmPC/IB or in the study protocol, or the severity of 
the event is greater than that listed in the SmPC/IB or the study protocol (e.g. mild nausea is 
listed as expected in the SmPC/IB/study protocol but the event is moderate or severe nausea). 
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8.3 Reporting of Serious Adverse Events (SAE) 
The Sponsor is responsible for pharmacovigilance. Events defined as serious must be reported 
by fax to the sponsor, using the Serious Adverse Event Report form, within 24 hours of 
observing or learning of the event. Should you need a copy of the Serious Adverse Event Report 
form, contact the study co-ordinator. 
The following attributes must be assigned when reporting: 
• Detailed description of the event 
• Adverse event term (see Adverse Event Term section for details) 
• Date of onset and date of resolution 
• Severity of the event (see Severity section for details) 
• Assessment of relatedness to the protocol treatment (see Causality section for definitions) and 
action taken 
• Assessment of expectedness for the protocol treatment 
• Other suspect drugs/devices 
• Outcome 
All Serious adverse will be followed up until resolution. The investigator will be asked to 
provide interim and follow-up reports, as necessary, if the SAE has not resolved at the time of 
initial report. 
All deaths occurring on study must be reported as an SAE and on the CRFs to the SAO. For all 
deaths, available autopsy reports should be sent with the notification. 
Investigators may receive an Investigator Notification from the SAO at any time for any serious 
unexpected adverse reactions, which the sponsor for the study deem necessary. These should be 
processed according to the local regulations. 
8.4 Expedited Reporting of SUSAR 
As of May 1st 2004, the sponsor of a clinical trial conducted in the EU must ensure that all 
relevant information regarding suspected unexpected serious adverse reactions (SUSARs) are 
recorded and reported in an expedited fashion. It is a legal requirement of the sponsor to report 
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fatal or life threatening SUSARs within 7 calendar days to the relevant Regulatory Authorities 
after receiving first notification of the event. Non-fatal and non life-threatening SUSARs must 
be reported to the Regulatory Authorities within 15 calendar days. As from 01/09/10 all SUSAR 
reporting must be carried out electronically using the MHRA eSUSAR website. 
9.0 STATISTICAL METHODS 
9.1 Determination of the Sample Size 
The determination of the sample size is based on the comparison of the BMD at baseline and 12 
months. Assuming the true change in BMD of the lumbar spine is T0.01 g/cm2 (based on 
previous unpublished data from Dr S Tuck) and that the DXA scan is reproducible with a 
standard deviation of 0.02 g/cm2 (based on data from the manufacturer); then the study will have 
80% power to detect a statistically significant difference (at the 5% confidence level) if we have 
33 patients in the final analysis. A 1% increase in bone density will show that the study drug is 
effective based on a metaanalysis on antiresorptive agents in osteoporosis which concluded that 
a 1% gain in bone density of the spine was associated with a statistically significant reduction of 
8% in nonvertebral fractures and a study in a large population cohort showing decline of bone 
density over time in RA patients not treated with antiresorptive agentsa (13,14). To allow for 
20% dropout (based on the treatment criteria of NICE which mean some patients will 
discontinue therapy early due to treatment failure or complete disease resolution) 42 patients are 
needed based on a one sample T-test. 
9.2 Statistical Analyses 
A full statistical analysis plan has been completed for this study (available as a separate 
document). In brief descriptive statistics will be used to quantitatively summarise the 
distribution, central tendency and dispersion of the data set. The primary endpoint; change in 
BMD of the lumbar spine and secondary endpoints; changes in BMD of the hips (total hip and 
femoral neck) and forearms; bone turnover markers; inflammatory markers and disease activity 
between baseline and 12 months will be investigated using a one sample T-test. 
Pearson’s correlation coefficient will be used to correlate the changes in BMD with changes in 
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biochemical markers of bone turnover, in changes in biomarkers of inflammation and in changes 
in circulating B-cells. 
P values U0.05 will be considered statistically significant, and a trend towards significance will 
be defined as p <0.10. 
10.0 ETHICAL AND TRIAL ADMINISTRATIVE CONSIDERATIONS 
10.1 Study administration office 
All study administrative procedures are coordinated and conducted by the study administration 
office (SAO). These include: registration of patients, collection of registration forms, dispatch of 
case report forms, treatment allocation, data collection, data management. 
All questions concerning the data processing aspects of this study should be addressed to the 
study administration office. For contact details see cover page of protocol. 
All other questions should be addressed to the study chairperson (JM van Laar). See Protocol 
Synopsis for contact details. 
10.2 Finances 
The study is supported financially by Roche UK to cover trial administrative costs. 
There will be no contribution to medical costs, as the study concerns a study with a licensed 
drug. 
The study protocol will be submitted to UKCRN for adoption on the NIHR-portfolio. 
10.3 Publication Procedures  
No partial or complete written publication of the results will be made by the study coordinator 
without a previous information and agreement of the participating members selected as co-
authors on the basis of accrual of patients evaluable and eligible. The publications will include as 
co-authors the study coordinator and co-investigator from each participating centre. 
10.4 Trial Duration 
The trial launch is scheduled for 1 November 2010. Enrolment is expected to be completed in 
2011. Analyses of outcome parameters will commence once the last patient has completed one 
year follow-up. 
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10.5 Discontinuation of the Trial, a Centre or a Patient. Planned termination of the whole trial. It 
is planned that the study will be terminated as soon as the last patient has completed the study, in 
principle 12 months after registration. 
Early termination of the whole trial 
The trial may be prematurely terminated, if in the opinion of the Sponsor and the Coordinating 
Investigator there is sufficient reasonable cause. Written notification documenting the reason for 
study termination will be provided to the investigators by the terminating party. 
Circumstances that may warrant termination include, but are not limited to: 
• Failure to recruit patients at an acceptable rate 
• Insufficient adherence to protocol requirements 
• Insufficient complete and/or evaluable data 
Termination of a study centre by an investigator 
The investigator may terminate participation in the study. If this occurs they should provide a 
written statement of the reasons for terminating participation, and should provide the data 
coordinating office with all available and up-to-date study data. 
The Sponsor may also decide to terminate participation of an investigator or study centre for the 
following reasons: 
• Breach of agreement 
• Serious non-compliance to ICH-GCP standards 
• Insufficient patient recruitment 
If a participating centre closes, or is closed, prior to termination of the whole trial, the sponsor 
expects that data from patients already entered into the study will be reported as per protocol. 
Early withdrawal of patient 
Any patient enrolled into the protocol who is withdrawn at any time for any reason before the 
last follow up visit (at one year) is considered an early withdrawal and will not be replaced. A 
complete set of data including the reason for withdrawal should be collected on every patient up 
to the time of withdrawal from the study. 
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The investigator should withdraw a patient from the study treatment whenever continued 
participation is no longer in the patient’s best interests. Reasons for discontinuing treatment may 
include the occurrence of a serious adverse event or an intercurrent illness, a patient’s request to 
end treatment, or significant uncertainty on the part of the investigator that continued treatment 
would be prudent. 
Possible reasons for a patient to go off study 
1. Death whatever the cause 
2. Noncompliance of the patient 
3. Major protocol violations 
4. Loss to follow-up 
5. Adverse events to go off the study 
10.6 Good Clinical Practice (GCP) 
The study will be conducted in accordance with the International Conference on Harmonization 
for Good Clinical Practice (ICH-GCP) and the appropriate regulatory requirement(s). The 
investigator will be thoroughly familiar with the appropriate use of the study drug as described in 
the protocol and Investigator’s Brochure. Essential clinical documents will be maintained to 
demonstrate the validity of the study and the integrity of the data collected. A trial master file 
should be established at the beginning of the study, maintained for the duration of the study and 
retained according to the appropriate regulations. 
10.7 Ethical considerations 
The study will be conducted in accordance with ethical principles founded in the Declaration of 
Helsinki. The ethics committees will review all appropriate study documentation in order to 
safeguard the rights, safety and well-being of the patients. The study will only be conducted at 
sites where ethics approval has been obtained. The investigator will provide the relevant ethics 
committee(s) with the final version of the protocol, patient information and consent forms, any 
other written information given to patients, safety updates, annual progress reports, and any 
revisions to the study protocol or any other trial documentation. 
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No amendments are allowed to the protocol unless agreed to by the Sponsor and the 
Coordinating Investigator. Substantial amendments must be submitted for regulatory and ethical 
approval and the amended protocol will not be activated until such approval is in place. 
10.8 Informed Consent 
A “Patient and Donor Information Leaflet and Informed Consent form” will be provided as 
separate document. After the study has been fully explained, written informed consent will be 
obtained from either the patient and/or his/her guardian or legal representative prior to study 
participation. The method of obtaining and documenting the informed consent and the contents 
of the consent will comply with ICH-GCP and all applicable regulatory requirement(s): 
• A properly signed and personally dated informed consent form is required for each subject 
before any trial specific procedure. Subject should be given ample time to read the consent forms 
and ask questions. 
• The informed consent process should be recorded in source documents (date of information 
and consent, parties present). 
• The investigator is responsible for checking entries made by the patient on the consent form, 
and to request correction immediately in case of missing, illegible or incorrect dates. The person 
taking the patient consent should sign and date both consent forms to confirm he/she provided 
information to the subject. 
• All entries on the consent forms must be permanent (in ink, no pencil). 
• The Informed Consent form will be updated by the Investigator-Sponsor whenever important 
new information becomes available that may be relevant to subject’s consent. 
This may be a result of amendments to the protocol, new information regarding the trial 
medication alternative treatments. Revised versions must be approved by the relevant ethics 
committee(s). 
• The revised Consent Form must be signed by subjects who are entered in the trial and not yet 
completed, if these changes are relevant to the subject’s willingness to continue participation. In 
particular, if the Consent Form is updated with new safety information, a new version of the 
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informed Consent Form must be provided to all subjects in a timely manner as soon as written 
ethics approval is obtained. 
• Patient withdrawal of consent from the study should be explicitly documented in the source 
documents. 
10.9 Patient Confidentiality 
In order to maintain patient privacy, all data capture records, study drug accountability records, 
study reports and communications will identify the patient by initials and the assigned patient 
number. The full patient name should never be used in any correspondence with the Sponsor or 
on the CRF. 
The investigator will grant monitor(s) and auditor(s) and/or Regulatory Authority(ies) direct 
access to the patient’s original medical records for verification of data gathered on the data 
capture records and to audit the data collection process. Direct access includes examining, 
analysing, verifying, and reproducing any records and reports that are important to the evaluation 
of the monitoring. The investigator is obliged to inform the patient that his/her trial-related 
records will be viewed without violating their confidentiality and that the collected information 
will only be made publicly available to the extent permitted by the applicable laws and 
regulations. 
10.10 Protocol Compliance 
The investigator will conduct the study in compliance with the protocol given approval/favorable 
opinion by the ethics committee(s) and the appropriate Regulatory Authority. Any changes to the 
protocol will be made by the Coordinating Investigator in liaison with the Sponsor and will 
require approval and written ethics committee approval/favorable opinion prior to 
implementation, except when the modification is needed to eliminate an immediate hazard(s) to 
patients. The investigators will submit any protocol amendments, if applicable, to the ethics 
committee and the Regulatory Authority in accordance with the governing regulations. Version 
control of the protocol is the responsibility of the Sponsor in collaboration with the Coordinating 
Investigator. All protocol distribution is via the sponsor to ensure adherence to strict version 
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control. Any departures from the protocol, at a participating site must be fully documented in the 
source documents. Any such protocol violations will be reviewed by the Coordinating 
Investigator and remedial action taken if required. 
10.11 Quality Assurance & Monitoring 
Monitoring of trial data 
Reports of severe adverse events are dealt with in the appropriate manner, as described in section 
8 of the protocol. 
The study administration office collects the CRF paper-copies and the data is entered by trial 
specific trained person(s). Commonly made mistakes and misinterpretations of the CRFs 
questions should be picked up. Consistent reporting errors should lead to amendment and 
clarification of the 
CRFs. All data relating to the trial objectives/endpoints will be audited prior to publication. 
Monitoring frequency 
In adherence to CGP and EU Law, each study site will be initiated as well as monitored during 
the study. A close out visit to participating study sites will be conducted at the end of the study 
before final data analysis. 
Monitoring of participating study centres: 
Study centres will be initiated via a telephone conference, guided by PowerPoint presentation of 
the protocol and study procedures. At a minimum the principal investigator and 
coordinator/study nurse/data manager at the centre must participate, subsequently they may 
initiate any other relevant staff at the institution. 
On-site monitoring will be carried out, to focus primarily on safety data as all end point data will 
be verified through quality assurance procedures. Each site will be visited once during the study, 
and once for a close/out visit/ end point review. 
The scope of work for on-site monitoring will include the following activities: 
• Verify for each subject that Informed Consent was obtained prior to the subjects' participation 
in the study and that the correct version of the PIL/IC was used 
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• Ensure all approval documents are in the site file 
• Source Document verification will be carried out as specified below: 
a) Verify 100% of SAEs 
b) Verify 25% of protocol treatment information 
• Ensure that the process of reporting SAE is followed as outlined in the adverse events section 
• Document all activities and discussions with investigational staff in a written report and sent 
this to the trial data coordinating office. 
• Arrange for appropriate follow-up of all action items in the monitoring report. 
The Investigator is obliged to provide source documentation, CRFs of subjects and the trial 
related documents to the monitor during all monitoring visits. Investigators should have ample 
time to discuss problems and make corrections identified by the monitor. 
In addition remote monitoring will be done to ensure adherence to the protocol and ICH-GCP 
and relevant EU Directive(s). Monitoring of clinical and safety data will be carried out by 
statistical analysis of data submitted on the CRFs. As the most frequent cause of SAE reports is 
the hospitalisation of a patient from whatever cause, monitoring of SAE reporting will be carried 
out by checking the Adverse Event (AE) Data in the CRFs and cross referencing the number of 
AEs rated as serious with the number of SAEs submitted. Should such analysis identify 
anomalies or discrepancies then this will trigger a query and/or on site visit to the relevant 
Institution. 
Quality Assurance of Study Endpoints 
Each participating Investigator is responsible for reviewing the end point data of each patient at 
their site to: 
• cross reference the source documentation against the submitted CRFs 
• check that the evaluation of efficacy data points are correct 
This should be carried out as each patient completes the study treatment or as clinically dictated. 
The data review will be documented and any changes required to CRFs made and any amended 
CRFs submitted. The Coordinating Investigator will review all reviewed data from each site 
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prior to the planned analysis of the study. 
10.12 Audit and Inspection 
In accordance with applicable laws participating centres will allow direct access for monitoring, 
audit and inspection. Access will be granted to all trial related documentation and sites 
(including trial master file, patient files, clinics, laboratories and pharmacy). 
The sponsor maintains the right to perform audits during the active phase of the study and/or 
after the study has been completed. There are two types of audits: 
1) Routine audit: A systematic examination of study-related activities and documents to assure 
compliance with the protocol, and national/local regulations. The principal investigator of a 
selected centre will be given a 3 months notice period prior to the proposed audit visit. The aim 
of a routine audit is to: 
• inspect the study facilities 
• ensure that the study is conducted in accordance with ICH-GCP guidelines, the principles in 
the Declaration of Helsinki and relevant regulatory requirements 
• ensure that the site staff adhere to the protocol and SOP’s 
• review the informed consent process 
• review the SAE identification and reporting process 
• aid in identifying and correcting problem areas and provide suggestions to improve 
performance, if required 
The principal investigator will receive an audit report within 4 weeks of the site visit. 
2) “For-cause” audit: Where there is evidence or suspicion of non-compliance with important 
aspect(s) of the trial requirements. The notification period is dependent on the reason(s) 
triggering the audit. 
In case of a for cause audit a letter is sent to the Principal Investigator outlining: 
• the reason(s) for the for-cause audit 
• any hold that has been placed on the protocol related research 
• all of the documents that are to be reviewed 
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• interviews that will be conducted 
• planned inspections of the facilities (primarily how data is stored, drug storage, accountability, 
destruction etc.) 
• who will come and perform the audit 
• when the audit will likely occur 
The principal investigator will receive an audit report within 2 weeks of the site visit. 
10.13 Drug Accountability 
Accountability for the study drug at the study site is the responsibility of the principal 
investigator 
at each study center. The principal investigator may delegate this responsibility to the local 
pharmacist, or other appropriate personnel. The responsible person will ensure that the study 
drug is used only in accordance with this protocol. 
Drug accountability records, maintained by the clinical site, should indicate: 
• use by each patient (including Lot numbers) 
• disposal of unused drug or destruction of used vials (date and Lot numbers) 
10.14 Protocol Amendments 
No amendments to the protocol may be made without the explicit agreement of the Sponsor and 
Coordinating Investigator. Changes to any of the study related documentation and practices 
should always be made according to GCP. Prior to implementing the changes, significant 
amendments to the documentation must also be approved by the appropriate Ethics 
Committee(s) of participating centers. 
10.15 Storage and Archiving of Study Material 
It is the responsibility of the principal investigator at the study centre to keep all essential 
documents relating to the study for at least 5 years (or according to national legislation) after the 
completion or premature termination of the study. Essential documents are those which enable 
both the conduct of the study and the quality of the data produced to be evaluated and show 
whether the institution complied with the principles and guidelines of good clinical practice. 
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The medical files of patients enrolled into the study must be kept in accordance with national 
legislation and for the maximum period of time permitted by the institution. The sponsor or 
subsequent owner is required to keep all other documentation for the life of the product studied. 
The archived data can be kept in electronic form, provided that a back-up copy is kept and that a 
paper copy can be provided if necessary. 
The protocol, ethical and government approvals, together with all other documents concerning 
the study, including any audit and inspection certificates are all to be kept as part of the trial 
master reference file. All data about serious adverse events also need to be kept in this trial 
master file. 
All data should be available for inspection by the appropriate authorities on demand. 
10.16 Liability Insurance 
All centres collaborating in this multicentre study have NHS liability insurance cover, the terms 
of which include standard risks associated with biological therapy such as administered in this 
trial. 
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ESR erythrocyte sedimentation rate 
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Hb haemoglobin 
HCT haematocrit 
i.v. intravenous 
HAQ health assessment questionnaire 
DAS disease activity score 
CTX crosslaps 
OPG osteoprotegerin 
P1NP procollagen type 1 amino-terminal propeptide 
sRANKL soluble receptor activator of nuclear factor 
kappaB ligand 
 
 
 
 
 
 
 
 
 
 
Centre Number:  
Study Number:  
Patient Identification Number for this trial:  
 
CONSENT FORM  
Title of Project: Bone study 
Name of Researcher:  
Trust Logo 
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 Please initial box  
1. I confirm that I have read and understand the information sheet dated 1st February 2013 
(version 4.0) for the above study. I have had the opportunity to consider the information, 
 ask questions and have had these answered satisfactorily.  
 
2. I understand that my participation is voluntary and that I am free to withdraw at any time  
without giving any reason, without my medical care or legal rights being affected.  
 
3. I understand that relevant sections of my medical notes and data collected during the study,  
may be looked at by individuals from regulatory authorities or from the  
NHS Trust, where it is relevant to my taking part in this research. I give permission for these 
individuals to have access to my records.  
 
4. I agree to my GP being informed of my participation in the study.    
 
5. I agree with my blood samples being taken for research studies as outlined in the patient 
information sheet dated 1st February 2013 (version 4.0). 
 
6. I agree to take part in the above study. 
       
Name of Patient    Date     Signature  
 
 
Name of Person    Date     Signature  
taking consent  
When completed: 1 for participant; 1 for researcher site file; 1 (original) to be kept in medical 
notes. 
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Flow cytometric analysis of patient 0101 (Sample of all visits) 
 
 
Baseline visit 
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Flow cytometric analysis of patient 0101 using FlowJo software 
3 Months visit 
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6 Months visit 
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9 months visit 
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12 Months visit 
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A) Standard operation procedures (SOPs): 
- Patients fulfilling the eligibility criteria were invited to join the trial. If the patient showed 
interest in joining the trial, the patient information leaflet was provided to the patient. The patient 
is allowed few weeks to discuss the trial’s information leaflet with the treating physician and 
his/her family. 
- Eligible patients who wanted to join the trial were then explained all the procedures of 
the trial and then consented.  
- All patients were anonymised by a four-digit study ID. The first two digits represent the 
centre’s ID and the second two digits represent the patient’s number on the corresponding site. 
No patient identifiable data are being stored in the trial master file or the regional site file 
according to the ethics committee and MHRA guidelines. 
- The DXA scans and the first rituximab infusion were usually done within a week prior to 
the baseline visit. Follow up visits were appointed 3 months from the baseline visit date. 
However, in some patients this was not possible due to patient or staff reasons. 
- Patients who responded to the first course received a second course at 6 months unless 
they attained a state of low disease activity, in accordance with clinical practice. Retreatment was 
delayed in patients with low disease activity (DAS score less than 3.2) at 6 months until a state 
of moderate disease activity was documented. 
- All samples are collected fasting and whenever possible in the morning as bone markers 
tend to change dramatically during the day and are markedly affected by food intake. 
- Bone biomarkers samples are stored in -80 C while flow cytometry is done on fresh 
samples on the same day of being taken. FACS samples are analyzed using the medical school 
FACSCanto II (1). Data are analyzed using FLOWJO software.  
- Data management: 
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Case record forms are regularly collected from the 10 participating centres. Data are then 
completed including HAQ scores, DXA results calculation if not supplied by the reports. All data 
are being entered on our database after undergoing extensive quality control checks using the 
CRFs data and supplied copies of laboratory and radiology reports. Quality control is also being 
done to all DXA reports to check the proper positioning of the part scanned and the validity of 
the results provided. 
 
B) FACS protocol 
 
1- Pipette the pre-titrated volume recommended for each antibody into the TruCount tube 
2- Avoid resuspending the bead by pipetting the volume on top of the mesh located at the 
bottom of the tube, which serves to hold the TruCount bead in place 
3- Once all the antibodies have been added, add 100µl of whole blood via reverse pipetting 
to the same location where the antibodies were added 
4- Tap the bottom of the tube to thoroughly mix the blood with the antibodies, and incubate 
in the dark for 20 minutes at room temperature 
5- After 20 minutes, add 1000µl of the 1:10 BD Pharm Lyse lysis buffer to the blood / 
antibody mix to lyse all non-nucleated cells 
6- Mix thoroughly by tapping the bottom of the tube and incubate in the dark for 20 minutes 
at room temperature 
7- Analyse the sample on FACSCANTO 1 
FlowJo analysis protocol: 
1. Locate the .fcs files that you exported to the shared drive immediately after acquisition. 
2. Back up these raw files, in case of unforeseen circumstances 
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3. Keep a copy of said files on the analysis computer you are using otherwise FlowJo will 
get confused!! 
4. Open FlowJo via the Application folder or taskbar, use one FlowJo workspace per 
patient, to allow the presence of all timepoints 
5. To add the .fcs files to the workspace, either drag and drop the files, or add tubes via the 
tube icon at the top of the worksheet 
6. Click upon the layout editor icon, to generate a page layout for each timepoint whereby 
you can place copies of the plots upon 
7. Double-click on the tube of interest, which will open the forward vs. sideward scatter dot 
plot 
 
 
 
8. To isolate the lymphocytes, 
change the x-axis from forward scatter 
(FSC) to CD45. 
9. Gate around the lymphocytes 
which are CD45+, sideward scatter (SSC) 
dim, whilst avoiding the debris located at the dimmest point 
of the sideward scatter 
 
 
10. To ensure purity of population, double click on the gate, or the label, and revert the x-axis 
back to forward scatter and see that the cells / events are in the correct Lymphocyte location 
11. If there is some debris contamination then, gate around the 
lymphocytes within this gate.  
  
164 
12. Working within the lymphocyte gate, change the x axis to CD19 and gate around the 
CD19+ cells 
13. Now generate graphs plotting CD19 as the x-axis, against CD24, CD27 and finally CD38 
as the y-axis, and drag a copy of each to the layout editor 
14. Now we need to create a plot with only CD19+ B lymphocytes in. And have the x-axis as 
CD38 and the y-axis as CD24 
15. The resultant plot will show 3 CD19+ populations 
i) CD19+ CD24hi CD38hi 
Largely comprised of CD27- negative Immature B cells (approx. 90%) 
ii) CD19+ CD24+ CD38- 
Mainly memory B cells 
iii) CD19+ CD24int CD38int 
Which are primarily mature B cells 
 
16. To confirm the naïve status of all the above subsets. For instance 
the CD19+ CD24hi CD38hi, open a plot with just these cells and split 
them between CD27 positive and negative. In theory, the majority of 
them should be negative, confirming their naïve status. 
17. Open the original ungated dot plot and by comparing different surface markers with each 
other, try to locate the 
TruCount beads, whereby you should gate upon them. 
18. Note the number of events of each population of interest, and the number 
of beads acquired. Also have to hand the exact number of TruCount beads 
present in the tubes used (according to the sachet of the batch). Use 
these numbers in the below calculation. Test volume includes antibodies 
lysis buffer and blood volume. 
  
165 
 
 
 
 
19. In the instance of dead cells, gate around said cells and label as such 
20. Highlight the original ungated graph and generate a Boolean Gate where by you ask 
FlowJo to use all lymphocytes “AND NOT” the dead cells which you have gated on 
21.  The resultant Boolean gate will therefore be your lymphocytes, without the dead cells 
 
22. Now print off all the pages containing your multiple timepoint layouts, as well as a layout 
summarising all the timepoints. Also print off the table containing the event numbers of each 
gate etc 
23. Input all the relevant numbers into the spreadsheet and do the necessary calculations 
 
C) DKK1 assay protocol:  
Day 1: 
1- All contents must be at room temperature 
2- Mark the Blank/Standard/Sample/Control sheet 
3- Samples: 
 
Dilute as 1:4 with assay buffer (25 µl sample + 75 µl assay buffer). 
4- Standards (STD) & Control (CTRL): 
Dissolve each in 400 µl deionised water for 10 mins at room temperature. Then mix it well 
manually then leave it for 5 mins then mix it well. (Total of 15 mins) 
5- Antibody (AB): 
- Reconstitute the 2 antibody vials.  
- Each vial is reconstituted in 11 ml assay buffer for 15 mins at room temperature. 
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6- Add 50 µl of STD/Sample/CTRL into wells except blank 
7- Add 200 µl of AB into all wells except blank 
8- Swirl gently 
 
 
 
 
 
Day 2: 
1- Prepare the plate reader to measure absorbance at 450 nm with reference 620 nm. 
2- Wash buffer (WASHBUF): 
Dilute as 1:20 (50 ml WASHBUF + 950 ml distilled water at room temperature. 
3- Wash 1: 
 
 
 
 
 
4- Add 200 µl Conjugate (CONJ) into all wells. 
 
5- Wash 2: 
 
 
 
 
 
6- Add 200 µl substrate into all wells. 
Incubation 1: 
 
Cover tightly and incubate for 18-24 hours at room temperature in the dark. 
 
 
- Fill 5-6 containers with diluted wash buffer 
- Wash 5x using multi-pipette with 300 µl wash buffer. 
- Hit the plate against paper towel after last wash. 
 
- Fill 5-6 containers with diluted wash buffer 
- Wash 5x using multi-pipette with 300 µl wash buffer. 
- Hit the plate against paper towel after last wash. 
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7- Add 50 µl STOP solution into all wells. 
8- Measure absorbance immediately at 450 nm with reference 620 nm. 
Reference data: 
 
 
 
 
Calculation of the results: 
1- Subtract the blank from all other values. 
2- The assay is evaluated using 4PL algorithm. 
3- The dilution factor 1:4 
 
D) Sclerostin assay protocol 
Day 1: 
- All contents must be at room temperature 
- Mark the Blank/Standard/Sample/Control sheet 
- Standards (STD) & Control (CTRL): 
Dissolve each in 400 µl deionised water for 10 mins at room temperature. Then mix it well 
manually then leave it for 5 mins then mix it well. (Total of 15 mins) 
- Add 150 µl of assay buffer (ASYBUF with red cap) into all wells.  
- Add 20 µl of STD/Sample/CTRL into wells except blank 
- Add 50 µl of AB (Green cap) into all wells except blank 
Incubation 3: 
 
Incubate for 30 mins at room temperature in the dark without cover. 
 
Mean = 52.6 pmol/l 
Median = 45.7 pmol/l 
SD = 20 pmol/l 
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- Swirl gently 
 
 
 
 
 
Day 2: 
- Prepare the plate reader to measure absorbance at 450 nm with reference 630 nm. 
- Wash buffer (WASHBUF): 
Dilute as 1:20 (50 ml WASHBUF + 950 ml distilled water at room temperature. 
- Wash 1: 
 
 
 
 
 
- Add 200 µl CONJ (CONJUGATE, AMBER CAP) into all wells. 
 
 
 
9- Wash 2: 
 
 
 
 
 
- Add 200 µl Substrate (BLUE CAP) into all wells. 
Incubation 1: 
 
Cover tightly and incubate for 18-24 hours at room temperature in the dark. 
 
 
- Fill 5-6 containers with diluted wash buffer 
- Wash 5x using multi-pipette with 300 µl wash buffer. 
- Hit the plate against paper towel after last wash. 
 
- Fill 5-6 containers with diluted wash buffer 
- Wash 5x using multi-pipette with 300 µl wash buffer. 
- Hit the plate against paper towel after last wash. 
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10- Add 50 µl STOP solution (WHITE CAP) into all wells. 
11- Measure absorbance immediately at 450 nm with reference 620 nm. 
Reference data: 
 
 
 
 
Calculation of results  
1- Subtract the blank from all wells. 
2- The assay is evaluated with 4PL algorithm 
 
 
Incubation 3: 
 
Incubate for 30 mins at room temperature in the dark without cover. 
 
Mean = 19.3 pmol/l 
Minimum = 10.9 pmol/l 
Maximum = 28.7 pmol/l 
